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Pulmonary hypertension (PH) is an incurable disorder of the pulmonary circulation, 
characterised by progressive vascular remodelling, vasoconstriction and increased 
right ventricular afterload. The direct consequence of this is impaired cardiac 
output, initially in response to exercise and in later stages of the disease at rest. 
Progressive exercise limitation is the cardinal clinical feature and ultimately 
premature death from right heart failure ensues.  
Available disease targeted treatments slow progression, however, PAH remains 
incurable with a high symptom burden and prognosis remains poor. Lung 
transplantation provides the only hope of cure. A small proportion of patients are 
eligible and fit enough for transplantation, notwithstanding the availability of 
suitable donor lungs and associated post-transplant morbidity in those who survive. 
Current drug therapy is expensive and is limited to three classes of pulmonary 
arterial vasodilator. The most effective form of treatment, epoprostenol, is 
invasive, requiring central venous access and significantly impacts on quality of life 
despite the associated improvements in exercise capacity.  
The abnormalities in the right ventricle and pulmonary circulation are well 
established in PH. More recent evidence has highlighted multi-system 
abnormalities in PH patients, with muscle dysfunction from a clinical to cellular 
level, systemic inflammation and insulin resistance. It is unclear whether these 
changes are a result of the atrophying effects of low cardiac output, or a systemic 
process associated with PH but independent from cardiac function.  
Historically exercise had been avoided in PAH, however recent evidence suggests it 
provides significant benefit in terms of exercise capacity and quality of life. 
Exercise is an attractive therapeutic option for many reasons. With established 
infrastructure, it is cost effective, sustainable and provides wide-ranging benefits 
out with the pulmonary circulation, such as reduced risk of diabetes, 
cardiovascular disease and improved mental health. The exercise programmes 
studied in PAH have been wide ranging in terms of the approach used and have 
shown variable degrees of success. The most successful programmes have 
employed fairly intensive exercise regimens and many countries do not have the 
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resource or infrastructure to adopt this approach. The role of exercise therapy in 
PAH and the mechanisms by which it exerts a beneficial effect remain poorly 
understood. It is also unclear what the best outcome measure is to determine the 
efficacy of exercise-based interventions in PAH. The feasibility of intensive 
exercise therapy in countries where residential exercise programmes are not 
robustly established remains untested. 
The aims of this thesis are 
• To establish the population demand, feasibility and safety of PH specific 
exercise therapy in a UK pre-capillary PH population.  
• To explore potential physiological and biological mechanisms behind the 
improvements seen in exercise capacity in order to gain a greater 
understanding of the disease process.  
• Identify key components of the exercise programme to allow 
recommendations for effective PAH exercise prescriptions moving forwards.  
To address the aims of the thesis, three studies were performed. The first two 
studies were precursors to the main study discussed in chapters 5 to 9: 
1. “Assessing the demand for exercise therapy in a Scottish PAH population” 
(Chapter 2):  
2. “The ventilatory, gas exchange and haemodynamic response to upright and 
supine exercise”, (Chapter 3),  
3. “The effect of adding exercise training to optimal drug therapy in Pulmonary 
Arterial Hypertension”. 
Chapter 1 provides an introduction to exercise physiology in PAH and describes the 
current state of knowledge regarding exercise therapy in PAH  
Chapter 2 describes the current standard of care for patients with PAH in Scotland 
and the demand for exercise therapy in the Scottish PAH population. From this 
 4 
data, it is clear that there is significant enthusiasm for exercise rehabilitation in 
PAH. Potential barriers to its uptake or implementation were explored and these 
included employment, carers commitments and proximity to the exercise venue.   
In Chapter 3, the ventilatory, gas exchange and haemodyanamic responses to 
upright and supine exercise are discussed in order to determine the degree to 
which exercise capacity is reduced in the supine position and the physiological 
changes that accompany this. This information was used to help design the 
protocol used for supine endurance exercise with invasive haemodynamic 
measurements, discussed in Chapter 7. From this data, it is clear that exercise 
capacity is significantly reduced in the supine position, this appeared to be due to 
changes in ventilatory efficiency and was associated with significant alterations in 
the stroke volume – heart rate response to exercise.  
Chapter 4 outlines the study protocol and exercise intervention for the main study 
in this thesis “The effect of adding exercise training to optimal drug therapy in 
Pulmonary Arterial Hypertension”.  
Chapter 5 describes the overall efficacy of exercise therapy in PAH in relation to 
the primary outcome measures of the study “The effect of adding exercise training 
to optimal drug therapy in Pulmonary Arterial Hypertension”; specifically, 6 
minute walk distance (6MWD), quality of life and right ventricular ejection 
fraction. Analysis of potential “responders” and “non-responders” and factors 
associated with poorer prognosis are discussed in an exploratory post-hoc analysis.  
Chapters 6 to 9 adopt a systems-based approach to describe the physiological and 
pathobiological changes that are present in the studied PAH cohort and the factors 
that change with exercise therapy.  Each chapter discusses the specific 
relationship with responders and non-responders to exercise therapy in more 
detail. The specific methods used to assess each system are discussed in the 
individual chapters and the overall protocol for the exercise therapy is discussed in 
Chapter 2.  
Chapter 6 discusses the impact of exercise therapy on lung function, looking at 
cardiopulmonary exercise testing (CPET), pulmonary function tests and mouth 
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pressures.  The sensitivity of different exercise outcome measures are also 
explored including cycling endurance time, 6MWD, and incremental CPET.  
Chapter 7 investigates invasive haemodynamic responses to exercise therapy using 
both resting and exercise right heart catheterisation. A steady state exercise 
protocol is used to assess serial measurements of haemodyamics and oxygen 
extraction throughout exercise.  
In Chapter 8, a non-invasive approach to assessing cardiac status before, during 
and after exercise therapy is investigated using cardiac magnetic resonance 
imaging and N-terminal pro brain natriuretic peptide (NTproBNP). These changes 
are correlated with invasive haemodynamic markers. 
Chapter 9 discusses the impact of exercise therapy on muscle function, metabolism 
and levels of systemic inflammation. Serum and muscle biomarkers are explored to 
provide pilot data on potential mechanisms for PAH myopathy and how it may be 
reversed.   
Collectively these chapters demonstrate improved exercise capacity and quality of 
life in response to exercise therapy in PAH. This is associated with improved 
ventilatory efficiency and cardiovascular function, with changes being linked to 
prognosis. Potential mechanisms behind these improvements are explored and 
include the reversal of deconditioning, lung recruitment, improved vascular 
endothelial health, reduced atrial stretch and reduced hyperventilation. Chapter 
10 outlines the major findings and conclusions of this research and future research 
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Chapter 1 Introduction 
 Pulmonary Arterial Hypertension  
Pulmonary arterial hypertension (PAH) is an incurable disorder of the pulmonary 
circulation that results in breathlessness, reduced exercise capacity, syncope, 
right heart failure and ultimately death.  
Proliferation of vascular endothelial and smooth muscle cells lead to thickening of 
the tunica intima and tunica media in the pulmonary arteries. Accumulation of 
proteins such as collagen, formation of plexiform lesions, and occlusion of small 
pulmonary arterioles occur. This results in a severe and progressive remodelling of 
the pulmonary arterial tree. The mechanical consequences of this are an increase 
in pulmonary vascular resistance (PVR), an increase in vascular stiffness and 
elevation of pulmonary artery pressure (PAP) at rest and on exercise. The 
cumulative effect of these changes is an increase in right ventricular (RV) 
afterload, this eventually leads to RV failure, the principal cause of death in PAH.  
Typical symptoms of PAH are exercise intolerance, fatigue and dyspnoea. As RV 
failure ensues, pre-syncope, chest pain and ankle swelling develop. Clinical 
features are often subtle in the early stages. As the condition progresses, a 
tricuspid murmur will be heard, an RV heave may be present and a split second 
heart sound.  Later clinical signs are of resting tachycardia, hypoxaemia and 
eventually features of right heart failure, with elevated JVP and peripheral 
oedema.  
 Clinical classification 
Pulmonary Hypertension (PH) is defined by a mean pulmonary artery pressure 
(mPAP) greater than 25mmHg. Pulmonary Arterial Hypertension (PAH) is 
characterised by an mPAP ≥ 25 mmHg, Pulmonary Artery Wedge Pressure (PAWP) ≤ 
15 mmHg and a Pulmonary Vascular Resistance greater than 3 Wood Units (WU)[1, 




Table 1.1 Clinical classification of Pulmonary Hypertension 
1. Pulmonary Arterial Hypertension 
1.1 Idiopathic 
1.2 Heritable 
 1.2.1 BMPR2 mutation 
 1.2.2 Other mutations 
1.3 Drug or toxin induced 
1.4 Associated with 
 1.4.1 Connective Tissue Disease 
 1.4.2 Human immunodeficiency virus (HIV) infection 
 1.4.3 Portal Hypertension 
 1.4.4. Congenital Heart Disease 
 1.4.5 Schistosomiasis 




1’.3 Drug, toxin and radiation induced 
1’.4 Associated with 
 1’.4.1 Connective tissue disease 
 1’.4.2 HIV infection 
2. Pulmonary Hypertension due to left heart disease 
3.  Pulmonary Hypertension due to lung disease and / or hypoxia 
4.  Chronic Thromboembolic Pulmonary Hypertension and other 
pulmonary Artery Obstructions 
 4.1 Chronic Thromboembolic Pulmonary Hypertension 
 4.2 Other Pulmonary Arterial Obstruction 
 4.2.1 Angiosarcoma 
 4.2.2 Other intravascular tumours 
 4.2.3 Arteritis  
 4.2.4 Congenital pulmonary arterial stenosis 
 4.2.5 Parasites (hydatidosis) 
5 Pulmonary Hypertension with unclear and / or multifactorial 
mechanisms 
Adapted from ERS guidelines on the diagnosis and treatment of pulmonary hypertension [3] 
 
 Treatment of PAH  
Treatment of PAH can be disease targeted or supportive. Supportive treatment 




• Maintaining sinus rhythm (cardioversion or with drug therapy) 
• Vaccination (influenza and pneumococcal) 
There are three classes of disease targeted therapy in PAH and all are pulmonary 
arterial vasodilators[4]: 
• Endothelin Pathway (Endothelin Receptor Antagonists) 
• Nitric Oxide Pathway (Phosphodiesterase Type 5 Inhibitors and Soluble 
Guanylate Cyclase Stimulators) 
• Prostacyclin Pathway (IP prostacyclin-receptor agonists) 
Therapy is prescribed in accordance with international guidelines, based on a 
clinical assessment of severity [5]. Two significant changes have occurred in the 
last 20 years, which have resulted in improved survival or requirement for lung 
transplantation. Intravenous Epoprostenol was introduced in 1996 and was the first 
and to date only therapy to demonstrate robust survival benefit [6]. Secondly, goal 
orientated therapy has been adopted, with more patients being on combination 
therapy at an earlier stage in their disease [7]. Despite these advances, Pulmonary 
Hypertension remains incurable with significant associated morbidity. 
A number of novel drug targets and therapies have been investigated over the past 
ten years, to address other pathological mechanisms that drive vascular 
remodelling and systemic manifestations of PAH[8].  
• The BMPR2 pathway (Tacrolimus) [3] 
• Inhibition of platelet derived growth factor using the tyrosine kinase 
inhibitor Imatinib [9] 
• Insulin resistance: Metformin and Ranolizine [10] 
• Inflammation and immune modulation (Rituximab[11], Tocalizumab[12])  
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• Oxidative stress (Apoptosis signal-regulating kinase 1 inhibitor)[13] 
• Serotonin antagonists (Terguride) [14] 
• Pulmonary artery denervation [2]  
 
None of these pathways or targets have yielded clinically beneficial effects with 
tolerable or acceptable safety profiles to date. There remains an un-met need for 
additional therapies in order to improve survival and morbidity in PAH. For this 
reason, there has been increasing interest in exercise therapy as a potential 
adjunct to disease targeted therapy. Impressive improvements in exercise 
capacity, both maximal and submaximal, and quality of life (QOL) have been 
demonstrated in several studies[15] however there are a number of unknown 
factors that prevent its widespread adoption. These factors are discussed in 
further detail below.  
 
 Exercise physiology  
Exercise requires the production of force by muscles, which requires the 
breakdown of adenosine triphosphate (ATP). This occurs through the transfer of 
oxygen from the atmosphere to muscle mitochondria to allow ATP production 
through cellular respiration, with the simultaneous removal of the waste product 
carbon dioxide. Internal cellular respiration needs to be coupled to external gas 
exchange to meet the metabolic requirements of the working muscle, this occurs 
through the integrated responses of the cardiovascular and respiratory 
systems[16]. The physiological response to exercise is dependent on the intensity, 
duration and frequency of the exercise as well as environmental conditions[17]  
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As exercise progresses, oxygen uptake (VO2) and carbon dioxide output (VCO2) 
increase. Oxygen consumption can be described by the Fick equation: 
 
VO2 = CO x (CaO2 – CvO2) 
VO2 = Oxygen Consumption, CO = cardiac output, CaO2 = arterial oxygen content, CvO2 = 
venous oxygen content. 
This equation can be expanded to interrogate the individual contributors to a given 
VO2 
VO2 = (SV x HR) x (HB x (SaO2 – SvO2)) 
SV = stroke volume, HR = heart rate, Hb = haemoglobin concentration, SaO2 = arterial 
oxygen saturation, SvO2 = venous oxygen saturation.  
The Fick equation encompasses the requirements for efficient coupling of internal 
and external respiration[18]: 
1. Appropriate intracellular structure, energy substrate and enzyme 
concentration 
2. Effective heart pump function to circulate oxygenated blood 
3. A network of blood vessels capable of distributing blood flow to match local 
tissue gas exchange requirements  
4. Normal Haemoglobin concentration 
5. Normal lung mechanics 
6. Ventilatory control mechanisms capable of regulating arterial blood gas 
tensions and hydrogen ion concentrations.  
The normal exercise response can be broadly divided into the cardiovascular 
response, ventilatory response and the muscle and metabolic response.  
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 Muscle and metabolic response 
Skeletal muscle consists of two basic fibre types, type I and type II, classified on 
the basis of their contractile and biochemical properties[16]. Type I fibres are slow 
twich fibres, with higher levels of myoglobin and mitochondria, therefore 
containing a greater concentration of oxidative enzymes. Type I fibres are 
predominantly involved in longer duration, aerobic exercise. Type II muscle fibres 
are termed fast twitch muscle fibres and have a higher glycolytic potential than 
type I fibres, they are involved in higher intensity, shorter duration activity. Type 
II fibres are further subdivided into type IIa (fast oxidative) and type IIx (fast 
glycolytic), type IIa have higher myoglobin and mitochondrial concentration 
compared to type IIx fibres. Type IIA fibres therefore have a higher resistance to 
fatigue than IIX fibres. 
Four biochemical energy supply systems exist in skeletal muscle 
1. Breakdown of inherent Adenosine Triphosphate (ATP) 
2. Breakdown of phosphocreatine (AT-CP system) 
3. Generation of ATP by anaerobic glycolysis 
4. Generation of ATP by oxidative phosphorylation 
At rest, less than 20% of the body’s resting energy expenditure is attributed to 
skeletal muscle metabolism. Almost all the changes that occur during exercise are 
related to increased energy metabolism, largely within the skeletal muscle. During 
intense exercise, energy expenditure is up to 15-25 times greater than at rest. The 
immediate energy source for muscles during exercise is adenosine triphosphate. 
The inherent intramuscular ATP concentration is small and only sufficient to power 
a short duration of muscle contraction, for example, the concentration of ATP in a 
human quadriceps muscle is typically 8mM [19], while the average rate of ATP 
turnover during moderate intensity knee extension is 24 mM min -1[20]. The rate of 
ATP breakdown ranges from 70 to 140 mM min−1 during isometric contractions of 
various intensity to as much as 400 mM min−1 during intense, dynamic activity. 
Metabolic pathways must therefore be activated during exercise to maintain ATP 
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synthesis to meet the demands of the exercising muscle. Buffering of ATP by 
phosphocreatine extends the duration of activity possible, however sustained 
activity requires continual regeneration of phosphocreatine. This is achieved 
through oxidative processes when there is sufficient tissue oxygen content (Krebs 
cycle and electron transport chain) or anaerobic glycolysis during intense activity, 
when oxygen content is insufficient[21]. Aerobic metabolism is far more efficient 
than anaerobic glycolysis at producing ATP, as demonstrated in Figure 1.1 
 
Figure 1.1 Aerobic and anaerobic metabolism energy generation 
 
Different intensities of exercise result in different metabolic responses (Error! 
Reference source not found.). The contribution of anaerobic sources to exercise 
energy metabolism is inversely related to the exercise duration; energy to perform 
short duration, high-intensity exercise primarily comes from anaerobic sources, 




Figure 1.2: Relative contribution of metabolic systems through different exercise durations 
 
In transition from rest to light exercise, steady state oxygen output (VO2 ) and 
heart rate (HR) are reached within 1-4 minutes in untrained adults, this time may 
be longer in disease states and shorter in highly trained individuals. The time 
required to reach a steady state increases at higher work rates. Because VO2  does 
not increase instantaneously to steady state, anaerobic energy sources contribute 
to meet the energy demand at the beginning of exercise. Once steady state is 
achieved, aerobic metabolism then takes over. In normal environmental 
conditions, steady state VO2 can usually be maintained for 10-60 minutes of 
submaximal continuous exercise [22]. 
In progressive incremental exercise, oxygen uptake increases in a linear fashion 
with work rate until peak VO2 is reached; in the early stages of incremental 
exercise, ATP comes predominantly from aerobic metabolism, during later stages 
of exercise, there is increasing reliance on anaerobic metabolism and blood levels 
of lactate increase. The point at which the rate of lactate production surpasses the 
rate of lactate clearance is known as the anaerobic threshold (AT)[22].  
Short term, high intensity exercise relies on the AT-CP system at durations under 5 
seconds (e.g. weight lifting) and a combination of AT-CP and anaerobic glycolysis 
at durations between 5 to 60 seconds.  
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In recovery from exercise, oxygen consumption remains elevated above resting 
levels. Metabolism is higher after high intensity exercise than light or moderate 
intensity and likewise is more prolonged with longer duration exercise than 
shorter.  
Exercise testing, including measurement of the metabolic response to exercise is 
covered in Chapter 6.  
 Cardiovascular response 
The cardiovascular system responds to exercise by increasing blood flow to meet 
the requirement of skeletal muscle metabolic activity. Increasing oxygen demand 
reflects the energy requirement of the working muscles and increased blood flow 
also serves to allow removal of the metabolic products carbon dioxide (CO2) and 
lactate in order to maintain acid-base homeostasis [23]  These changes are relative 
to the workload faced by the active muscles. 
Cardiac output increases through increases in Stroke Volume (SV) and Heart Rate 
(HR). HR increases initially due to a reduction in vagal tone, followed by increase 
in sympathetic tone. In health, HR rises in a linear fashion with WR and VO2 . SV 
increases almost immediately due to increased venous return from contracting 
muscles, decreased intrathoracic pressure due to increased tidal volume and 
increased cardiac inotropy. It then plateaus at around 50% of maximum WR; 
further increases in CO thereafter are through increasing HR. At peak exercise, SV 
may decrease due to reduced diastolic filling time. The pulmonary vascular bed 
dilates to accommodate the increased RV SV, without significant increase in 
afterload. 
In addition to increased CO, blood flow is diverted to exercising muscles from the 
skin, splanchnic, renal and hepatic circulations. Cerebral blood flow is maintained. 
Local blood flow distribution is determined by the autonomic nervous system and 
local humoral control, with endothelial nitric oxide resulting in skeletal muscle 
vasodilation. 
There is a linear rise in systolic blood pressure (BP) with increasing WR. BP is 
directly related to cardiac output and peripheral vascular resistance and therefore 
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can provide non-invasive information about cardiac performance during exercise. 
Mean pulmonary artery pressure (mPAP) rises during exercise due to increased CO 
and increased left atrial pressure (LAP). The mPAP-CO relationship during exercise 
is used as a surrogate for total pulmonary vascular resistance (TPR). An abnormal 
exercise response is felt to be present when TPR is greater than 3 WU and mPAP is 
³ 30mmHg [24] 
 Ventilatory response 
At rest, minute ventilation (VE) is approximately 6L/min in a healthy man. 
Ventilation must increase appropriately to  maintain arterial oxygen tension and 
eliminate the H+ associated with CO2 and lactate. The rate of increase is linear to 
VO2  until AT is reached, after which VE increases more rapidly than VO2 . At low 
work rates, increasing ventilation is achieved primarily through increases in tidal 
volume, beyond AT, respiratory rate increases to a greater extent. At maximal 
exercise, VE increases 15 to 25 fold from resting values.  
The ventilatory system is not normally the limiting factor to peak aerobic exercise,  
however in some healthy individuals exercise induced arterial hypoxaemia (EIAH) 
can occur. EIAH can occur in untrained individuals[25] but is more prominent 
highly trained athletes at high exercise intensities (>80% VO2 max), particularly if a 
large proportion of muscle mass is engaged in the exercise process[26]. 
 Factors affecting exercise performance 
The limit to peak aerobic exercise capacity in most healthy untrained adults has 
traditionally been attributed to the cardiovascular system. Exercise limitation is 
more complex than this however, and a number of factors must be taken into 
account including technical, physiological, social and psychological factors[27].  
The traditional and widely held model of “peripheral fatigue” or “cardiovascular” 
exercise limitation was first proposed by Archibald Hill in 1923. This model 
theorises that an inadequate supply of oxygen to the heart causes myocardial 
ischaemia, this limits cardiac output and means skeletal muscle blood flow is 
inadequate to match the high skeletal muscle oxygen demands during maximal 
exercise[28, 29]. A resulting skeletal muscle anaerobiosis then causes lactic acid to 
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accumulate, which impairs skeletal muscle relaxation, ultimately terminating 
exercise.  
A central governor model has been proposed more recently as an alternative 
mechanism of exercise limitation, by Noakes et al[30]. The model proposes that it 
is the central nervous system maintains homeostasis in all bodily systems during 
exercise, by integrating both psychological inputs (e.g, motivation, previous 
experience, self belief, expectations) and physiological inputs (e.g. hydration 
status) to then “feed forward” to regulate the number of motor units recruited by 
the exercising muscles, thus adjusting metabolic demands. The central nervous 
system simultaneously receives physiological “feedback” from all organs,  in order 
to maintain homeostasis and modify exercise behaviour. Thus it is the central 
nervous system that limits exercise performance in this model.  
 Exercise limitation in PAH 
Exercise intolerance is a hallmark symptom of pulmonary hypertension. 
Traditionally, exercise limitation in PAH has been attributed predominantly to 
impaired right ventricular (RV) function and an inability of the heart to increase 
stroke volume (SV) in response to exercise [31]. Disease targeted therapy improves 
SV by reducing pulmonary vascular resistance (PVR) and therefore afterload[32], 
with combination drug therapy being superior in this regard[33]. Despite advances 
in medical therapy, most patients remain symptomatic on optimal drug treatment, 
with the vast majority of patients being in WHO functional class III in the 2019 UK 
PH National Audit [34]. This lack of improvement in exercise tolerance suggests 
additional mechanisms other than poor SV are responsible for exercise limitation. 
In addition to a high symptom burden, survival remains poor, with 40% survival at 5 
years for group 1 patients[35]. It is therefore desirable to explore the persistent 
exercise intolerance in PAH to identify possible pathways that may be amenable to 
therapeutic intervention and this will be explored throughout the thesis in a 
systems based approach. 
Examining the processes that underpin efficient exercise reveals possible 
mechanisms for persistent exercise intolerance in PAH. Pathological changes in 
PAH that may be potentially linked to exercise intolerance in PAH are summarised 
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in  Table 1.2. Chapters 5 to 9 go on to describe the changes in muscle function, 
respiratory physiology and cardiovascular function and exercise capacity in PAH in 
a system based approach and explore the role of exercise therapy in modulating 
these pathological changes.  
Robust data do not presently exist to support the relative contributions of the 
problems presented in Table 1.2 to exercise intolerance in PAH, nor have studies 
to date explored psychological and behavioural contributions despite the high 
prevalence of psychological and psychiatric comorbidity in PAH[36].  
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Table 1.2: Potential mechanisms of exercise limitation in PAH 
Exercise Requirement  Pathology impairing 
exercise performance in 
PAH 
Appropriate intracellular structure, energy 
substrate and enzyme concentration 
Reduction in skeletal muscle 
oxidative enzyme activity. 
Reduced mitochondrial 
function [37] 
Effective heart pump function to circulate 
oxygenated blood 
Impaired stroke volume 
response to exercise and 
chronotropic 
incompetence[38]. 
A network of blood vessels capable of 
distributing blood flow to match local tissue 
gas exchange requirements 
Microvessel rarefaction at a 
muscle level[39]. 
Pulmonary arterial 
vasculopathy and vascular 
bed obliteration, resulting in 
V/Q mismatch[40]. 
Normal Haemoglobin concentration High prevalence of iron 
deficiency and anaemia[41] 
Normal lung mechanics Respiratory muscle 
weakness[37] 
Ventilatory control mechanisms capable of 
regulating arterial blood gas tensions and 
hydrogen ion concentrations 
High prevalence of 




 Exercise prescription 
Exercise prescription ranges from optimising performance in athletes to disease 
prevention and treatment of chronic illnesses. Prior to an exercise prescription 
being made, an individual must have an assessment of cardiovascular and 
musculoskeletal fitness along with an assessment of comorbidities. It is important 
that exercise prescription is tailored to the individual and the benefits of exercise 
are balanced with risks, including injury and aggravation of any underlying medical 
condition[22]. 
Exercise prescription is based on 5 principles: type, duration, frequency, intensity, 
and volume. Type refers to mode of exercise training, with the main forms being 
aerobic (i.e. endurance training), resistance (i.e. strength training), flexibility, and 
balance. The length and number of exercise sessions performed within a given 
time frame, are described by duration and frequency, respectively.  
Generic prescription recommendations for the initiation of exercise programmes 
have been made by the American College of Sports Medicine (ACSM) [22]. The 
exercises used in the study “The effect of adding exercise therapy to optimal 
treatment in pulmonary hypertension” used aerobic and resistance exercises, 





Table 1.3 Adapted from ACSM recommendations for exercise prescription 
Type Frequency Intensity Time/Duration Examples 
Aerobic 
(Endurance) 
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Has not been 
determined. 
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 Aerobic exercise prescription  
Intensity is the level of effort being exerted by the participant and can be 
measured in a variety of ways[22]. Common measures of aerobic intensity include: 
• The Borg Rating of Perceived Exertion scale  
• Target heart rate: % Maximum heart rate, Karvonen Formula or Heart Rate 
Reserve (HRR) 
• Metabolic Equivalents (METS) 
• Percentage of peak VO2 
Examples of these measures in quantifying exercise intensity are summarised in 
Table 1.4 
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Modified Borg (0-10) < 5 5-6 ≥ 7 
HR max 50- 63% 64- 76% 77-93% 
% peak VO2 20-39% 40-59% 60-84% 
 
The dosage of an aerobic exercise programme is a function of the frequency (F), 
intensity (I) and duration (time) (T) of the exercise performed in combination with 
the type (T) of activity, the FITT principle[43]. The level of intensity and 
frequency required to generate improvements in an individuals fitness is 
dependent to a large extent on their baseline level of fitness, for example Swain 
et al found that subjects with a relatively low VO2 under 40 mL.Kg-1.min-1 were 
successful at increasing peak VO2 after completing an exercise programme at low 
intensity (30% peak VO2 or less) compared to subjects with a VO2 of 40-50 mL.Kg-
1.min-1, who demonstrated no improvement in peak VO2 at this intensity [44].  
In terms of optimising benefits from an aerobic exercise programme, it has been 
demonstrated that interval training (repetitions of short periods of vigorous 
intensity (e.g. 2 minutes) interspersed with recovery or low intensity (e.g. 5 
minutes)) results in greater improvements in peak aerobic exercise capacity, in 
comparison with continuous training at low, moderate or vigorous intensity in both 
health and chronic medical conditions and also appears to be safe[45, 46]. The 
ACSM therefore recommend the incorporation of interval training into exercise 
programmes.  
 Resistance exercise prescription 
A resistance programme can be adjusted depending on the goal of the programme, 
with heavier load and lower repetitions for increasing strength (< 8 repetitions) 
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and higher repetitions with lighter load (> 15 repetitions) if endurance is the 
aim[22].  
 Progression of exercise prescription  
Progression involves some or all of increasing the frequency, intensity, and 
duration of an exercise programme. Advancement of an exercise program should 
be incremental to encourage participant adherence and avoid injury. Overall 
volume should be monitored for adverse effects and decreased if necessary. 
Aerobic exercise is progressed by initially increasing the duration of each session 
by 5-10 minutes every 1 to 2 weeks over the first 4 to 6 weeks, then increasing the 
frequency and intensity as tolerated over subsequent months[43].  
Resistance exercise is progressed by increasing repetitions before increasing load. 
Once the maximum repetitions for a target range have been achieved, load can be 
increased by approximately 5% so that no more than the lower limit of repetitions 
can be performed.  
 Exercise therapy in disease states 
Wide-ranging beneficial effects of exercise and exercise therapy exist in a variety 
of chronic illnesses and these are outlined below in sections 1.6.1 and 1.6.2. Left 
heart disease and chronic pulmonary diseases such as Chronic Obstructive 
Pulmonary Disease (COPD), share many common features with PAH including 
exercise intolerance, fatigue and dyspnoea. Additionally, pathophysiological 
abnormalities such as myopathy, autonomic dysfunction and inflammation are 
common in both conditions. Exercise therapy has been more widely investigated in 
these diseases, with established clinical guidelines regarding its role[47, 48]. It is 
therefore of interest to explore the beneficial effects and mechanisms of these 
benefits in chronic cardiorespiratory conditions. There are clear differences 
however, between the optimum mode of training and the mechanisms by which it 
exerts its beneficial effects between different disease groups, therefore 
highlighting the need for dedicated research for individual disease entities.  
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 Exercise therapy in left heart disease 
In medically stable patients with left ventricular failure, exercise therapy has been 
shown to be safe and efficacious across a wide range of aetiologies, age groups, 
ethnic groups and disease severities [49]. Exercise capacity and health related 
quality of life improve, hospital admissions are reduced [50] improvements are also 
seen in serum markers of inflammation [49] and autonomic function[51] 
Improvements in exercise capacity are related to the exercise intervention, with 
different results seen in resistance versus aerobic exercise and more marked 
improvements in high versus moderate intensity exercise. In recent years, in 
addition to continuous exercise training, high-intensity interval training and 
pyramid training have effectively been established for coronary artery disease 
(CAD) patients. [52].  
 Exercise therapy in chronic respiratory conditions 
Pulmonary Rehabilitation is established as a key component in the management of 
many chronic respiratory conditions and more recently as a pre-operative adjunct 
to surgery in lung cancer [53], with improved longer term post-operative exercise 
capacity and function. The main body of literature relates to COPD, with clear 
evidence of benefit in exercise capacity, quality of life and symptoms [54], 
positive effects exist in other conditions such as interstitial lung disease, but with 
relatively a smaller body of evidence compared to COPD[55]. As is seen in PAH, 
there is clear evidence of cachexia, inflammation and skeletal muscle dysfunction 
in COPD, with potential epigenetic mediated improvements with exercise 
therapy[56] 
Unlike left heart disease, increasing exercise intensity during interval training does 
not appear to provide additional benefit, compared with moderate intensity 
exercise in COPD[57]. Despite equivalent improvements in symptoms, resistance 
training appears to have a less potent effect on skeletal muscle oxidative function 
than aerobic training. Limited data suggest that neither resistance or aerobic 
training result in significant improvements in vascular function or capillarisation 
[58].  
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 Exercise therapy in PAH 
Exercise therapy in PAH has a smaller body of evidence in comparison to other 
chronic cardiorespiratory conditions. Historically, exercise in PAH had been viewed 
as hazardous due to potential harm from increased RV afterload [59] and it was 
recommended that physical activity was minimised, however no evidence existed 
to support this recommendation.  
Over the past decade, it has been demonstrated that exercise training in PAH can 
improve exercise capacity and quality of life (QOL). Exercise training has been 
shown to result in more significant improvements in exercise capacity and QOL 
than the majority of pharmacological therapies[60], with reassuring safety and 
health economics [61]. The level of evidence is now sufficient that the 2015 
ESC/ERS guidelines on the management of pulmonary hypertension, recommended 
supervised exercise training for stable PH patients (class II, level of evidence B) 
[5]. The evidence supporting this recommendation is discussed below in section 
1.6.3.1 
 Mode of training: exercise type, duration, setting and outcome 
measures 
Within the current literature, a variety of approaches to delivering exercise 
therapy have been adopted, with exercise training being initiated either in an 
inpatient hospital setting (11 studies) or as an outpatient based programme (14) 
with 12 published outpatient hospital programmes or less commonly, entirely home 
based approaches (2). These studies are summarised in Table 1.5, including 
outcome measures, specific PH subgroups studied, duration of exercise, exercise 
type, monitoring of study participants and trial design. The majority of randomised 
control trials (RCTs) have been conducted at a single centre in Heidelberg, 
Germany, therefore this protocol is referred to in Table 1.5 as the “Heidelberg 
model”. This specific exercise protocol is described in further detail in section ‘ 
Personal experience: training in exercise rehabilitation1.6.3.3’.  
Most studies have utilised the 6MWD as a primary outcome measure, along with a 
measure of QOL, most commonly SF-36. Few studies have utilised endurance tests 
as outcome measures despite the majority of exercise programmes employing 
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aerobic and low intensity exercises. In COPD, endurance tests such as the 
continuous work rate ergometer test and the endurance shuttle walk test  are 
more responsive to interventions (both pharmacological and exercise based) than 
incremental tests and the 6MWT[62]. There is less evidence for endurance testing 
in PAH, however it is possible that the same effect may be seen. There is a 
suggestion that this may be the case in the study published by De Man [63], where 
quadriceps endurance improved significantly after an outpatient exercise 
programme but no improvements were seen in peak VO2 or the 6MWD. Only one 
study has included invasive haemodynamic measurements on exercise[64], this was 
a step wise incremental protocol that was uniform amongst all participants, 
despite widely ranging exercise capacity, therefore limiting the value of the data 
obtained. Given the critical role of the RV and pulmonary circulation on prognosis, 
exercise intolerance and symptoms in PAH, it would be highly desirable to 
investigate this area further. The ability to develop an appropriate exercise testing 
protocol during right heart catheterisation is limited by the fact that this test is 
generally performed in the supine position and it is unknown to what extent 
exercise capacity is affected by this posture and what physiological changes 
accompany this, this is discussed further in Error! Reference source not found.. 
Further research is therefore required to establish these differences in order to 
formulate an optimal protocol for exercise right heart catheterisation. 
PAH and CTEPH are the most represented PH subgroups within the current 
literature, the majority of studies have included more than one sub-group, in order 
to have sufficient power, reflecting the relatively low incidence of IPAH. 
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BP: blood pressure; ECG: electrocardiogram; HADS: Hospital anxiety and depression 
score; HR: heart rate; SaO2: oxygen saturation; CPET: cardiopulmonary exercise 
testing; RCT randomised control trial; SGRQ: St George’s Respiratory Questionnaire. 
Content adapted from the ERJ 2019 clinical statement on exercise training in Pulmonary 
Hypertension. [88] 
 
 Adverse events 
There is no direct evidence from human studies that exercise in PH is harmful, 
however safety is a logical concern. Physiologically, exercise results in increased 
pulmonary artery pressures and therefore could potentially precipitate right heart 
failure in PH patients[89]. Additionally some patients may be at risk of exercise-
induced hypoxaemia and malignant arrhythmia[90], such as those with congenital 
heart disease.  There have been no human studies published of exercise training in 
patients with clinically unstable PH, however in an animal model, exercise training 
significantly reduced the survival of rats that received higher monocrotaline 
dosage representing a progressive form of PH compared to those with stable PH, 
implying that exercise is potentially harmful in unstable PH[70]. Careful patient 
selection and close monitoring are therefore very important.  
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The recently published European Respiratory Journal guidelines on exercise 
training in PAH [91]comprehensively reviewed adverse events in a pooled analysis 
of 674 patients participating in exercise rehabilitation studies, with 511 in an 
inpatient setting and 138 in an outpatient setting. Events were classified as related 
to exercise or unrelated to exercise. No cases of death were reported. The most 
common adverse event related to exercise was reported as desaturation in 16 of 
the 674 participants (2.4%), followed by dizziness (1.2%), arrhythmia (0.4%), 
hypotension (0.1%), syncope (0.1%) and fatigue (0.1%). Clinical worsening of 
symptoms and heart failure related to exercise therapy were not reported in any 
of the studies included in the pooled analysis.  
Of adverse events not directly related to exercise, the most frequent adverse 
event (3.4%) was respiratory tract infection, which led to antibiotic treatment and 
short discontinuation of the training. Other reported events included syncope 
(0.3%), Pre-syncope (0.7%), mild haemoptysis (0.1%), other infections (0.2%).  
 Personal experience: training in exercise rehabilitation and 
development of study protocol 
To gain further experience in the rehabilitation of patients with pulmonary 
hypertension, I spent two weeks in Heidelberg, Germany, under the supervision of 
Professor Ekkehard Grünig. This placement involved attending two sites, the Thorax 
Clinic in Heidelberg and a rehabilitation centre, Rehaklinik Heidelberg-Königstuhl, 
where there is an established rehabilitation programme for patients with chronic 
cardiorespiratory conditions, including PH.  
At the Thorax clinic, patients were referred from across Germany for consideration 
of suitability to take part in the pulmonary hypertension specific exercise 
rehabilitation programme at the Rehaklinik in Königstuhl. The programme was run 
by Professor Grünig, with a team of specialist physicians and physiotherapists. I 
attended the Thoraxclinic and shadowed the PH physicians during their assessment 
and investigation of patients referred. A typical patient journey involved a clinical 
assessment by PH physician, this included WHO functional class determination, 
current medication, symptoms and physical examination. Along with this 
assessment, some or all of the following investigations were performed if the 
patient was deemed suitable to participate: CMR, RHC, exercise echo using a 25 
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watt stepwise protocol and 6MWT. Once clinical stability was confirmed by means 
of the above assessments, patients were enrolled in the exercise programme and 
given a date to attend for this in the forthcoming months.  
At the Rehaklinik in Königstuhl, I shadowed a group of patients for ten days in total 
to observe typical components of rehab programme. The exercise programme 
observed consisted of a three week residential programme consisting of four daily 
sessions that were a combination of bicycle ergometer, walking or treadmill, 
education sessions, progressive muscle relaxation sessions, respiratory muscle 
training and resistance exercises. The initial exercise prescription was completed 
by a PH physician and monitored and titrated by specialist physiotherapists. 
Sessions took place in small groups of 8-10. Each of the following were performed 
five times per week for the first three weeks of a fifteen week programme 
• Bicycle ergometer sessions: intervals of 1 min higher intensity (~ above 
anaerobic threshold) and 30 seconds lower intensity (~ below anaerobic 
threshold) for 10–25 min depending on the fitness of the participant.  
• Walking with “positive mental imagery” (60 min) (described below) 
• Resistance exercise; low-weight dumbbell training or body weight upper and 
lower limb strength training (30 min) 
• Respiratory muscle training (30 min) 
• Progressive muscle relaxation – 1-2 times per week, (30 min) 
I conducted informal interviews with specialist physiotherapists in order to learn 
about individual components of the exercise programme and how parameters were 
set, including training zones, safety parameters and how patients were monitored. 
A comprehensive physical assessment had been performed at the Thorax clinic 
prior to the patient starting the programme and all aerobic sessions were 
monitored either using a pulse oximeter (walking) or telemetry with continuous 
monitoring (bicycle ergometer). These assessments were used to inform the target 
power for bicycle ergometer sessions and guide the duration and intensity of 
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walking session, the latter being judged subjectively by experienced 
physiotherapists.  
When the three week residential rehabilitation programme was completed, 
patients performed a 6MWT and were provided with an exercise programme for 
home, this consisted of around 1-1.5 hours of cumulative exercise daily, including 
the components above. A physiotherapist called the patients every 1-2 weeks to 
determine if the programme needed altered. Patients then returned for a final 
6MWT and assessment of quality of life, using the SF-36 questionnaire, to 
determine the effectiveness of the programme.  
Mental imagery was incorporated into the walking programme in Heidelberg. 
Mental images are defined are cognitive constructions of hypothetical events or 
reconstructions of real events. Different types of mental imagery can promote 
goal-directed behaviours; it has been shown in a healthy adult population that 
regular exercisers frequently use imagery and that by employing imagery 
exercisers can learn exercise tasks (technique imagery) and set appearance-related 
goals (appearance imagery)[92]. Duncan et al demonstrated that targeted imagery 
interventions could be used to increase self-efficacy for exercise among female 
exercise initiates enrolled in a 12-week cardiovascular exercise programme[93]. 
Examples of mental imagery used in the Heidelberg were of successfully 
completing frequently encountered physically challenging situations such as an 
incline in the participants area of residence, or a flight of stairs. The participant 
was instructed to visualise themselves having successfully completed the hill or the 
flight of stairs before the session began and a representative terrain at the 
rehabilitation facility was then used to practice walking. 
In terms of developing a protocol for the study “The effect of adding exercise 
training to optimal therapy in Pulmonary Arterial Hypertension”, the two main 
influences for this were the training I received in Heidelberg, along with the 
current evidence demonstrating the “Heidelberg model” appeared to be the most 
consistent and result in the most significant improvements in exercise capacity and 
quality of life. This led to a modified version of the Heidelberg exercise protocol 
being used, this protocol is described in detail in Chapter 4. 
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  Current barriers to implementing exercise therapy in PAH  
Despite being widely recognised as a safe, efficacious and cost-effective therapy 
[91], exercise therapy is not part of standard care in the UK and many other 
European countries. There are several unanswered questions that pose a barrier to 
its widespread implementation; these fall into three main domains: 
1. Relationship with drug therapy  
With robust risk stratification and goal-orientated therapy now being the standard 
of care, the majority of patients with PAH should be on combination therapy at an 
early stage [94]. Current evidence supporting exercise therapy for PAH is based on 
studies pre-dating this treatment strategy and consequently the majority of 
patients are on monotherapy [61]. No study has exclusively assessed the effect of 
exercise training in addition to optimal PAH therapy. 
2. Optimal mode of delivery  
The optimal mode of delivering exercise therapy has not been definitively 
established. This remains a key research question that is essential to answer in 
order to deliver an effective treatment. Current evidence demonstrates that the 
“Heidelberg model” adopted by Mereles et al [61], is more likely to be efficacious 
in improving exercise capacity compared with outpatient rehabilitation [63]. In 
order to best ascertain what components of the programme are essential and what 
components can be excluded or refined, a clearly structured programme that is 
highly likely to be efficacious first needs to be adopted and the physiological and 
biological changes associated with improvement tested. It can then be refined to 
exclude the less useful components and enhance the general applicability by 
reducing the time required at hospital for the patient and the resource and time 
burden for the NHS.  
3. Potential mechanisms underlying improvements in exercise capacity and quality 
of life with exercise therapy 
Limited data exist to explain the beneficial effects of exercise training in PAH. 
There are a number of pathophysiological and pathobiological processes in PAH 
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that may impair the exercise response. These factors have not been studied in 
relation to the effect of exercise training. In order to best prescribe a PAH specific 
training programme, it is essential that the underlying mechanisms of improved 
exercise capacity are fully understood; this will dictate the content, duration and 
intensity of exercise. It is likely that it affects some or all of the factors listed 
below, Chapters 5-9 will discuss these factors in detail, they are summarised 
briefly below. 
Respiratory muscle function 
Inspiratory and expiratory muscle strength are reduced in IPAH, independently of 
haemodynamic severity, leading to a reduced ventilatory capacity[95]. Specific 
respiratory muscle training has been shown to be an important component in 
exercise training programmes.[96].  
Cardiac function 
In animal models, exercise training reduced RV hypertrophy and pulmonary artery 
remodelling, suggesting a direct effect on the pulmonary vasculature and 
myocardium[97, 98]. Exercise training in patients with stable PH on treatment 
improved cardiac index and reduced mPAP[64]. In rats with stable monocrotaline 
induced PAH, exercise trained rats had increased capillary density in 
cardiomyocytes and improved exercise endurance compared with sedentary 
matched controls.[99]  
Autonomic function 
A higher resting heart rate (HR), reduced heart rate recovery (HRR), reduced HR 
variability (HRV)[100] and evidence of altered baroreceptor sensitivity (BRS) 
support autonomic dysfunction in PAH. These findings are independent of 
haemodynamic severity but correlate with peak oxygen uptake (VO2 )[38] 
Systemic inflammation and metabolism 
Inflammatory cytokines may contribute to proteolysis and damage contractile 
proteins involved in skeletal muscle function. Cytokines such as interleukin (IL)-6, 
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IL-8, IP-10 and monokine induced interferon-γ (MIG) are elevated in the serum of 
IPAH patients. In chronic thromboemolic pulmonary hypertension (CTEPH), IP-10 
negatively correlates with cardiac index and 6MWD [101]. In left ventricular 
failure, cytokines such as TNF-alpha reduce with exercise training and correlate 
with improved exercise capacity [102].   
Epigenetics 
Systemic angiogenic defects contribute to skeletal muscle microcirculation 
rarefaction and exercise intolerance, independently of haemodynamic severity. 
Reduction in the expression of pro-angiogenic miR-126 in the skeletal muscle of 
humans with PAH correlates with capillary density and peak VO2  and is 
significantly reduced compared with healthy controls. In a PAH rat model, miR126 
down regulation reduce capillary density and this correlates with exercise 
capacity.[103] In health, change in expression of miRs such as miR-20a correlate 
with changes in VO2  following exercise training[104].  
 
 
Figure 1.3 Potential mechanisms for improved exercise capacity in PAH 
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 Thesis Aims 
1. Establish the demand for exercise therapy in the Scottish PAH patient 
population and potential barriers to its uptake 
2. Determine the degree to which cycle ergometry exercise capacity is reduced 
in the supine position in order to determine an appropriate protocol to use 
during exercise right heart catheterisation.  
3. Determine whether exercise therapy can enhance exercise capacity and 
quality of life when undertaken in addition to optimal therapy in PAH in a 
UK setting. 
4. Generate pilot data on the mechanisms of exercise limitation and the 
factors that improve with training, assessing: 
I. Exercise capacity 
II. Cardiac function  
III. Gas exchange, lung function and respiratory muscle function 
IV. Clinical markers of muscle function and serum and muscle markers of 
muscle function  
V. Profile of systemic inflammation and metabolism 
 Original hypotheses of thesis 
Sufficient demand exists amongst the PAH population in Scotland to pursue 
research into establishing a PAH–specific exercise rehabilitation programme.  
Supervised exercise training in patients with stable PAH on optimal therapy in a 
Scottish health care system is safe, feasible and improves exercise capacity, 
quality of life and right ventricular (RV) ejection fraction. 
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The improvement in exercise capacity occurs for reasons beyond improvements in 
cardiac output and RV function  
Exercise training affects the control mechanisms for skeletal muscle function. 
Improvements are due to changes in the inflammatory cytokine profile and in 
expression of micro-RNA associated with angiogenesis, myogenesis and 
inflammation. 
Endurance testing is a more sensitive tool for detecting change following exercise 
therapy in PAH than incremental exercise testing. 
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Chapter 2 Assessing the demand for exercise 
therapy in a Scottish PAH population 
 Introduction  
Over the past 10 years, the body of evidence supporting exercise training as an 
effective treatment for PAH has grown significantly, such that the 2015 consensus 
statement on the management of PAH upgraded its recommendation to class I, 
level A. The consensus recommends that exercise training of PAH patients should 
be undertaken by centres experienced in both the management of PAH and 
rehabilitation of compromised patients[105].  Despite this, dedicated exercise 
training programmes do not exist in the UK and many other European countries. In 
these countries, exercise training is delivered to a small, unselected population of 
PH patients in an ad hoc manner, by services specialised for chronic obstructive 
pulmonary disease or left heart failure.  
Several factors may hinder the widespread adoption of specialised exercise 
training for patients with PAH. Firstly, the infrastructure and expertise that exists 
in German rehabilitation clinics, where the much of this research has been 
conducted, does not exist in many other centres, raising the question of whether 
these results can be replicated elsewhere.  Secondly, the successful approach 
described by Mereles et al [60] involved an initial intense inpatient phase followed 
by a monitored outpatient period, using multi-modality, PAH specific 
rehabilitation.  Such an approach is demanding both on patient time and hospital 
resources.  The optimal structure for a rehabilitation programme has not been 
established and other investigators have evaluated lower intensity exercise 
programmes, with less successful outcomes.  De Man et al utilised existing 
outpatient cardiac rehabilitation facilities and observed improved muscle 
endurance but failed to show an improvement in six minute walk distance [63] 
suggesting that there are advantages to the initial intensive residential approach.  
Finally, no long-term data exist to support a prognostic benefit.  
The Scottish Pulmonary Vascular Unit (SPVU) in Glasgow serves a population of 5.3 
million and is the national referral centre for PAH in Scotland, with a prevalent 
population of 47 per million[106].  Scotland is a geographically challenging country 
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to deliver intensive health care in certain sub-populations, due to low population 
density and large distances between tertiary centres and remote areas. To 
establish a training programme for Scottish PAH patients, it must first be 
determined that there is demand amongst the patient population for such a 
treatment and established potential logistical difficulties.   
 Aims 
The aims of this study were  
1. Establish the demand for a dedicated PAH specific exercise rehabilitation 
programme in the Scottish population in order to determine the viability of 
establishing a PAH specific rehabilitation programme.  
2. Explore potential barriers to the uptake of exercise rehabilitation 
 Methods  
The West of Scotland Research Ethics Committee assessed the research proposal 
and deemed that formal ethical review was not required.  
At SPVU, demographic and clinical data is prospectively maintained on the 
InfoFlex® database, Heretfordshire, UK by a clinical data manager. The Infoflex 
database was used to generate a list of suitable survey participants in September 
2014, based on the following criteria:  
• WHO functional class I-III 
• 6MWD  ≥ 150m 
• PAH diagnosed by right heart catheterization (mean pulmonary artery 
pressure ≥ 25mmHg*, pulmonary capillary wedge pressure ≤15mmHg and 
PVR > 3 WU) (*prior to the 2019 proposed new haemodynamic definition of 
PAH) 
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Patient interest and willingness to participate in a PAH-specific exercise 
rehabilitation programme of 2 weeks residential rehabilitation at the Golden 
Jubilee National Hospital, followed by 12 weeks outpatient, remotely monitored 
rehabilitation mirroring that of Mereles et al[60] was assessed. The programme 
described consisted of aerobic and resistance exercises, respiratory muscle training 
and education. The full survey can be found in Appendix 1: Patient survey letter. 
Demographics and routinely measured clinical and prognostic variables were 
collected from the database 
• RHC haemodynamics at diagnosis 
• Most recent quality of life score (EmPHasis-10) 
• Most recent 6MWD 
• NTproBNP 
• PAH subtype  
• WHO functional class 
• Use of oxygen therapy. 
 Statistics  
Data are presented as mean (SD) for normally distributed data. NT-proBNP data 
were not normally distributed therefore a log transformation was performed to 
produce normal data. Paired analyses were performed using an unpaired t-test. 
Comparisons of unpaired categorical variables were performed with a chi-squared 
test. IBM® SPSS® Statistics software was used to perform all statistical analyses.  
 Results  
224 patients met the inclusion criteria. These patients were contacted by mail 
with a copy of the survey.  
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Forty three percent of patients (96/224) responded to the survey. 62.5% (60/96) 
were interested in all components of the rehabilitation programme (residential and 
outpatient), a further 11.5% (11/96) were interested in outpatient rehabilitation 
only.  
Those interested in the rehabilitation programme tended to be younger, with 
better functional class and were less likely to be on oxygen therapy. There were no 
significant differences between groups in baseline haemodynamics, quality of life 
or NTproBNP (Table 2.1). Some participants did not identify themselves, therefore 
it was not possible to phenotype them; 6 of the “not interested in rehabilitation” 
responders and 2 of the “interested in rehabilitation responders. 












Thermodilution CO (L/min) 
 
45.3 ±12.47 
64.1 ± 8.9 
4.5 ± 1.33 
 
44.7 ± 14.40 
64.7 ± 8.63 












26.0 ± 19.4 
7.2 ± 6.7 
10.8 ± 6.4 
9.3 ± 7.1 
22.07 ± 15.2 
 
31.6 ± 18.2 
10.0 ± 7.9 
10.6 ± 6.1 
11.2 ± 6.8 







6 minute walk distance 
(metres) 
348 ± 129 381 ± 111 0.250 
Age 68.1 ± 13.1 56.42 ± 13.32 0.001 
Log NT-pro BNP 2.62 ± 0.67 2.57 ± 0.60 0.707 









Group 5  
 
23%    (7/30) 
30%    (9/30) 
6.7%   (2/30) 
6.7%   (2/30) 






12.1%  (7/58) 
12.1%  (7/58)  
6.9%   (4/58) 
24.1% (14/58) 
1.7%   (1/58) 
3.4%   (2/58) 

















Oxygen therapy 5/32 (15.6%) 3/61 (4.9%) <0.005 
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Additionally, patients provided free text responses. Many reported enthusiasm 
towards the proposal and felt it would improve their confidence, overall health 
and quality of life. The following reasons were cited in patients who felt at least 
one aspect of the programme would be unsuitable, Figure 2.1:  
• Too far from home, 19.4% (7/36) 
• Work or carer commitment 27.8% (10/36) 
• Too old or too many comorbidities 27.8% (10/36) 
• Too big a time commitment 5.6% (2/36) 
• Active enough 8.3% (3/36) 
• Equipment in their house would be unacceptable 2.8% (1/36) 
• No reason given 8.3% (3/36) 
 
Figure 2.1 Reasons given for not wishing to participate in PAH-specific exercise rehabilitation 
 
 
Too far from home (19.4%) Work or carer commitment (27.8%)
Age/Comorbidity (27.8%) Time commitment (5.6%)
Active enough (8.3%) Equipment in their house unacceptable (2.8%)
No reason given (8.3%)
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 Discussion  
The population included in this study had typical features of pulmonary 
hypertension, with reduced exercise capacity, poor quality of life and 
cardiorespiratory failure. All those included were on optimal disease targeted 
therapy, further underlining the need for additional treatment options for PH 
patients.  
Amongst the population who responded, there was significant interest in a 
dedicated PAH exercise programme, particularly amongst patients with IPAH. 
Exercise rehabilitation in PAH has been shown to improve quality of life and 
exercise capacity across a range of disease sub-types and functional classes. 
Despite this, those who did not show interest in participating, had poorer 
functional class and QOL. From assessment of free text responses, this may be due 
to age or other comorbidities. Additionally, the intensive time commitment 
required in the initial residential phase of the exercise programme appeared to 
discourage those with jobs or carers commitments. 
A concerted effort must be made to ensure patients with a higher burden of 
disease are reassured regarding the safety of exercise therapy in PAH and efforts 
are made from a logistical and rehabilitation perspective to make such an 
intervention more acceptable. Barriers need to be understood and overcome in 
order to deliver exercise therapy to those who are geographically isolated or 
committed to work or carer responsibilities in order to ensure an equitable service 
and deliver effective therapy to those who need it most. Further research is 
needed to establish the optimal timing, structure, content and duration of PAH-
specific rehabilitation. 
 Conclusions  
Sufficient demand exists in the PAH patient population in Scotland to develop a 
PAH-specific rehabilitation programme. Employment, social and geographic factors 
contribute significantly to the proportion of patients who do not wish to consider 
this treatment option. 
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Chapter 3 The ventilatory, gas exchange and 
haemodynamic response to upright and supine 
exercise  
 Introduction  
Standard right heart catheterisation is performed in the supine position. Exercise 
can be performed during right heart catheterisation with the use of a supine cycle 
ergometer. Exercise haemodynamics provide valuable insights into the response of 
the pulmonary circulation and heart to exercise both at an isolated time point and 
in response to treatment. Indications for performing exercise right heart 
catheterisation in PH are:  
1. To assess for “exercise induced” pulmonary arterial hypertension in at risk 
populations with normal resting pulmonary artery pressures: [107-109] 
a. Connective Tissue Disease  
b. Chronic Thromboembolic Disease  
c. Family History or suggestive symptoms / investigations  
2. To assess for occult left heart disease by measuring the pulmonary artery 
wedge pressure before and during exercise 
3. As a research tool to assess the impact of an intervention on the pulmonary 
circulation 
As discussed in Chapter 1, evaluating the response of the pulmonary circulation to 
exercise before and after an exercise rehabilitation programme by means of 
exercise RHC may be pivotal in understanding the mechanisms by which exercise 
capacity may improve symptoms and exercise capacity in PAH. Unlike upright 
standard incremental exercise testing, standardised protocols do not exist for 
exercising in the supine position; there is a paucity of data on the degree to which 
exercise capacity is altered in supine versus erect exercise and the changes in 
physiology that accompany the two different postures. In order to formulate 
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suitable supine exercise testing protocols and interpret results, it is important to 
understand the normal physiological responses to supine exercise and the 
magnitude to which exercise capacity differs from the upright position. 
Although RHC is a standard and necessary test in PH, in studies of healthy 
individuals who do not otherwise require RHC, a non-invasive approach to assessing 
the exercise response is desirable, both to reduce the risk to research participant 
and to increase the ease to which the test can be serially performed.  
Cardiopulmonary exercise testing provides information not only on the degree of  
exercise impairment but also on the relative contribution to that impairment from 
ventilation, gas exchange, and oxygen transport and delivery as discussed in 
Chapter 6.  
Inert gas rebreathing (IGR) is an established technique for the non-invasive 
measurement of CO. It is based on the principle that when rebreathing in a closed 
circuit, the rate at which a specified non physiological gas dissolves in blood is 
proportional to the blood flow through the pulmonary capillaries. The pulmonary 
blood flow (PBF) is equal to the cardiac output in the absence of a significant 
intracardiac or intrapulmonary shunt, therefore CO and stroke volume can be 
calculated. IGR has been validated against the direct Fick method using acetylene 
and mass spectrometry in chronic heart failure[110] and using photoacoustic 
analysis of nitic oxide in pulmonary hypertension against invasive haemodynamics 
and CM [111]. 
IGR and CPET therefore provide reliable and accurate means of non-invasively 
assessing the exercise response and relevant physiological changes that occur 
between the upright and supine position.  
 Effect of body posture on exercise capacity  
Current evidence is relatively sparse and conflicting in terms of the normal 
response to supine exercise in health and disease. Comparisons between studies 
are also difficult as a variety of incremental and endurance protocols have been 
used. Stepwise protocols have the advantages of achieving periods of steady state, 
to allow measurements of gas exchange to be performed and appear to provide 
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similar information in relation to gas exchange[112].  Incremental cycle exercise 
testing in the erect position compared with supine is associated with an increase in 
exercise capacity, both peak VO2 and in total exercise time [113]. The factors 
contributing to this reduction in exercise capacity are discussed below.  
 Ventilation and gas exchange 
When the body position is changed from upright to supine there is a reduction in 
FVC in healthy individuals, variation exists between subjects depending on age and 
sex. The supine position promotes airway closure in dependent lung regions, this 
change is more prominent in older subjects. Movement of the rib cage and 
abdomen also contribute to reduction in FVC.   
At rest, In the supine position, perfusion (Q) is increased to dorsal dependent 
regions, however less is known about the distribution of ventilation (V), with 
limited data to suggest the distribution does not change significantly[114], 
therefore matching between ventilation and perfusion may be impaired in the 
supine position with increased dependent blood flow but reduced ventilation[115]. 
Attempts have been made to discriminate between PAH and CTEPH with resting 
breath-by-breath measurements of VO2 and VCO2 in the supine and erect 
position[116], however the effect of posture on gas exchange has not been studied 
in PAH during exercise.   
In healthy individuals during stepwise erect and supine exercise, the VE/VCO2 slope 
was not affected by posture, however minute ventilation was higher [117]. A small 
study of 9 patients with heart failure demonstrated no difference in perception of 
exertion (RPE) nor the ventilatory response to CO2, but found that peak ventilation 
was higher in the erect position [118]. 
 Cardiovascular function 
At rest, stroke volume is increased in the supine position compared to erect. This 
is a consequence of increased venous return to the right heart from the elevated 
legs[119]. The increased SV is associated with a lower supine heart rate due to 
vagal activation and sympathetic withdrawal.  
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In coronary artery disease, exercising in the supine position versus upright, 
resulted in higher left ventricular end diastolic volumes and pressures, and higher 
stroke volume at rest and during sub-maximal exercise[120]. Earlier studies 
however, demonstrated reductions in supine heart rate during stepwise, 
interrupted exercise, but with no changes in ventilatory parameters or RPE and 
similar HR/VO2  slopes [120]. Less conventional exercise protocols have been 
studied, including leg raises and static forearm exercise, this study suggested that 
SV reduced 5-8% during supine exercise, however did not compare this with erect 
responses [121].  
 Muscle function  
The gravitational effect of exercising with elevated legs in the supine position 
decreases blood flow to the active muscles[122].  
Near infrared spectroscopy (NIRS) non-invasively assess dynamic changes in 
skeletal muscle oxygenation. The NIRS signal provides continuous, non-invasive 
monitoring of the relative concentration changes in oxygenation ([HbO2]), deoxy- 
hemoglobin ([HHb]) and total hemoglobin ([Hbtot]) concentrations[123] 
In a small study of healthy individuals, using constant load cycling and NIRS, found 
that muscle oxygenation was reduced in the supine position, this may be due to 
increased oxygen extraction and did not alter the rate of muscle fatigue compared 
to the same load in the upright position [124]. More recent data using EMG 
demonstrated that fatigue was significantly greater during supine compared with 
upright high-intensity cycling and was accompanied by a reduced activation of the 
exercising muscles[125]. 
 Aims 
Determine the normal cardiovascular and ventilatory responses to erect and supine 
exercise during cardiopulmonary exercise testing (CPET) 
Determine the extent to which exercising in the supine position reduces peak work 
rate in order to inform exercise protocol design in the supine position  
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 Methods 
This study was assessed by the West of Scotland Research Ethics Committee and 
did not require formal ethical approval.  
Inclusion criteria: 
1. No significant current or past medical health problems 
2. No contraindications to exercise testing such as unexplained syncope 
3. Able to provide informed consent 
Thirteen healthy volunteers participated in the study.  Subjected were recruited 
through written and verbal advertisement at Glasgow University Medical School 
and the Golden Jubilee National Hospital. Recruited took place between 
September 2014 and April 2015. The study and all exercise tests were performed in 
the SPVU at the Golden Jubilee National Hospital, Clydebank, Scotland.  
Four exercise tests were performed in total (Figure 3.1). Two maximal incremental 
tests; one erect and one supine. These tests were used to determine the peak 
erect and peak supine work rate. Subjects then performed sub-maximal step-wise 
exercise with inert gas rebreathing (IGR) measurements of pulmonary blood flow at 
20, 40, 60 and 80% of peak work rate. There was a minimum rest period of 24 




Figure 3.1: Protocol for exercise testing 
 
 Incremental cardiopulmonary exercise testing 
Cardiopulmonary exercise testing was performed as described in Chapter 6 using 
the LodeTM electromagnetically braked upright ergometer and the LodeTM supine 
ergometer. Breath by breath measurements were performed using the 
lovemedical® software in upright and the Innocor®, Innovsion, Denmark in the 
supine position.  
In the incremental test, the work rate varied from a ramp of 15 to 30 watts per 
minute and was determined by the study investigator (AM) based on the subjects’ 
level of fitness.  
Comparisons of resting, unloaded and peak variables were made between 
incremental tests. Isotime comparisons were also made, isotime being defined as 
the same time point in loaded exercise between two tests. The ramp rate was the 
same for individual participants between erect and supine tests, therefore isotime 
corresponded to isowork. Highest isotime comparisons were used in this study, 
meaning the highest time point was taken from the test of shortest duration for 
that individual, comparisons were then made using the equivalent time point in 
the test of greater duration (Figure 3.2) 
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Figure 3.2: Illustration of isotime measurements on an incremental exercise test 
 
 Inert Gas Rebreathing with Innocor 
Inert gas rebreathing (IGR) was performed using Innocor®, Innovision, Denmark 
(Figure 3.3). IGR was used to determine pulmonary blood flow and therefore right 
ventricular stroke volume at rest and during exercise. 
 




Prior to each IGR measurement, a Douglas bag was pre-filled with an oxygen 
enriched mixture containing blood soluble 0.5% nitrous oxide (% ) and blood 
insoluble 0.1% sulphur hexafluoride  (SF6). This was obtained by mixing a bolus 
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from a gas bottle containing 94% oxygen, 5% N2O  and 1% SF6 with ambient air. 
Under normal resting conditions, an automated bolus fraction of 10% and air 
fraction of 90% was used to give a gas mixture of 28.3% oxygen, 0.5% N2O and 0.1% 
SF6. The volume in the rebreathing bag was adjusted to accommodate for the 
increasing tidal volume and oxygen demand during exercise. The target volume 
was calculated automatically by the Innocor software and was the highest of the 
following volumes: 44% of predicted vital capacity, averaged tidal volume during 
the preceding five breaths and the volume required to meet the maximum carbon 
dioxide (default 6%) and minimum oxygen limits (default 13%) in the rebreathing 
bag. At higher work rates, the increased oxygen demand was met by either 
increasing the bolus fraction or rebreathing bag volume. 
To perform the test, the subject sealed their mouth around a mouthpiece, a nose 
clip was used to create a sealed circuit from the Innocor machine to the lungs, 
with a gas delivery line and a gas sampling line.  The patient was instructed to 
breathe at a rate of at least 20 breaths/min and empty the Douglas bag during 
each inspiration. Once gas concentrations were stabilised after 2 to 3 breaths, the 
re-breathing test was commenced by AM and the one-way respiratory valve was 
activated. At end expiration the subject inhaled the gas mixture and a 
photoacoustic infrared gas analysed measured the rate of disappearance of N2O 
from the exhaled gas over four to five respirations. This did not take longer than 
30 seconds, to avoid recirculation of N2O. Alveolar N2O concentration was 
normalised for changes in lung volume using SF6 concentration before the start of 
each PBF calculation.  
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Figure 3.4: Normalised N2O concentration against time 
 
PBF was calculated automatically by the Innocor software using the following 
formula 
 
PBF = -b . VL . C1 + C2 
ab 
b = Slope of the regression line  
VL = Total systemic volume (automated calculation from initial and end SF6     
concentration in relation to the volume of the rebreathing bag) 
C1  = Ambient pressure – 47mmHg / 760 mmHg 
C2 = Constant for the absorption of N2O into lung tissue (0.407 STPD x 0.6L) 




Pulmonary blood flow is equivalent to cardiac output, therefore stoke volume 
could be calculated as: 
SV = PBF  
      HR 
 Resting IGR measurements 
At the first visit the subjects were shown how to perform an IGR manoeuvre and 
practice attempts with only air in the rebreathing circuit were performed until the 
patient could perform the test with ease. Before subsequent tests, a practice test 
was performed to confirm familiarity with the technique. 
For supine tests, subjects lay at rest for 10 minutes to ensure the recorded 
measurements were a true reflection of the resting supine state. After the first IGR 
manoeuvre, 5 minutes was given between subsequent tests to ensure N2O washout 
had occurred (<0.002%). The IGR manoeuvres were repeated in the supine position 
until 3 technically acceptable results were obtained. 
 Exercise IGR measurements 
Stepwise exercise was performed in the supine and erect position. 3 minutes of 
rest was followed by 3 minutes of unloaded exercise then a stepwise work rate 
increasing by 20% of peak work rate every 3 minutes until peak exercise (Figure 
3.5). At each increment in the exercise protocol, IGR measurements of PBF and HR 
were taken. If the N2O remained greater than 0.002%, exercise continued at that 
step until full washout had occurred. This was rarely more than 30 seconds beyond 
the allocated 3 minutes.  
 77 
 
Figure 3.5: Inert gas rebreathing measurement protocol, each step was 3 minutes in duration, 
IGR measurements occurred at points marked by the arrow 
 
 
 Statistics  
The primary outcome measure was the difference in peak oxygen consumption 
(VO2) between the upright and supine position. Sample size calculation based on 
the study by Terkelsen et al [117]. With a power of 0.8 and two sided significance 
(α) of 0.05, this generated a sample size of 10. 13 subjects were recruited to 
account for the possibility of non-analysable data and dropouts.  
Statistical analyses were performed using IBM ® SPSS ® Statistics, version 26. 
Comparisons of paired data were made using Wilcoxon signed-rank test given the 
small population size.  No corrections were made for multiple comparisons. P < 
0.05 was considered statistically significant.   
 Results  
Useable data were collected from twelve of the thirteen participants, one subject 
was excluded due to an inability to reliably perform the IGR measurements.   
 
7/11 (63.6%) subjects were male, the average age was 28 (22- 53) and was BMI 
22.5 (19.6 – 29.7).  
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 Exercise capacity 
Peak work rate was higher in the erect position 249 watts (43) than the supine 
position 222 watts (37), p 0.003. VO2 at anaerobic threshold was lower supine 
(1.614L/min) than erect (1.713L/min) (p 0.004) and total exercise duration was 
higher in erect 668 seconds (66) versus 602 seconds (80) in the supine position, 
p0.020. VO2 and RER differences are displayed in Table 3.1 
Table 3.1: Markers of exercise capacity in the supine versus upright position 
VO2 (L/min) Erect Supine p 
Rest 0.43 (0.16) 0.38 (0.04) 0.410 
Unloaded 0.65 (0.10) 0.63 (0.13) 0.814 
Peak 2.9 (0.6) 2.7 (0.4) 0.182 
VO2 ml/kg    
Unloaded 9.5 (1.6) 8.9 (1.6) 0.637 
Peak 42.6 (11) 39.2 (7.3) 0.099 
RER Erect Supine p 
Rest  0.85 (0.11) 0.85 (0.06) 0.937 
Unloaded 0.84 (0.06) 0.83 (0.08) 0.937 
Peak 1.21 (0.1) 1.25 (0.1) 0.185 
 
 Cardiovascular response – CPET  
Heart rate was higher throughout all stages of exercise in the erect position than 
supine (Table 3.2) 
Table 3.2: Cardiovascular response to exercise in erect versus supine position 
Heart rate Erect Supine p 
Rest 80 (12) 66 (11) 0.002 
Unloaded 90 (16) 78 (13) 0.006 
Peak 170 (12) 159 (13) 0.012 
VO2/HR Erect  Supine p 
Rest 5.4 (1.7) 6.1 (1.2) 0.158 
Unloaded 7.2 (1.3) 7.9 (1.4) 0.182 
Peak 17.5 (4.1) 17.3 (2.8) 0.754 
 
 Cardiovascular response – IGR  
Stroke volume was higher in all stages of exercise in the supine position, reaching 
statistical significance in the later stages of exercise. Peak stroke volume was 
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reached at an earlier stage in exercise in erect cycle ergometry than supine (Error! 
Reference source not found.), (Table 3.3, Figure 3.6) 
Table 3.3: Stroke volume response to erect and supine exercise 
SV (mL) at 
different stages 
of peak work 
rate 
Erect Supine p 
Rest SV 72.6 (21.0) 92.2 (23.6) 0.116 
Unloaded SV 87.6 (4.7) 101.2 (17.1) 0.144 
20% SV 104.7 (14.0) 103.7 (12.0) 0.878 
40% SV 103.2 (10.9) 103.6 10.9) 0.721 
60% SV 97.9 (13.9) 110.6 (17.7) 0.050 
80% SV 91.7 (9.1) 102.7 (13.2) 0.036 
Peak SV 92.1 (12.6) 105 (15.2) 0.028 
Mean Highest SV 
in test 
111 (14.4) 119 (12.1) 0.345 
% peak WR at 
highest SV 
28 (18) 55 (14) 0.026 
 
 
Figure 3.6: Heart rate response to supine and erect exercise 
Rest Unloaded 20% 40% 60% 80%
Erect 75 77 97 119 142 167
















% of peak work rate







Figure 3.7: Stroke volume response to supine and erect exercise 
 
No statistically significant difference were found in CO, a trend was seen in the 
early stages of exercise to higher CO in the supine position and in the later stages 
of exercise, to higher CO the erect position Table 3.4 
Table 3.4: Cardiac output response to exercise in erect and supine position 
Cardiac output (L) at progressive 
stages of exercise (% peak WR) 
Erect Supine p 
Rest CO 5.7 (1.5) 6.8 (1.5) 0.116 
Unloaded CO 6.6 (1.6) 7.7 (1.1) 0.273 
20% CO 10.0 (1.6) 9.5 (1.5) 0.674 
40% CO 12.1 (1.2) 11.4 (1.7) 0.407 
60% CO 13.9 (1.1) 14.2 (2.4) 0.575 
80% CO 15.5 (1.1) 15.3 (2.2) 0.889 
Peak CO 15.8 (1.7) 15.1 (2.3) 0.310 
 
 Ventilatory response  
Tidal volume was higher in all stages of erect exercise and there was an associated 




















% of peak WR 
Stroke volume response during progressive exercise
Erect Supine
* * 
• P <0.05 
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Table 3.5: Ventilatory responses to erect and supine exercise 
RR Erect Supine p 
Rest 14 (5) 16 (5) 0.128 
Unloaded 17 (5) 19 (4) 0.182 
Peak  36 (5) 40 (6) 0.023 
VE (l/min) Erect Supine p 
Rest 14.0 (3.5) 13.3 (2.7) 0.433 
Unloaded 19.7 (3.3) 18.7 (3.3) 0.530 
Peak 100.3 (20) 97.4 (13.5) 0.480 
Vt (L) Erect Supine p 
Rest 1.1 (0.4) 0.9 (0.2) 0.083 
Unloaded 1.3 (0.4) 1.1 (0.3) 0.050 
Peak 2.85 (0.6) 2.51 (0.42) 0.050 
 
 
Figure 3.8: Tidal volume and respiratory rate changes between erect and supine exercise 
 
 
 Gas exchange response  





































Ventilatory response to erect versus supine exercise
Erect RR Supine RR Erect TV Supine TV
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Table 3.6: Gas exchange variables supine and erect exercise 
PETCO2 (mmHg) Erect Supine p 
Rest 5.2 (0.6) 5.5 (0.7) 0.099 
Unloaded 5.4 (0.7) 5.6 (0.6) 0.346 
Peak 5.7 (0.8) 5.6 (0.7) 0.638 
VE/VCO2 Erect Supine p 
Rest 35.1 (7.1) 33.7 (4.6) 0.368 
Unloaded 32.8 (5.1) 31.0 (5.1) 0.209 
Peak 27.6 (4.4) 27.4 (3.7) 0.929 
 
 Isotime CPET analysis  
Highest exercise isotime was used to compare the exercise response between 
upright and supine incremental tests. Ventilation and gas exchange were more 
efficient, with a trend to higher VO2, higher WR and lower HR in the erect cycling 
position (Table 3.7) 
Table 3.7: Highest isotime CPET comparison between erect and supine ergometry 
Highest Isotime Erect Supine p 
VO2 (ml.kg.min) 41 (9.8) 39.8 (7.4) 0.317 
Heart Rate 
(bpm) 
162  (13) 162 (13) 0.878 
Respiratory Rate  29.7 (6.2) 39.6 (6.2) 
0.004 
VE (L/min) 83.2 (10.7) 95.8 (12.9) 
0.010 
VCO2 (L/min) 3.1 (1.0) 3.4 (0.4) 
0.041 
VO2 (L/min) 2.8 (0.5) 2.7 (0.4) 0.594 
RER 1.1 (0.3) 1.2 (0.1) 
0.007 
VO2/HR 17.7 (4.7) 17.4 (2.8) 0.722 
PET O2 (mmHg) 15.3 (0.8) 16.2 (0.6) 
0.008 
PET CO2 (mmHg) 6.2 (0.8) 5.7 (0.5) 
0.013 
VeqCO2 25.4 (3.4) 26.6 (2.5) 0.230 
VeqVO2 28.7 (4.2) 32.9 (3.3) 
0.016 





This study demonstrated that exercise capacity is greater in the upright position. 
Work rate was seen to be 12% higher in the upright position than supine, the 
anaerobic threshold was reached at a later stage and exercise duration was 11% 
longer. These changes are in keeping with overall reduced efficiency of exercise in 
the supine position and reduced VO2/WR relationship. Knowledge of the degree to 
which peak work rate is reduced in the supine position helps to determine 
appropriate work loads for supine exercise testing for PAH patients undergoing 
exercise right heart catheterisation. The factors contributing to this reduction in 
efficiency in the supine position are discussed below.   
Efficiency of ventilation appeared to be contribute to this difference. Peak RR was 
lower and tidal volume higher in the erect exercise, suggesting more efficient 
ventilation. The improved ventilatory efficiency was also evident at highest 
exercise isotime, with lower VCO2, VeqCO2 and respiratory rate in the upright 
position and higher tidal volume. This may be due to reduced diaphragmatic 
excursion in the supine position due to the effects of the abdominal compartment. 
It is well established that vital capacity is reduced in the supine position[3],  
Cardiovascular changes did not reach statistical significance, however there was a 
trend to higher stroke volume in the supine position, associated with lower heart 
rate. This may be due to increased venous return from the elevated lower limbs 
and lower vagal tone in the spuine position, further research, for example looking 
at regional muscle blood flow, would be required to verify this .  
Changes in muscle function or muscle fatigue were not measured in this study and 
may contribute to the observed changes seen.  
This data allows prediction of suitable work rates for supine incremental and 
steady state exercise testing in health, based on incremental upright CPET data. It 
is possible that an exaggerated difference may be seen in supine and upright 
exercise in PAH, due to the pre-existing myopathy, ventilatory and cardiovascular 
inefficacy. 
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 Conclusions  
Exercise capacity is reduced by approximately 12% in the supine position in young, 
healthy individuals.  
The reduction in exercise capacity appears to be multifactorial, with reduced a 
ventilatory efficiency and a trend towards reduced cardiovascular efficiency. 
Muscle function and fatigue were not assessed in this study and could also be a 
contributing factor.  
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Chapter 4 Methods “The effect of adding exercise 
training to optimal therapy in pulmonary arterial 
hypertension” 
 Introduction 
After establishing sufficient demand for exercise training in Scotland, the study 
“The effect of adding exercise training to optimal therapy in pulmonary arterial 
hypertension”, was conducted. The protocol design was based on existing evidence 
on exercise training in PAH as discussed in Chapter 1. The most effective strategy 
to date appears to be that adopted by Grunig et al [61], involving 3 weeks of 
supervised residential exercise comprising personalised resistance and aerobic 
exercises – both endurance and interval training, followed by 12 weeks of remotely 
monitored exercise with home exercise equipment and specific goal setting. This 
strategy resulted in the greatest increase in QOL scores and 6MWD, therefore was 
the most likely to provide a translatable benefit in the UK, where no formal 
exercise rehabilitation exists for PAH and provide insights into the physiological 
changes that occur. In designing the study protocol, primary end points were 
chosen to reflect exercise capacity, cardiac function and quality of life. A number 
of exploratory secondary end points were employed to investigate the 
physiological and biological changes with exercise therapy.  
 Ethical Approval 
This study was approved by the West of Scotland Research Ethics Committee on 
4th September 2015 (REC Reference 15/WS/0197, IRAS project ID 181697). NHS 
National Waiting Times Board acted as the study sponsor.  
Within the main study, two optional sub-studies existed. One to assess invasive 
haemodynamic responses to exercise therapy, requiring exercise right heart 
catheterisation. The second to assess muscle structure and function, requiring 
muscle biopsy before and after the exercise programme. Both sub-studies required 
separate written consent. 
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 Study Setting  
This research was conducted at the SPVU, Golden National Jubilee Hospital, 
Clydebank, Glasgow. The SPVU serves a population of 5.3 million and is the 
Scottish tertiary referral centre for PAH. The incident population of treated PH 
patients during the period this research was conducted rose from 498 in 2014 to 
649 in 2018. 
Exercise rehabilitation sessions were performed at the Golden Jubilee National 
Hospital (GJNH) Physiotherapy Gym. Muscle biopsies were performed between 
Gartnavel General Hospital and Glasgow Royal Infirmary Radiology departments. 
All other investigations were conducted at GJNH.  
 Study Population 
Patients with PAH, confirmed by right heart catheterisation (RHC) in accordance 
with European guidelines, were recruited from the Scottish Pulmonary Vascular 
Unit (SPVU) outpatient clinic. Written information regarding the study was 
provided and prospective participants were asked to provide a response within 14 
days.  
Inclusion criteria: 
1. World Health Organisation functional class (WHO-FC) II-III 
2. Stable on optimal disease targeted PAH therapy for ≥ 3 months 
3. 18 years of age or older 
4. Able to provide written informed consent  
Exclusion criteria: 
1. Unable to provide informed consent 
2. Significant peripheral vascular disease, neurological or musculoskeletal 
comorbidity precluding exercise 
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3. Exercise induced syncope, cardiac arrhythmia or chest pain 
4. Pregnancy 
5. Specific component exclusions: Cardiac MRI (CMR): Any contraindication to 
MRI 
 Study design 
This was a prospective, single centre, controlled crossover study. It included two 
groups: a group receiving exercise therapy for 15 weeks (Group A) and a group 
receiving standard care for 15 weeks (Group B). Crossover to the exercise arm 
occurred with group B participants after 15 weeks of standard care. In group A, the 
study intervention was performed in two phases.  
Phase 1:  A 3-week residential exercise training programme, based at the Golden 
Jubilee Hospital, Clydebank 
Phase 2:  A 12-week ambulatory exercise training programme remotely 
monitored by a specialist physiotherapist.  
In Group B, the study intervention was performed in 3 phases: 
Phase 1:  15 weeks of standard medical care for PAH 
Phase 2: A 3-week residential exercise training program, based at the Golden 
Jubilee Hospital, Clydebank 
Phase 3:  A 12-week ambulatory exercise training program remotely monitored 
by a specialist physiotherapist.  
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Figure 4.1 Flow chart of study protocol. Green indicates intervention, blue indicates 
assessment time point 
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 Outcome measures  
 Primary outcome measures  
To reflect the potential physiological and functional changes relevant to clinical 
improvement in PAH, three well validated primary end points were selected for 
the study.  
1. Change in 6-minute walk distance (6MWD) from baseline to end of study  
2. Change in quality of life (QOL) parameters (SF-36, CAMPHOR and EmPHasis-
10) from baseline to end of study  
3. Change in resting RV ejection fraction measured by Cardiac MRI (CMR) from 
baseline to end of study 
6MWD:  The 6-minute walk test (6MWT) is validated and commonly used outcome 
measure in PAH. It is a sub-maximal exercise test where the subjects walks as far 
as they can within the 6 minute time frame. The 6MWD was performed in line with 
the ATS standards for conducting the 6MWT [126]. 
SF-36™ version 2  by Optum® is an established patient reported quality of life 
scoring system. It reports on eight domains: Physical functioning, role physical, 
bodily pain, general health, vitality, social functioning, role emotional, and mental 
health. There are two summary scores, physical and mental. The SF scoring 
software system was used to generate scores and an appropriate software license 
was obtained. (Appendix 12: SF-36) 
EmPHasis-10, by the Pulmonary Hypertension UK Society, is a PAH-specific health-
related quality of life (HrQOL) score that consists of 10 items relating to 
breathlessness, fatigue, control and confidence ( 
Appendix 10: EmPHasis-10) 
CAMPHOR (Cambridge Pulmonary Hypertension Outcome Review), Galen Research, 
is an earlier PH specific HrQOL tool, consisting of 65 items relating to symptoms, 
activities and quality of life ( 
Appendix 11: Camphor) 
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 Secondary outcome measures  
A variety of secondary outcome measures were collected to generate pilot 
mechanistic data. The rationale and methods of each testing modality are 
discussed in detail in chapters 5 to 9 and are briefly outlined below: 
1. Exercise capacity: 
a. Standard incremental cardiopulmonary exercise test (CPET) (Chapter 
6) 
b. Supine ergometer endurance time  
c. Cardiac and haemodynamic function  
2. Cardiac function  
• Cardiac MRI [127] (0) 
• N-terminal pro brain natriuretic peptide (NTproBNP) concentration [128]  
• Standard RHC measurements at rest and supine exercise performed on a 
cycle ergometer (Chapter 7) 
3. Ventilatory function and gas exchange (Chapter 6) 
a. Full pulmonary function tests 
b. Mouth pressures 
4. Peripheral muscle function (0) 
a. Volitional quadriceps and grip strength measured by a myometer. 
5. Profile of systemic inflammation and metabolism  
a. Interleukin-6 cytokine assay 
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b. Specific micro-RNA primers reflecting angiogenesis, myogenesis and 
inflammation 
c. C-peptide and fasting glucose concentration 
 
 Sample size calculations  
The primary outcome measure was change in 6 minute walk distance (6MWD) at 15 
weeks. Power calculation for 6MWD was performed based upon a between group 
difference at 15 weeks of 74m [61] with a standard deviation of 56m, power of 80% 
and confidence level of 0.05. This provided a sample size in each group of 11.  
Thirty participants were enrolled to cover for unexpected dropouts.  
The table below summarises the power calculations for the other key outcome 
variables, including QOL and RVEF, the two additional primary outcome measures.  
The calculations are based on paired changes, treatment compared with control, 
with a power of 80% and confidence level of 0.05 
















17 14 22 [61] Minimum clinically 
important difference 
(MCID) defined in a 
paediatric population of 






5 4.9 32 [127, 130] No validated MCID in PAH, 
mean change of 4.6% over 
1 year observed in a 
multicentre study on the 
effect of disease targeted 
therapy. This was 
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associted with improved 
6MWD.[131]   
NTproBNP 
(ng/L) 
-400 -175 8 [132] No defined MCID exists for 
NTproBNP in PAH, 
maintenance in low 
category (< 300ng/L) 
associated with improved 
prognosis versus 
intermediate (300-1400 





1.0 1.0 32 [134] Change in exercise CI with 
pulmonary vasodilator 
therapy resulted in a mean 
of 0.4. Change in exercise 
CI following exercise 
therapy in PAH is also 




0.2 0.12 12 [134, 136] A change of 0.2L/min has 
been seen following 
exercise therapy in PAH 
and associated with 






3 2 14 [100, 137] MCID does not exist for 
MIP, a lower limit of 
normal has been proposed 
as 9.95 kPa for men and 




12 3.5 4 [63, 139] An MCID of 7.5nM has been 




 Allocation to groups 
Randomisation was planned to be performed with the use of pre-sealed 
envelopes. Due to the time commitments for subjects involved in the study (3 
weeks residential stay for exercise therapy) and competing commitments 
(childcare, employment), it proved very difficult for many subjects to accept their 
randomised study allocation.  Therefore, in order to maintain recruitment, these 
subjects were offered the most convenient study slot for them.  Thereafter, 
subjects were allocated to study group based on subject availability and balanced 
clinical and demographic factors. This amendment was discussed with the 
approving research ethics committee.   
 Assessments 
The contents of assessments are outlined in Table 4.2 and the timeline for these 
assessments are described below. All assessments with the exception of muscle 
biopsy, were performed within the designated assessment periods mentioned 
below. Muscle biopsies were performed at least one week prior to commencing the 
exercise programme to allow sufficient healing time and on completion of the 
exercise programme, biopsies were performed in the following week.  
Group A had three assessments  
1. A.1 Baseline 
2. A.2 End of the residential exercise therapy (Week 3) 
3. A.3: End of study (Week 15) 
Group B had four assessments  
1. B.1: Baseline  
2. B.2: After 15 weeks of standard care, prior to commencing the exercise 
programme (Week 15) 
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3. B.3: At the end of 3 weeks residential exercise (Week 18) 
4. B.4 End of study  (Week 30) 
Table 4.2: Outline of assessment visits and investigations performed 
Assessment time point Content of assessment 





Assessment A.1 and B.2 








Metabolic blood panel 
Exercise RHC** 
Muscle Biopsy ** 
Assessment A.2, B.3 







Assessment A.3, B.4  






Metabolic blood panel 
Exercise RHC** 
Muscle Biopsy ** 
Abbreviations: 6-minute walk distance (6MWD), Cardiac MRI (CMR), Quality of life 
(QOL), N-terminal pro brain natriuretic peptide (NTproBNP), Cardiopulmonary 
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exercise test (CPET), Right heart catheterisation (RHC) 
** In subjects who consented to these sub-studies 
 
 Safety  
Exercise was supervised continuously by a specialist physiotherapist and doctor 
when required. All patients were confirmed as being in a clinically stable condition 
by a clinician with PAH expertise prior to commencing the rehabilitation 
programme. Oxygen saturations and heart rate were monitored intermittently 
during exercise using a Nonin® Go2 pulse oximeter™.  
1. For all exercise sessions, supplemental oxygen was used if oxygen saturations were 
below 90%, using a static oxygen concentrator for stationary exercises and oxygen 
cylinders for dynamic exercises. The modified Borg scale ( 
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Appendix 2: Modified Borg dyspnoea scale) was used to assess subjective levels of 
breathlessness and leg fatigue.  
For safety reasons, exercise intensity was reduced or terminated according to the 
following criteria: 
• Heart rate (HR) was consistently over 120 beats per minute. 
• Modified Borg level was greater than 5.  
• Physician or physiotherapist discretion 
• Patient request 
 Study intervention  
The exercise programme consisted of low dose resistance and aerobic training. 
Five main components were included in the programme 
1. Walking  
2. Stationary bicycle ergometer interval training  
3. Upper and lower limb resistance training  
4. Respiratory muscle training and breathing control techniques 
5. Relaxation and education sessions 
Prior to commencing the exercise programme, patients were provided with an 
exercise diary ( 
Appendix 3: Exercise Diary). They used this diary to log pre-defined goals they 
wished to achieve by the end of the exercise programme. The diary was also used 
to monitor compliance and provide reinforcement of the exercise techniques.  




Appendix 5: Sample residential ) consisted of a combination of aerobic and 
resistance exercise, education or relaxation and respiratory muscle training. A 
total of 1.5 to 2 hours per day of exercise and education were performed over four 
sessions, with rest intervals between. At weekends, lower intensity, unsupervised 
exercise was prescribed, mirroring the outpatient phase. Ongoing exercise 
prescription and titration of exercise intensity was made by the medical and 
physiotherapy team on an individual patient basis. Exercise prescriptions were 
modified based on tolerability, progress and heart rate response.  
 Walking and treadmill 
Sessions occurred on a PhysioMill® treadmill in the Golden Jubilee National 
Hospital (GJNH) Rehabilitation Department or in the grounds of the hospital. 
Sessions were 30-60 minutes in duration depending on the baseline functional level 
and the stage in the exercise programme (Figure 4.2). 
To achieve steady state aerobic exercise, target heart rate range for walking 
sessions was 50-60% of peak heart rate and Borg was aimed for 3-4, therefore in a 
low intensity range, selected from a safety perspective to monitor initial tolerance 
and given the potential for exercise induced desaturation. The protocol for walking 
training and data collection can be found in  
Appendix 6: Walking training. 
In addition to providing aerobic cardiovascular training, walking sessions also 
focussed on 3 key areas: 
1. Controlling the level of exertion (avoiding under or over exertion), patients 
were educated on the Borg scale , HR and SpO2 to objectively assess this, 
for example being able to talk in short sentences. Once the subjects were 
familiar with the pulse oximeter and Borg scale, they were asked to modify 
exercise intensity based on these parameters, with the support of the 
physiotherapist (JF) or study doctor (AM) 
2. Psychological intervention: a validated psychology method, positive mental 
imagery, reinforcing positive thinking towards achieving short term, realistic 
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goals relating to exercise and physical performance[93]. This is described in 
Chapter 1, Section “Personal experience: training in exercise rehabilitation 
and development of study protocol” 
3. Practical considerations: Developing mechanisms for dealing with 
challenging environments or situations such as hills, stairs, uneven terrain.  
 
Figure 4.2 Participants performing treadmill exercise with supplemental oxygen (left) and 
outdoor gait practice with supplemental oxygen (right) 
 
 
 Bicycle ergometer 
Bicycle ergometer sessions occurred on an Ergoline Optibike ®, Bitz Germany, 
Ergometer in the GJNH rehabilitation gym.  
An individualised interval programme was prescribed by the study doctor (AM) 
based on peak power (watts) from the study entry incremental CPET.  To generate 
an interval programme that was predominantly aerobic, with short anaerobic 
spells, the following protocol was used: 
1. 5 minutes warm up aerobic zone or unloaded cycling  
2. 7.5 or 12 minutes of intervals at the following ratio depending on subject 
fitness 
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a. 1 minute at 40% of peak exercise capacity 
b. 30 seconds at 60% of peak aerobic exercise capacity 
3. 5 minutes cool down 
Heart rate and SpO2 monitoring were continuous throughout exercise. Borg was 
checked in the warmup phase, twice in the interval phase and in cool down. 
Exercise was modified by the study doctor on an individual patient basis depending 
on Borg and HR. Supplemental O2 was provided if SpO2 were consistently below 
90%. Breathing control exercises (described below) were added to the ergometer 
sessions as the subject progressed (Figure 4.3). The full ergometer training 
protocol can be found in  
Appendix 7: Bicycle ergometer protocol. 
 
Figure 4.3: Bicycle ergometer training, with breathing control exercises (left) 
  
 Respiratory muscle training  
Respiratory training involved 2 key components based on standard respiratory 
muscle training techniques[141] 
1. Respiratory muscle strengthening 
a. Thoracic expansion techniques 
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b. Diaphragmatic breathing  
2. Breathing control and control of hyperventilation 
Passive and active exercises were performed whilst the subject was seated and a 
towel was used to provide proprioceptive feedback on thoracic expansion before 
and after the exercise session (Figure 4.4). The full protocol for respiratory muscle 
training can be found in  




Figure 4.4: Respiratory muscle training (top image) and using towel for thoracic expansion 
(lower image) 
 
 Skeletal muscle training  
Body weight exercises or light weights were used and selected by the 
physiotherapist based on the subjects’ initial assessment; the highest weight that 
could be lifted ten times easily was selected. Heavy weights were avoided due to 
the risk of increased pulmonary artery pressure and increased afterload.  
The resistance programme was based on standard upper and lower limb 
rehabilitation methods typical of those used in pulmonary rehabilitation[142]. The 
full protocol for resistance training can be found in  
Appendix 9: Skeletal muscle training. Each resistance training session consisted of 
the following sequence (Figure 4.5):  
1. Upper and lower limb warm up stretches 
2. Upper limb low weight repetitions (20 – two times sets of ten) 
a. Elbow flexion 
b. Shoulder extension 
c. Lateral raises  
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3. Lower limb body weight or low ankle weight repetitions (20- two times sets 
of ten) 
a. Knee extension 
b. Hip flexion 
c. Hip abduction 
4. Cool down stretches 
 
Figure 4.5: Low weight upper limb resistance exercises 
 
 Outpatient phase 
After three weeks of residential, supervised exercise therapy, each participant was 
issued with an individually tailored training programme. This programme was 
based on their exercise parameters and progression during the 3-week residential 
exercise phase.  
A cycle ergometer (domyos®, UK), dumbbell weights (domyos ® UK) and a pulse 
oximeter (Nonin ® UK) were provided for home. Participants were educated and 
independent in the use and interpretation of these devices prior to commencing 
the out-patient programme.  
The daily home exercise programme mirrored the components of the residential 
phase, however, was less intensive and was designed to be incorporated into their 
daily routine. Typically, three sessions per day totalling 1.5 hours of exercise were 
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prescribed from a combination of: walking, cycle ergometry, resistance limb 
exercises, respiratory muscle training.  
Participants were given the following advice on their safe exercise limits: 
• Borg no greater than 6 
• Heart rate no higher than 120 consistently 
• SpO2 no lower than 90%. Provided there were no contraindications to home 
oxygen, those with exertional hypoxaemia were supplied with an oxygen 
concentrator (Dolby vivasol ®). Relevant oxygen education was given by a 
respiratory nurse specialist (RT).  
• Stop exercising if any of: chest pain, distressing breathlessness, lightheaded 
or dizzy.  
Subjects returned an exercise log ( 
Appendix 4: Sample outpatient timetable)  each week detailing the sessions 
completed, heart rate, Borg score and oxygen saturations. This was followed up 
with a weekly phone call by either the physiotherapist or study doctor. This 
information was used to assess safety and adverse events, determine compliance 
and whether the programme required adjustment.  
  
 104 
Chapter 5 Efficacy of exercise training in patients 
on optimal therapy for Pulmonary Arterial 
Hypertension 
 Introduction 
As discussed in chapter 1, treatment for pulmonary hypertension results in 
modestly improved symptoms and in the case of Epoprostenol, provides a survival 
benefit. Survival from PAH has improved significantly over the past 20 years since 
the advent of Epoprostenol and additional classes of disease targeted 
therapy[143]. This improvement is mirrored in the Scottish PAH cohort from 1997 
to 2019 (Figure 5.1)
 
Figure 5.1: Kaplan Meier Curves for SPVU IPAH survival (1997-2019) 
 
Despite this, Pulmonary hypertension remains a life limiting illness with around 
55% of patients with IPAH being alive 5 years from diagnosis and under 50% with 
CTD-PAH (Figure 5.2) [34].  
SPVU IPAH/HPAH Survival





















Figure 5.2: UK National Audit data 2009-2019 on PAH sub type survival 
 
These patients have a significant symptom burden. Despite a small proportion of 
patients moving into more favourable functional classes, the majority remain in 
functional class III and have impaired quality of life despite optimal 
pharmacological therapy (Figure 5.3). 
 
Figure 5.3 Effect of disease targeted therapy on WHO-Functional Class in SPVU patients 2015-
2019[144] 
 
Multi-system effects are evident in PAH, such as skeletal muscle atrophy and 
systemic inflammation, therefore pulmonary arterial vasodilators alone do not 
target all the manifestations of the disease. This has led to exercise therapy being 
explored as a potential to target these systemic effects and improve morbidity and 
mortality in PAH.  






























PAH specific rehabilitation has been shown to be safe and effective in single 
European and North American centres and as such has been recommended for 
stable patients with PAH in a statement recently published by the European 
Respiratory Society [91], however the availability of PAH specific exercise therapy 
out with a small number of countries remains low.   
 Determining efficacy  
In determining the efficacy of exercise therapy, it must be ensured that 
appropriate outcome measures are used, the population selected are 
representative of the disease process being studied and the intervention is 
delivered in a way that will provide meaningful conclusions about its true effect. 
As discussed in Chapter 1, single centre studies from Germany have established 
that in patients with PAH on a variety of treatment regimens, exercise 
rehabilitation in a monitored inpatient setting prior to ongoing outpatient therapy 
is more efficacious than outpatient rehabilitation alone. It is unclear if this 
translates to different health care systems or populations on optimal therapy. The 
best outcome measures and timing of therapy have not yet been established.  
 Outcome measures 
To encompass the physiological and functional hallmarks of PAH – exercise 
limitation, RV impairment and impaired quality of life, three primary end points 
were selected for this study. 
1. Change in 6 minute walk distance  
2. Change in RV ejection fraction 
3. Change in quality of life: SF-36, CAMPHOR and EmPHasis-10 
The 6MWT is a sub-maximal test used to asses exercise capacity. It is self-paced 
and requires a flat, straight 30m corridor. Borg dyspnoea scores are recorded 
before and after the test. The subject is asked to walk as far as possible in the 6-
minute period, heart rate and oxygen saturations are recorded continuously. The 
total distance walked in 6 minutes is recorded.  
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The 6MWT has been the most commonly employed primary end point in PAH 
pharmacotherapy studies over the past 20 years and has been utilised as the 
primary end point in the majority rehabilitation studies. The relationship between 
Δ6MWD and short- and long-term outcomes, such as need for hospitalisation, lung 
transplantation or death, have failed to consistently demonstrate significant 
associations[145]. For this reason, there is a move towards composite end points in 
PAH therapy, including time to clinical worsening and hospitalisation. In trials of 
exercise therapy in PAH, change in 6MWD has been associated with improved QOL 
scores [61] and appears to be a robust and relevant primary outcome measure.  
The 6MWD minimum clinically important difference (MCID) is generally accepted at 
around 30m in PAH [146]. There a ceiling effect in fitter patients, therefore 
limiting its use as a sole end point.  
PAH-specific QOL scoring systems (EmPHasis-10 and CAMPHOR) relate to treatment 
response, prognosis and exercise capacity [147]. Most importantly QOL scores 
provide an objective means of assessing the impact of the intervention on the 
individual in their daily life. For PAH specific QOL, there are no accepted minimum 
clinically important difference (MCID) values.  
Right ventricular ejection fraction is representative of right ventricular function 
and the load faced by the RV secondary to increased pulmonary vascular 
resistance. It is a strong determinant of patient outcome in PAH and relates to the 
underlying disease process[148] 
 Patient selection and timing of intervention 
There is a paucity of evidence in relation to the optimal timing of PAH specific 
exercise therapy and how it should be incorporated into the treatment algorithm. 
It is also not clear what specific sub populations are most likely to derive benefit 
or conversely be unsuitable; no studies have been performed to look at the 
responses in pure populations of PAH subgroups [91]. All studies have included 
subjects who are clinically stable and established on drug therapy; however, this 
has ranged from monotherapy to triple therapy.  
Compliance and patient motivation 
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In PAH specific rehabilitation, compliance ranges from 58% to 100% and benefits 
are dose dependent [149]. Dedicated studies have not assessed factors that 
influence or improve compliance in PAH. These areas have been more closely 
studied in cardiac and pulmonary rehabilitation [150, 151]. Common factors 
associated with reduced compliance are: 
• Environmental: work commitments, travel, disruption to the patient’s usual 
routine, cost burden. 
• Medical: current smokers, lower baseline functional status, higher BMI 
• Patient and physician beliefs: too ill or not ill enough, beliefs around the 
role or safety of exercise, cultural reasons 
Developing an Individualised therapy programme, psychological support, regular 
telephone or email support and involving a family or friend in the exercise routine 
have all been shown to enhance compliance[152, 153].  
Patient motivation and education directly influence compliance. Validated 
strategies exist to enhance motivation: Long term, realistic goal setting should 
take place at the beginning of a programme; Goals should be contextualised and 
adjusted as needed; Specific psychological techniques such as mental imagery can 
also be employed with specialist training of staff [60].  
 Aims  
The aims of this chapter are  
1. To establish the efficacy of PAH specific exercise therapy in a UK pre-
capillary population stable on optimal disease targeted therapy 
2. To determine the feasibility of PAH specific exercise rehabilitation, 




Chapter 2 describes the study protocol including recruitment, exercise 
intervention and outlines primary and secondary outcome measures.  
 Primary outcome measures 
1. Change in 6 minute walk distance from baseline to end of study 
2. Change in SF-36, EmPHasis-10 and CAMPHOR scores from baseline to end of 
study 
3. Change in MRI right ventricular ejection fraction from baseline to end of 
study  
 6MWD 
6 minute walk tests were performed according to ATS guidelines[126] in a 30m 
corridor. Oxygen saturations and heart rate were continuously recorded during the 
test and for 3 minutes afterwards. The total distance walked in 6 minutes was 
recorded. If the subject was on oxygen, the flow rate was standardised for each 
test 
 QOL 
After initial instruction on how to complete the surveys, SF-36, EmPHasis-10 and 
CAMPHOR scoring sheets were completed by subjects without assistance. Subjects 
were familiar with the PAH specific scoring systems through routine clinical care.  
 RVEF 
Right ventricular ejection fraction was measured by MRI as per standard clinical 
practice and is described in detail in Chapter 8:   
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Non-invasive assessment of the cardiovascular response to exercise therapy in PAH. 
 Secondary Outcome measures 
Chapter 2 outlines the secondary outcome measures studied and these are 
discussed in detail in chapters 6 to 9. WHO Functional Class (FC) is also discussed 
in this chapter alongside quality of life. The WHO FC score is a commonly 
employed clinical tool in the initial diagnosis and follow up of patients with PAH. It 
is used in conjunction with other prognostic parameters to aid treatment initiation 
and escalation decisions and objectively inform on clinical stability. WHO FC was 
collected at baseline, end of the residential phase of exercise and at the end of 
the study.  
 Safety reporting 
Serious Adverse Events (SAE) were defined in accordance with the HRA guidance 
[154] as an occurrence that met one of the following criteria:  
• Resulted in death 
• Life-threatening 
• Required hospitalisation or prolongation of existing hospitalisation 
• Resulted in persistent or significant disability or incapacity 
• Otherwise considered medically significant by the investigator.  
A prospective log was maintained of all AE and SAEs for individual participants in 
the exercise training phase and recorded in a master log. “Related” events were 
deemed to have resulted from research procedures, “Unexpected” events were 
unrelated to the study intervention and not listed in the protocol as an expected 
occurrence. Events reportable to the ethics committee were defined as both 
serious and related to the study intervention. Unrelated SAEs were recorded in a 
master AE log that was submitted to the R&D department with the final study 
report.  
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 Monitoring of adherence  
Subjects discussed personal goals or motivating factors for participating in the 
exercise programme at enrolment, this was recorded in their exercise diary. During 
the residential phase, attendance at sessions and adherence with the exercise 
programme was recorded in the subjects’ exercise diary by the physiotherapist. In 
the outpatient phase, exercise logs were returned by email or post on a weekly 
basis. This allowed monitoring of adherence, HR and SPO2data to assess safety and 
completed intensity / distance to allow titration / adjustment of exercise 
programme. This was followed up with a weekly telephone call and recorded in a 
master log. 
 National PAH population data 
In order to provide context to the size of changes seen with exercise therapy, data 
on the treatment effect seen with medical therapy from the 2019 SPVU annual 
audit are presented in conjunction with the primary outcome measures. These 
data are obtained from the prospectively maintained InfoFlex® database on an 
annual basis. All data relates to treatment changes seen between diagnosis and 
following 3 months of medical therapy.   
 Statistical analysis 
Statistical analysis was performed using IBM SPSS software version 26. Continuous 
variables were tested for normality using D’Agostino and Pearson omnibus 
normality test. Normally distributed variables are shown as mean (SD) and non-
normally distributed variables are shown as median (IQR).  
Categorical variables are presented as number (%). Comparison between baseline 
and follow-up continuous variables were made by Wilcoxon signed rank test. 
Comparison between baseline and follow-up WHO FC was made by χ2test. 
Comparison between control and treatment variables were made by Mann-Whitney 
U test. All tests were non-parametric due to the small sample size.  
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 Results  
 Population characteristics  
73% were female with a median age of 53 (26-73). The majority of patients had 
IPAH (Table 5.1) 
Table 5.1: PAH sub type 
Diagnosis   
IPAH 66.7% (20/30) 
CTD-PAH 20% (6/30) 
POPH 3.3% (1/30) 
CHD-PAH 3.3% (1/30) 
Heritable 3.3% (1/30) 
CTEPH 3.3% (1/30) 
 
All patients were stable, on optimal therapy as defined by the European 
Respiratory Society Guidelines on Pulmonary Hypertension [155]. 17/30 (57%) were 
on dual oral therapy and 13/30 (43%) were on triple therapy. Baseline 
characteristics were typical of a pre-capillary PH population, with reduced 
exercise capacity, impaired gas exchange and reduced quality of life (Table 5.2). 
Table 5.2: Baseline characteristics 
 Mean / Median SD / Range 
Age (y) 50 34-74 
Sex (M) 8/30 (27%)   
Time since Diagnosis (months) 100 101 
BMI (kg/m2) 35 20-48 
6MWD (m) 422 96 
DLCO (ml/min/Kpa) 4.68 1.96 
DLCO (%) 52.3 21.1 
Peak VO2 (L/min) 0.99 0.29 
VO2 (ml/kg/min) 12.5 3.6 
Peak WR (watts) 75 26 
WR (%) 63 27 
VE/VCO2 gradient 42 12 
Log NTproBNP 2.3 0.6 
EmPHasis-10 26 14.3 
 
At enrolment, Group A and B comparisons revealed well matched groups (Table 
5.3) 
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Table 5.3: Drug therapy and PAH sub type between groups 
 Group A (n 16) Group B (n 14) 
Drug therapy     
Triple Therapy 56% (9/16) 29% (4/14) 
Dual Oral Therapy 44% (7/16) 71% (10/14) 
Diagnosis      
IPAH 69% (11/16) 64% (9/14) 
CTD-PAH 19% (3/16) 22% (3/14) 
POPH 6% (1/16) 0 
CHD-PAH 6% (1/16) 0 
Heritable 0% 7% (1/14) 
CTEPH 0% 7% (1/14) 
 
Table 5.4: Group A and B unpaired comparisons 
 Group A  SD / IQR Group B SD / 
IQR 
P  
Age* 54 17 48 21 0.715 
Sex (M)** 25% (4/16)   21% (3/14)  0.544 
Time since 
Diagnosis * 
76 83 30 114 0.457 
BMI (kg/m2)* 29 13 26 11 0.193 
6MWD (m) 413 101 427 91 0.559 
DLCO (ml/min/Kpa) 4.51 2.15 4.96 1.7 0.486 
RVEF (%) 53.1 24.1 58.9 15.4 0.156 
Peak VO2 L/min 0.93 0.21 0.97 0.38 0.440 
VO2 ml/kg/min 11.9 24.4 13.3 2.8 0.025 
Peak WR (watts) 71 21 84 34 0.294 
VE/VCO2 gradient 43 14 42 11 1.000 
Log NTproBNP 2.4 0.47 2.3 0.43 0.371 
EmPHasis-10 28 6 24 7 0.232 
* Median / IQR 
displayed,  
** CHI squared test 
 
 Recruitment and retention 
The target of 30 patients were recruited to the study between January 2016 and 
March 2018 (Figure 5.4). The final patient, final visit occurred in July 2018.  
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Figure 5.4: Study recruitment and retention flow diagram 
 
 Subject withdrawal from study 
There were 5 dropouts from the study (16.7%), this is comparable to studies of PAH 
pharmacotherapy [156]. One subject from group B was withdrawn in the control 
phase because of worsening PH.  Four subjects dropped out during the active 
intervention in the outpatient phase (two having started in Group A and two in 
Group B).  The causes were recurrent chest infections, withdrawal due to 
worsening right heart failure (peripheral oedema) and renal function, lung 
transplantation (in a subject listed for this before entry into the study) and lost to 
follow up because of failure to attend for final assessment. 
 Excluded from analysis 
One subject in Group A missed the week 3 assessment because of viral 
labyrinthitis. One subject in Group B was excluded as a control subject.  He 
enrolled on a non-study structured exercise programme whilst in the control 
phase, resulting in a 100m improvement in 6MWD from 418 to 518m prior to 
starting the active intervention phase of the study. He has, however, been 
included in analyses of change during the active intervention.  
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 Primary Outcome measures  
 Six minute walk distance  
In the 28 patients who completed the initial 3 week residential phase of the 
exercise programme and the 6MWT, the 6MWD increased by 38m. Two subjects did 
not complete the week 3 6MWT due to intercurrent illness. Twenty five subjects 
completed the full exercise programme, 6MWD increased by 35m (Table 5.5) 
Table 5.5: Change in 6MWD with exercise therapy 
 
An unpaired comparison of change in 6MWD in all subjects who received exercise 
therapy (Group A & B) and in group A versus the control arm (Group B) 
demonstrated significant improvements in 6MWD with exercise therapy (Table 5.6, 
Figure 5.5) 
Table 5.6: Change in 6MWD control (B) versus exercise therapy 
n 28 Baseline  SD Week 3 SD  P 
6MWD (m) 429m 97 467m 108 0.0001 
n 25 Baseline SD End of study SD  P 
6MWD (m) 443m 88 478m 100 0.002 
 Exercise intervention   Control (B) P 
Delta 6MWD (A) (n 14) 32m (49) 5m (16) 0.045 
Delta 6MWD (A+B) (n 25) 35m (47) 5m (16) 0.039 
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Figure 5.6 Change in 6MWD in control group (B) versus treatment group (A) 
 
The majority of improvement in walk distance occurred in the initial residential 










Figure 5.7: Individual change in 6MWD; baseline, end residential phase, end of study 
 
 
The study was not designed to detect a difference in treatment response between 
PAH subgroups. Post hoc analysis was performed on the two largest subsets, IPAH 
and CTD-PAH (Table 5.7). Patients with IPAH had a higher pre-exercise 6MWD and 
appeared to have a more positive response to exercise therapy.  
Table 5.7: Comparison of change in 6MWD between IPAH and CTD-PAH 
 
 
In comparison, in the SPVU PAH population between 2015-2019, a treatment effect 


















Individual changes in 6MWD with exercise therapy
 Baseline (SD) End of Study (SD) p 
IPAH (17) 461 (82) 498 (73) <0.005 
CTD PAH (6) 337 (53) 349 (62) 0.204 
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(Figure 5.8), with the greatest effect being seen in IPAH and lowest effect in CTD-
PAH (Table 5.8) 
 
Figure 5.8 Mean change in 6MWD at 3 months following initiation of drug therapy in SPVU PAH 
population 2015-2019 
 
Table 5.8: Effect of medical therapy on 6MWD in SPVU PAH sub-groups 2015-2019[144] 
Diagnosis Mean Improvement 6MWD (m) N p 
IPAH 34 195 <0.0001 
CTD-PAH 20 118 0.003 
Portopulmonary 45 40 0.002 
CTEPH (medical treatment) 20 121 0.0006 
 
 Quality of life 
Pulmonary hypertension specific QOL. 
A validated pulmonary hypertension specific QOL scoring system EmPHasis-10 was 
used in addition to a generic QOL scoring system (SF-36). QOL improved from a 
mean baseline score of 25 (14) to 19 (15) at week 3, p 0.013, and this improvement 
was maintained at the end of the study with a mean score of 18 (15), p 0.01. The 
improvement in QOL followed a similar pattern of initial significant improvement 
then maintenance, to changes seen with 6MWD (Figure 5.9,  
 



















Figure 5.9 change in 6MWD and EmPHasis-10 with exercise therapy 
 
Table 5.9: Change in QOL with exercise therapy  
 
This relationship was confirmed with a significant Spearman’s correlation between 
baseline 6MWD and EmPHasis-10 score – 0.519, p 0.004 (Figure 5.10) and between 
































n 26 Baseline  SD Week 3 SD  P 
EmPHasis-10 24.7 15 19.4 15 0.002 
n 23 Baseline SD End of study SD  P 
EmPHasis-10 23.3 15 18.3 15 0.017 
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Figure 5.10: Scatter plot of baseline EmPHasis-10 and walk distance 
 
EmPHasis-10 scored improved in those receiving exercise therapy in comparison 
with the control arm (Table 5.10) 
Table 5.10: Change in QOL in exercise group versus control (B) 
 
Changes seen with drug therapy at diagnosis in the SPVU PAH population from 
2015-2019 demonstrated a trend to improved EmPHasis-10 score by a mean of 1.3 
points across all subtypes of PAH (figure 13) with improved performance in IPAH 
patients ( 
 
Table 5.11), notably lower than the improvement seen with exercise therapy.  
 Exercise intervention   (n 10) Control (B) P 
EmPHasis-10 (A) (n 12) -6.7 (14) 2.1 (4) 0.07 
EmPHasis-10 (A+B) (n 22) -5.2 (11) 2.1 (4) 0.02 
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Figure 5.11: Effect of drug therapy on QOL in SPVU population 2015-2019 [144] 
 









IPAH 2.9 64 0.047 
CTD PAH 0.2 57 NS 
Portopulmonary 0.3 13 NS 
CTEPH (medical treatment) 1.3 53 NS 
 
Generic QOL score: SF-36 
SF-36 was measured at baseline, the end of residential exercise (ER) phase and at 
the end of the study (EOS). Complete surveys were available for 26 subjects from 
baseline to the end of the residential phase (Table 5.12) and for 23 patients from 
baseline to the end of the study ( 
Table 5.13) 
  

















Table 5.12 SF36 scores baseline to end of residential therapy (n=26) 
SF-36 Component Baseline ER p 
Physical function 42 (24) 51 (26) 0.060 
Role limitation due to physical problems 33 (40) 53 (44) 0.010 
Pain 68 (28) 68 (25) 0.980 
General health perception 36 (19) 44 (21) 0.020 
Energy/vitality 45 (26) 59 (24) 0.004 
Social functioning 61 (32) 71 (33) 0.009 
Role limitation due to emotional problems 59 (46) 79 (33) 0.020 
Mental health 63 (21) 73 (20) 0.002 
Physical component summary 44 (21) 54 (23) 0.001 
Mental component summary 53 (24) 65 (21) <0.0001 
 
Table 5.13: SF36 scores baseline to end of study (n=24) 
SF-36 Component Baseline  EOS  p 
Physical function 44 (24) 56 (26) 0.010 
Role limitation due to physical 
problems 
35 (40) 56 (44) 0.006 
Pain 70 (29) 67 (28) 0.590 
General health perception 36 (20) 43 (25) 0.110 
Energy/vitality 49 (25) 56 (24) 0.010 
Social functioning 66 (31) 76 (24) 0.080 
Role limitation due to emotional 
problems 
65 (44) 71 (40) 0.470 
Mental health 68 (20) 67 (20) 0.230 
Physical component summary 46 (22) 55 (24) 0.005 
Mental component summary 57 (24) 62 (23) 0.280 
 
Changes in SF-36 score between baseline, end of the residential exercise phase and 
the end of the study in those completing the exercise programme are show in in 




Table 5.14: Change in SF36 in subjects completing the exercise programme (n=22) 
Assessment 
time point 
Baseline  End 
residential  
p EOS  p 
Physical 
function 
45 (24) 54 (26) 0.080 57 (23) 0.02 
Role limitation 
due to physical 
problems 
36 (41) 56 (44) 0.007 57 (43) 0.01 
Pain 71 (28) 70 (26) 0.810 67 (27) 0.590 
General health 
perception 
38 (19) 47 (21) 0.020 44 (24) 0.180 
Energy/vitality 49 (26) 62 (25) 0.002 55 (24) 0.02 
Social 
functioning 





62 (45) 79 (35) 0.060 70 (41) 0.380 
Mental health 67 (21) 76 (20) 0.010 65 (20) 0.210 
PCS 47 (21) 57 (24) 0.001 55 (23) 0.009 
MCS 56 (25) 68 (21) 0.0005 62 (23) 0.130 
PCS – physical component score, MCS - mental component score 
 




When comparing the effect of the exercise intervention to the control arm, two 
analyses were performed. The first (Table 5.15) was an unpaired comparison of the 
control arm (Group B) vs the immediate exercise therapy arm (Group A). Of the SF-
36 components, only “Mental Health” improved significantly.  
Table 5.15: SF-36 control (Group B) versus Immediate Exercise therapy (A) 
 Mean change 
treatment (A) (n 
13) 
Mean change 
control (B) (n 9) 
P   
Physical function 14 (25) 0.56 (19) 0.180  
Role limitation due to 
physical problems 
23 (31) 2.8 (34) 0.370  
Pain -5.6 (12) 0.0 (0.0) 0.230  
General health 
perception 
7.7 (18) 1.3 (8.4) 0.570  
Energy/vitality 3.5 (11) 0.0 (5.0) 0.540  
Social functioning 7.7 (27) 2.8 (16) 0.890  
Role limitation due to 
emotional problems 
2.6 (48) 15 (29) 0.390  
Mental health -3.4 (17) 3.1 (5.6) 0.047  
PCS 8.4 (15) 1.0 (9.8) 0.460  
MCS 0.64 (22) 4.6 (6.5) 0.300  
 
In an unpaired comparison of all patients who received the exercise intervention 
(Group A and group B patients following the control phase) to the control arm, no 
variables showed a convincingly significant improvement	(Table 5.16). 
Table 5.16: SF-36 control (B) versus all subjects post exercise therapy (A+B) 
 Mean change 
treatment (A + B) 
(n 24) 
Mean change 
control (B) (n 9) 
P   
Physical function 13 (23) 0.56 (19) 0.15  
Role limitation due to 
physical problems 
21 (30) 2.8 (34) 0.35  
Pain -4.0 (12) 0.0 (0.0) 0.29  
General health 
perception 
7.3 (19) 1.3 (8.4) 0.49  
Energy/vitality 6.5 (10) 0.0 (5.0) 0.07  
Social functioning 9.9 (25) 2.8 (16) 0.54  
Role limitation due to 
emotional problems 
5.6 (41) 15 (29) 0.41  
Mental health -1.8 (14) 3.1 (5.6) 0.11  
PCS 8.8 (13) 1.0 (9.8) 0.27  
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MCS 3.7 (18) 4.6 (6.5) 0.74  
 
WHO FC 
WHO FC was measured at baseline, the end of the residential phase and at the end 
of the study. No significant difference was detected pre and post exercise therapy 
in the 26 patients who completed the programme and final assessment, x2 1.527, p 
0.676 (Table 5.17, Figure 5.13).   
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Table 5.17: Contingency table comparing WHO FC between baseline and End of Study 
 
* FC categories whose column proportions do 
not differ significantly from each other at 
the .05 level.  
Functional Class 
I II III IV 
Baseline Count 1* 11* 14* 0* 
Expected Count 1.0 12.0 12.5 .5 
EOS Count 1* 13* 11* 1* 
Expected Count 1.0 12.0 12.5 .5 
 
 
Figure 5.13: Distribution of WHO FC from baseline to EOS 
    
 Right ventricular ejection fraction 
There was no significant change pre and post exercise therapy in right ventricular 
ejection fraction (RVEF); At baseline RVEF was 44.6% (13.3) and at the end of 
study was 47.5% (13.2), p 0.15 
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In those who received the active intervention (n 26) mean RVEF change was 2.93% 
(8.7) at the end of study versus -1.1% (11.2) in the control group, p 0.51 
The response of cardiac MRI variables to exercise therapy is discussed in Chapter 8. 
 Adverse events  
Adverse events were monitored during the active intervention by direct 
communication (in person or by phone) and through patient diaries.   
 Serious adverse events  
No deaths occurred during the study and no study related serious adverse events 
(SAE) occurred. One death occurred within 30 days of a subject exiting the study 
(Subject A1). This subject had withdrawn from the study due to recurrent lower 
respiratory tract infection and comorbidities requiring hospitalisation. The cause of 
death (fall, rib fractures and pneumonia) was reported to the REC and deemed 
unrelated to the study intervention. All other subjects resumed the study 
intervention after the SAE resolved 
Table 5.18 Serious Adverse Events 
SAE Frequency 
Pneumonia or chest infection requiring hospitalisation 4 
Viral illness requiring hospitalisation (labyrinthitis, non-
specific) 2 
Ventricular pauses requiring pacemaker 1 
Cholecystitis 1 
Syncope – noncompliance with PAH medication and fluid 
deplete 1 
Rib fractures after fall (unrelated to exercise) and chest 
infection 1 
 
 Adverse events  
The total number of adverse events recorded was 55, ranging from 0 to 5 per 
subject, with a median of 2 (Table 5.19, Figure 5.14). The miscellaneous adverse 
events observed or reported were urinary tract infection, paroxysmal second-
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degree heart block, rectal bleeding, chronic cough, thrush, renal impairment, 
chest pain due to hypoxaemia, anxiety, headache and thrombocytopaenia 
Table 5.19: Adverse events  
Distinct episodes % of AEs 
Musculoskeletal problems 13 24 
Chest Infection 10 18 
Viral illness 9 16 
Dental problems 3 5 
Peripheral oedema 3 5 
Anaemia 3 5 
Ear Infection 2 4 
Fatigue 2 4 
Miscellaneous (frequency 1) 10 18 
 
 
Figure 5.14: Adverse events 
 
 
 Adherence  
Complete data for the residential phase was available for 24 subjects and 21 in the 
outpatient phase. The majority of the data omission was due to lack of completion 
of exercise logs. The subjects who did not return exercise logs on a weekly basis 
reported adherence with the study intervention during the weekly phone call to 










Musculoskeletal problems Chest infection Viral Illness
Dental Problems Peripheral oedema Anaemia
Ear infection Fatigue Miscellaneous
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Six subjects (29%) reported 100% compliance with the study intervention and also 
reported additional exercise sessions on top of those provided in the daily 
schedule.  
Adherence to the study intervention is reported in Table 5.20 
Table 5.20: Adherence to exercise therapy 
 Median N scheduled 
sessions (range) 






40 (36-41) 39 (36-41) 98% 
Outpatient  
n 21 
228 (107-380) 206 (45-273) 82% 
Total 
n 21 
268 (148-421) 256 (81-314) 86% 
 
Adherence was higher in all phases of the exercise programme in subjects who had 
an improved 6MWD following the study intervention, statistical significance was 
reached in comparisons of the residential phase only (Table 5.21) 
Table 5.21: Improvement based on delta 6MWD and relationship with adherence 
 Responders  n Non 
responders  
n p 
Residential  99.3% (±2) 14 96.8% (±5) 10 0.026 
Outpatient 87.9% (±12) 13  73.1% (±28) 8 0.238 
Overall 91.8% (±11) 13  76.2 (±25) 8 0.161 
 
 Predicting response and prognosis 
A post hoc analysis was performed to explore factors predictive of a positive 
response to exercise therapy and transplant free survival. 
 Responders and non-responders to exercise therapy 
A positive response to treatment was defined as an improvement in 6MWD of ≥ 
30m. Twenty five subjects had complete pre and post intervention data, due to 
the drop outs discussed in section 5.4.2. 25 subjects were therefore analysed for 
both baseline predictors and pre and post exercise analysis.  
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15 subjects improved 6MWD greater than 30m (Responders), 10 showed no 
clinically significant change or deteriorated 6MWD (non-responders). Subjects who 
improved had lower baseline NTproBNP and were less likely to have CTD-PAH 
(Table 5.22)  
Table 5.22: Baseline characteristics of responders versus non responders  
Baseline  Responders 
n 15 
Non responders   
n 10 
p 
Age (y) 53.5 (10.6) 52.6 (14.9) 0.814 
Sex (M) 6/15 (40 %) 2/10 (20%) 0.739 
Drug therapy      
Triple Therapy 7/15 (%) 5/10 (50%) 0.758 
Dual Oral Therapy 9/15 (%) 5/10 (50%) 
Diagnosis        
IPAH / Heritable 12/15 (80%) 5/10 (50%) 0.317 
CTD-PAH 2/15 (13%) 4/10 (40%) 
POPH 1/15 (7%) 0 
CTEPH 0 1/10 (10%) 
Time since Diagnosis  
(months) 
97.5 (128) 81.2 (63.9) 0.877 
BMI (kg/m2) 29.3 (6) 30.0 (7.6) 0.715 
6MWD (M) 439 (82) 438 (97) 0.657 
EmPHasis-10 24.6 (14) 23.3 (15) 0.677 
TLCO (ml/min/Kpa) 5.3 (1.8) 4.1 (2.2)* 0.156 
Peak CPET WR (watts) 85 (21) 70 (15) 0.033 
Peak VO2 (L/min) 1.06 (0.2) 0.89 (0.1) 0.049 
VE/VCO2 gradient  38.4 (6.7) 49.4 (14.7) 0.035 
Alive / transplant free at 
censoring 
14/15 (93%) 8/10 (80%) 0.129 
Log NT pro BNP  2.07 2.59 
0.019 
*8 subjects analysed for deteriorated TLCO, **9 subjects analysed for deteriorated NTproBNP 
Mann Whitney U test used for unpaired comparisons depending on normality. Anova for 
multiple comparisons  
 
In subjects who improved with exercise therapy, improvements were also seen in 
peak aerobic exercise capacity on CPET, ventilatory capacity at peak exercise, 
NTproBNP and quality of life (Table 5.23).  
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Table 5.23: Comparison of changes in key parameters with exercise therapy in those who 
improved vs deteriorated 
 Responders  
(n 15) 
Non responders  
(n10) p 
6MWD (m) 71.8 (29) -10.3 (28.4) 0.001 
Peak WR (W) 14.71* (15.7) 0.6 (9.9) 0.011 
Peak (VO2 ml/min/kg) 1.74* (2.0) -0.1 (1.4) 0.015 
End exercise O2 pulse 
(% predicted) 5.86* (9.8) -1 (7.1) 0.065 
Minute Ventilation 
(L/min) 6.43* (10.5) -0.4 (6.2) 0.04 
Tidal Volume (L) 0.24* (0.18) -0.17 (0.8) 0.015 
Log NTproBNP  0.11 (0.22) -0.38*** (0.9) 0.034 
VE/VCO2 at AT 
(mmHg) -4.2* (4.1) 0.68*** (5.1) 0.051 
Ve/VCO2 gradient -3.1* (4.8) -5.69*** (10.1) 0.313 
EmPHasis-10  -8 (12) 0.75** (2.1) 0.018 
N analysed *14, **8, ***9 
 
 Transplant free survival 
At the point of censoring (January 2019), 8 patients enrolled in the study had been 
transplanted (2) or died (6). There were no deaths during the study intervention. 
Twenty nine of the 30 subjects enrolled in the study were analysed. One subject 
was not analysed (B11) due to dropping out in the control phase, with no baseline 
data. This subject died after withdrawal from the study, therefore the analysed 
population had 22 alive, 5 deaths and 2 transplanted at censoring.  
Subjects who remained alive had a higher baseline 6MWD, higher TLCO, lower 
NTproBNP and higher peak aerobic exercise capacity (Table 5.24)  
Table 5.24: Baseline demographics of alive versus dead/transplant at censoring 
Baseline Alive at censoring 
(22) 
Transplant or dead at 
censoring (7) 
p 
Age  52.2 (11.4) 53.7 (11.6) 0.755 
Sex (M) 6/22 (27%) 2/7 (29%) 0.197 
Drug therapy     
Triple Therapy 10/23 (43.4%) 3/7 (42.8%) 0.966 
Dual Oral 
Therapy 
13/23 (56.6%) 4/7 (57.2%) 
Diagnosis        
IPAH 17/23 (69.6%) 4/7 (57%) 0.317 
CTD-PAH 4/23 (17.4%) 2/7 (28.6%) 
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POPH 1/23 (4%) 0 
CHD-PAH 0 1/7 (14.3%) 
CTEPH 1/23 (4%) 0 
Time since 
Diagnosis  
91 (112) 99 (55) 0.852 
BMI 29.5 (9) 31.5 (7.1) 0.544 
6MWD (M) 452 (77) 327 (87) 0.004 
EmPHasis-10 24 (15) 31 (12) 0.283 
CAMPHOR total 33 (18) 35 (15) 0.885 
RVEF (%) 45 (12) 42 (15) 0.629 
 
Due to the small size of the population, there were few statistically significant 
differences in variables pre and post exercise therapy in those alive without 
transplant at censoring (Table 5.25) 
Table 5.25: Comparison of changes in variable in those alive versus dead or transplanted  
Alive n Dead / Transplant n p 
6MWD (m) 45 (45) 21 9 (70) 4 0.200 
EmPHasis-10 -5.5 (2) 21 0.5 (11) 2 0.470 
Peak WR (%) 8 (10) 21 -9 (14) 3 0.026 
Peak VO2 (%) 6.6 (11) 21 -3 (0.6) 3 0.154 
Log NTproBNP -0.7 (1.4) 21 0.1 (0.2) 2 0.373 
VE/VCO2 gradient -4.6 (6.2) 21 1 (15.8) 3 0.743 
 
 Discussion  
This is the first UK based study of exercise therapy in PAH and the first study to 
assess patients exclusively on optimal therapy in accordance with ERS guidelines.  
6MWD improved significantly, in conjunction with QOL following a 15 week PAH 
specific exercise programme. In those who had no improvement in 6MWD, QOL 
remained unchanged. The increase in 6MWD of 38m seen in this study is above the 
MCID for 6MWD but appears low in comparison with earlier studies[61], where 
mean changes of up to 60m were seen. This may be explained by the fact the 
latter population were on a combination of monotherapy and dual therapy, in 
comparison to optimal therapy with either dual or triple therapy in this study. A 
significant proportion of subjects were several years post diagnosis and the timing 
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between diagnosis and initiation of exercise therapy may also have bearing on the 
observed difference.  
Despite the clear evidence that exercise is beneficial in PAH [60], the optimal 
outcome measures for assessing long-term efficacy have yet to be defined. There 
is a lack of data assessing the impact of exercise training on disease progression 
and survival. Recent studies of drug therapy in PAH have used composite end 
points and time to clinical worsening [8] it has also been proposed that time to 
clinical improvement may be a more meaningful outcome. In this study, baseline 
6MWD correlated with QOL as did changes in 6MWD and QOL. These changes were 
associated with more favourable baseline prognostic biomarkers, therefore the 
6MWD seems a robust primary outcome measure in determining the short term 
outcomes from studies of exercise intervention. Further research is required to 
identify appropriate biomarkers and patient centred outcomes that relate to 
transplant free survival and long term outcomes. 
Adherence is strongly associated with the success of any exercise training 
programme. In this study, subjects who improved with the exercise programme 
had a higher adherence rate than those who deteriorated or had unchanged 6MWD 
at the end of study visit. Adherence was high in the initial residential phase where 
there was intensive physiotherapy and medical input and lower in the outpatient 
phase. The residential phase allowed safe, structured and accelerated acquisition 
of the exercise techniques and also produced rapid benefit, giving the subject 
positive feedback and encouraging ongoing and future compliance. The dropout 
rate for the study was 16%, similar to published clinical trials evaluating PAH 
therapy. 
Given the intensive nature of the residential phase, and the lack of rehabilitation 
infrastructure in the UK, it is possible that an outpatient based rehabilitation 
programme would be more feasible from a resource perspective but have poorer 
compliance. It would therefore seem logical to target factors known to be 
associated with poor compliance such as mental health, social isolation and high 
BMI, with specific interventions such as psychology and dietetics to optimise 
compliance and yield from the therapy.  
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Training interruptions due to intercurrent illness were relatively common, 
predominantly due to respiratory tract infections and musculoskeletal problems. 
Due to the nature of the PAH disease process and associated comorbidities, 
training interruptions are likely inevitable and frequent. It is not known whether 
exercise and its associated anti-inflammatory effects have a negative effect on the 
immune system and result in higher rates of infection. Due to the absence of study 
related SAE or AEs, exercise therapy appears to be safe in a monitored and 
structured environment.  
During the study period, one patient with advanced IPAH on triple therapy 
underwent successful lung transplantation, having been listed prior to enrolment in 
the study. This subject demonstrated a 54m improvement in 6MWD from baseline 
and had significantly improved QOL scores. Exercise therapy therefore shows 
promise not only as an adjunctive therapy to pharmacological management, but 
also may have a role in “pre-habilitation” of patients for major surgery such as 
lung transplantation or pulmonary endarterectomy.  
A post-hoc analysis was performed to explore potential factors that may predict 
individuals more or less likely to respond well to exercise therapy and to see if this 
was associated with transplant free survival. The study was appropriately powered 
to detect a change in the primary outcome measures of 6MWD and QOL. It was not 
designed to predict survival or analyse sub-groups based on gender, disease 
category or survival. These data are therefore exploratory. Interesting signals as to 
sub-groups that are less likely to improve are present and discussed below, 
however a larger study with pre-defined and appropriately powered sub-groups 
would be needed to robustly address these questions and make definitive 
recommendations. 
Following the post-hoc analysis, there appeared to be a distinct population of 
patients who did not improve with exercise therapy and two subjects deteriorated 
during the study period due to progressive PAH. Those who did not improve had 
lower baseline exercise capacity and markers of poorer prognosis. There did not 
appear to be a significant difference in the time from diagnosis, however given this 
data, the yield from exercise training may be higher when patients are at an 
earlier stage in their disease process with less deconditioning. A potential strategy 
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could be to embark on exercise therapy as soon as patients have been stabilised on 
initial medical therapy around 3 months after diagnosis.  
The CTD-PAH population warrants specific study. A large proportion of the “non-
responders” had CTD-PAH. It is unclear whether this group are less responsive to 
exercise therapy or the lack of improvement reflects disease severity and 
inevitable poor trajectory associated with CTD-PAH. It is possible that despite the 
“lack of improvement” seen in the PAH group, exercise therapy may slow disease 
progression and it is possible that this population require different outcome 
measures. A dedicated, controlled study assessing exercise therapy in CTD patients 
is required to address these factors. 
 Conclusions 
Exercise therapy in a UK PAH population is efficacious as evidenced by significant 
improvements in quality of life and exercise capacity in an established PAH 
population on optimal drug therapy. With appropriate monitoring and expertise, 
exercise rehabilitation for PAH patients is feasible and safe outwith an established 
rehabilitation infrastructure, with an acceptable adherence rate.  
Baseline prognostic markers indicative of increased disease severity, such as 
reduced TLCO, low peak VO2 and high NTproBNP were associated poorer transplant 
free survival and a lack of improvement in exercise capacity. Further work is 
required to identify the optimal timing of rehabilitation in relation to initiation of 
drug therapy and the disease process. 
  
 136 
Chapter 6 Assessing the impact of exercise 
therapy on gas exchange, ventilation and 
exercise capacity in PAH 
 Introduction 
The most common presenting symptom in PAH is dyspnoea; it correlates closely 
with quality of life and self-reported dyspnoea scores have been shown to 
correlate with prognosis[23]. In PAH, dyspnoea is multifactorial and the 
pathophysiological abnormalities contributing to this symptom must be understood 
in order to develop therapies to improve it.  
Efficient exercise requires the simultaneous, coordinated activation of the 
cardiovascular and ventilatory systems to meet the metabolic needs of the working 
muscles. The requirements for efficient exercise are discussed in chapter 1 and 
cardiovascular responses to exercise are discussed in chapters 7 and 8. 
This chapter will explore how exercise training influences ventilation and gas 
exchange in PAH. It will also assess the role of different forms of exercise testing 
in determining the efficacy of exercise training in PAH.  
 Pulmonary Function in PAH 
 Overview of abnormalities in Lung function in PAH  
The most prognostically relevant abnormality measured in PFTs in PAH is in gas 
exchange, however a number of other abnormalities in physiology are common. 
These changes are summarised in  
Table 6.1 and discussed further below.  
Table 6.1: Lung function abnormalities in PAH 
Spirometry Normal or Airflow obstruction[157] 
Lung Volumes Normal or reduced TLC[158] 
Mouth Pressures Normal or reduced [159] 
Gas Transfer Reduced [160] 
Arterial Blood Gas Normal or reduced PaCO2[161] 
Normal or reduced PaO2 
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 Principles of gas exchange and measurement  
The Roughton and Forster model describes gas transfer (total diffusion resistance, 
mmol-1.min. kPa) as two resistances in series: the diffusion of the gas across the 
alveolar-capillary membrane (1/Dm), the transfer into the plasma and across the 
red blood cell membrane, and the chemical reaction of the gas with haemoglobin 
(Hb) (1/θV𝑐)[162]. The following equation summarises these concepts: 
1/DL = 1/Dm  +1/θV𝑐 
 
 
DL: total lung diffusing capacity; Dm alveolar-capillary membrane diffusing capacity; V: volume of 
blood in the pulmonary capillaries; and θ is the rate of reaction of the gas with the red cell.  
 
The transfer factor of the lung for carbon monoxide (TLCO) measures the partial 
pressure difference between inspired and expired carbon monoxide. TLCO provides 
information about the ability of the lungs to transfer gas from the alveolar space 
to the red blood cells in the pulmonary vessels. It is the product two 
measurements during breath holding at full inflation: KCO (the rate of uptake of 
carbon monoxide from alveolar gas), and the alveolar volume (VA). KCO is linearly 
related to the alveolar uptake efficiency for carbon monoxide and directly reflects 
the quality of alveolar–capillary gas uptake[163]. VA is the alveolar volume 
available for gas exchange.  
TLCO  = KCO x VA 
In normal subjects, the VA should be within 10% of the TLC. The VA/TLC ratio does 
not depend on age or body size, it decreases in maldistribution of ventilation and 
in intrapulmonary airflow obstruction. The same TLCO may occur with different 
combinations of KCO and VA, each representing different pathologies.  
Decreased VA occurs in  
1. Reduced alveolar expansion 
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2. Alveolar damage or loss 
3. Maldistribution of inspired gases with airflow obstruction 
Decreased KCO occurs with  
1. Alveolar-capillary damage 
2. Microvascular pathology 
3. Anaemia.  
Increased KCO occurs with:  
1. Failure to expand normal lungs to predicted full inflation (extra-pulmonary 
restriction) 
2. Increased capillary volume and flow; global (e.g. left to right shunt) or local 
flow and volume diversion (e.g. pneumonectomy) 
 Gas exchange in PAH 
Untreated, three quarters of IPAH patients have TLCO of <80% predicted. This 
abnormality has been consistently observed across studies, including when 
adjusted for smoking status. Low TLCO in PAH is independently associated with 
poorer survival, particularly at values under 45% [164].  
Both pulmonary membrane diffusion capacity and the pulmonary capillary blood 
volume are reduced in PAH. Reductions in pulmonary membrane diffusion capacity 
may be secondary to thickening of the alveolar capillary membrane due to 
endothelial cell proliferation. Reduction in pulmonary capillary blood volume may 
be the result of increased pulmonary vascular resistance, reduced cardiac output 
and local thrombosis [160].  
Confounding factors may affect the TLCO in PAH. In an observational study of 166 
IPAH patients, those with TLCO under 45% had higher BMI, older age, higher 
tobacco exposure and lower FEV1/FVC ratio[165].  
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From a physiological perspective, concern exists that reducing pulmonary arterial 
tone with vasodilators potentially results in a deterioration in V/Q matching[166], 
and therefore may worsen hypoxaemia; this effect has been seen with the 
vasodilator nitric oxide in critically ill patients with lung disease. More recent 
observational studies have suggested that improvements in gas exchange can occur 
with PAH therapy, with no deterioration in oxygenation[167]. Further prospective 
research is required to robustly establish the effect of different classes of 
vasodilators on gas exchange in PAH.  
 Effect of exercise on gas exchange 
Acutely during exercise, TLCO and KCO rise, with a constant VA. This is due to 
recruitment of alveolar vessels and distension of the pulmonary capillary bed due 
to the rise in PAP associated with exercise. This results in increased capillary 
volume and membrane diffusion capacity.  
No studies of exercise therapy in PAH have specifically looked at the effect of 
exercise training on changes in TLCO over time. A study comparing gas exchange in 
athletes to sedentary individuals, demonstrated that exercise diffusion capacity in 
athletes was higher due to increased membrane diffusing capacity rather than 
capillary blood volume. In the same study, resting alveolar capillary blood volume 
correlated with peak VO2[168]. In COPD, a study of 137 patients undergoing 
pulmonary rehabilitation found that TLCO improved regardless of disease severity 
or ventilatory inhomogeneity. The mechanisms proposed for this varied depending 
on the degree of ventilatory homogeneity, defined as  VA/TLC. Those with VA/TLC 
< 0.8 improved TLCO by increased alveolar volume, whereas those with VA/TLC 
>0.8 improved TLCO through improved KCO.  
 Respiratory Muscle Weakness 
Histological changes associated with striated muscle in PAH are discussed in 
Chapter 9. Data regarding respiratory muscle function in PAH are from small, 
single centre studies. One study of 27 IPAH patients found reduction in maximal 
inspiratory (MIP) and expiratory pressures (MEP), together with an increased mouth 
occlusion pressure within first 0.1 s of inspiration (P0.1) at rest, suggesting 
inadequate muscle effort with regards to central drive[95].   Volitional and non-
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volitional diaphragm strength is also reduced compared to age and sex matched 
controls[159].  
Very little evidence exists on respiratory muscle function during exercise in PAH. A 
small study of ten IPAH and HPAH patients found that around half had dynamic 
hyperinflation, this was associated with increased levels of dyspnoea, but no 
differences were found in oesophageal measurements of inspiratory muscle 
strength. The authors proposed this was due to altered respiratory muscle 
mechanics rather than muscle weakness [169]. 
Hyperventilation is common in PAH and further exacerbates the imbalance in 
inspiratory muscle demand and the impaired capacity to generate force due to 
muscle weakness. This is likely to contribute to reduced exercise capacity, 
dyspnoea and quality of life in PAH [170]   
Respiratory muscle training is an established component of pulmonary 
rehabilitation programmes. Inspiratory muscle training both in combination with 
aerobic exercise and in isolation, has been shown to improve dyspnoea scores and 
exercise capacity in IPAH, however the numbers studied have been small [171]. 
 Hyperventilation  
Hyperventilation occurs at rest, during exercise and has been observed during 
sleep in PAH. Low PaCO2 (PaCO2 <4.25kPa) in the arterial blood of PAH patients is 
a strong, independent marker of poor prognosis, and relates to cardiac output and 
exercise capacity[172]. The degree of ventilatory inefficiency is related to 
survival, particularly the VE/VCO2 slope (discussed below in 6.1.2.3) [173]. 
Intuitively, increased dead space secondary to V/Q mismatch results in an 
increased respiratory rate. End tidal carbon dioxide (PETCO2) is consistently low in 
PAH, meaning dead space increases alone do not explain hyperventilation. Studies 
in IPAH and CTEPH have suggested increased chemosensitivity to both hypoxia and 
hypercapnia[174] through CPET and blood gas analysis, however no studies have 
yet assessed neural drive to further characterise this.  
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 Airflow obstruction 
Airflow obstruction has been observed in up to one third of IPAH patients 
compared to matched healthy controls, being defined as a forced expiratory 
volume in 1 second (FEV1) to forced vital capacity (FVC) ratio (FEV1/FVC) of less 
than 0.7[175]. Mid-expiratory flow measurements are more commonly reduced in 
PAH; these measurements relate to peripheral airway obstruction and small 
airways disease. Parenchymal lung changes do not occur in IPAH, however it is 
postulated that hypertrophied blood vessels have a direct effect on small airways 
and can result in loss of distensibility. In keeping with this, some studies have 
observed that up to one quarter of patients have reduced total lung capacity 
(TLC)[158] 
 Exercise testing in PAH 
Exercise tests are reliable, responsive to rehabilitation and pharmacological 
intervention and provide information on the mechanisms of exercise intolerance. 
Their incorporation into clinical trial design and use as end points in PAH has been 
recommended by European guidelines and the European Medicines Agency[62]. The 
most commonly utilised exercise tests in PAH are the 6MWT and Cardiopulmonary 
Exercise Test (CPET). Other tests such as the shuttle walk test and endurance tests 
have been used but have a smaller evidence base. The 6MWT is discussed in 
chapter 5, endurance testing and CPET are discussed below.  
 Subjective exercise scoring systems  
The modified Borg dyspnoea score is a validated numerical score rated 0 to 10, 
used to measure patient reported dyspnoea during exercise testing. An equivalent 
scoring system exists for leg fatigue. In healthy individuals, leg fatigue is the 
predominant symptom at end exercise[176]. The Borg dyspnoea score is 
incorporated to various forms of exercise testing such as 6MWT and CPET. 
 Cardiopulmonary Exercise Testing – General Principles  
The standard incremental CPET allows evaluation of the physiological responses to 
submaximal and peak exercise responses to produce an output known as the nine-
panel plot (9PP) (Figure 6.1). The 9PP provides integrated data on exercise 
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capacity, effort, oxygen delivery, ventilation and gas exchange. The ATS provide 
robust guidelines on the required equipment and methods for performing an 
incremental cardiopulmonary exercise test[177].  
 
Figure 6.1: example of a 9-panel plot 
 
Relevant parameters regarding CPET interpretation are discussed below[18]  
1. Exercise capacity 
End exercise work rate (WR): Maximum number of Watts produced at end exercise  
Oxygen uptake (VO2): measured from expired gas, the oxygen uptake each minute.  
Respiratory Exchange Ratio (RER): The ratio of VCO2 to VO2 (VCO2/VO2), at rest 
should be equivalent the respiratory quotient (RQ) (VCO2/VO2 at tissue level). 
Affected by RQ and hyperventilation. 
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Anaerobic threshold (AT): An estimate of the onset of metabolic acidosis. 
Measured using the V-slope method, where there is an upwards deflection in the 
VCO2-VO2 relationship[178] 
Ventilatory compensation point (VCP): when the VE/VCO2 ratio increases in 
conjunction with the PETCO2 falling. Correlates well with critical power and may 
not be present in sub-maximal exercise tests 
2. Gas exchange  
Alveolar-arterial oxygen difference (A-a gradient): Difference between alveolar 
and arterial pressure of O2. Under 10mmHg is normal in young adults with values 
rising around 1mmHg for each decade of life. Raised values indicate gas exchange 
abnormalities 
Dead space fraction (Vd/Vt): Physiological dead space; the fraction of inspired air 
that does not exchange gas with capillary blood 
End tidal partial pressure of CO2 (PETCO2): partial pressure of CO2 in exhaled gas, 
surrogate marker for alveolar [CO2] 
Ventilatory equivalents for CO2 (VE/VCO2): the number of litres of ventilation per 
litre of CO2. Marker of ventilatory efficiency.  
VE/VCO2 slope: The relationship between minute ventilation and CO2 output, a 
marker of ventilatory efficiency 
3. Oxygen delivery (Cardiovascular Function): 
Oxygen pulse: The volume of O2 consumed per heartbeat. VO2/HR, units 
mLO2/beat 
HR/VO2 slope: Increases in this relationship imply lack of cardiac efficiency, 
reductions imply chronotropic incompetence.  
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VO2/WR slope: In health the ΔVO2/ ΔWR slope typically increases at 
10ml/min/watt until peak exercise. Reduction in the gradient of VO2/WR implies 
cardiovascular inefficiency. 
4. Ventilation 
Minute ventilation (VE): The volume of air exhaled in one minute  
Tidal volume (Vt): Volume of a single breath 
 
 Cardiopulmonary exercise testing in PAH  
Cardiopulmonary exercise testing (CPET) is a powerful tool for diagnosis, 
assessment of treatment response and risk stratification in PAH. Exercise 
intolerance is the hallmark of PAH; CPET recreates an environment in which 
patients experience limiting symptoms and the physiological changes that occur 
with these symptoms can be captured. It allows assessment of disease severity by 
measuring known prognostic markers such as the VE/VCO2 gradient. It is non-
invasive and reproducible in expert hands[179] and several large case series have 
reported on the high level of safety, with no deaths and an adverse event rate of 
0.2% or less [136, 180]. 
In PAH, peak aerobic exercise capacity is typically reduced, with impaired oxygen 
delivery and ventilatory inefficiency due to gas exchange abnormalities and 




Figure 6.2: Typical 9PP in PAH 
 
Gas exchange abnormalities: High Ve/VCO2 gradient, low PETCO2 at baseline 
and throughout exercise, high ventilatory equivalents for O2 and CO2. 
 Oxygen delivery abnormalities: High HR/VO2 gradient, low peak O2 pulse 
 Exercise capacity: Low peak VO2 
 End exercise desaturation. Otherwise normal ventilation.  
Exercise limitation and ventilatory inefficiency are strongly linked to survival; VO2 
< 15ml/min/kg and VE/VCO2 slope > 36 are associated with poorer prognosis[181]. 






CPET parameters have not been commonly employed end points of PAH clinical 
trials, despite their prognostic value. Early experience with CPET parameters as  
end points may have hindered future adoption in clinical trials; studies of 
Sitaxentan and Beraprost failed to demonstrate significant improvement in gas 
exchange or VO2 despite improvements in 6MWD, however it was possible that 
there were methodological limitations to these studies. Subsequent smaller non-
randomised studies of sildenafil and IV prostacyclin have shown improvements in 
peak VO2 with associated mortality benefit[179]. 
In studies of exercise therapy, a meta-analysis of 469 patients with PAH and CTEPH 
reported a significant improvement in peak VO2 of 1.84 ml/kg/min, however 
significant heterogeneity existed between included studies[182]. The majority of 
the studies were non-randomised, there were a combination of incremental and 
step-wise CPET protocols and a large proportion of patients were on monotherapy.  
No minimum clinically important difference in CPET parameters have been 
established in PAH, however treatment goals exist and advocate aiming for a peak 
VO2 of > 15ml/Kg/min and VeqCO2 of < 45L.min.L.min [183]  
 Endurance tests 
 Concept of steady state exercise  
Steady state exercise refers to aerobic exercise where there is equilibrium 
between energy supply and utilisation. At exercise levels below critical power, VO2 
increases exponentially until a steady state level Is reached [184](Figure 6.3). 
Under these circumstances, there is neither accumulation of lactate in muscle or 
blood, nor changes in muscle phosphocreatine concentration, and therefore VO2 
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represents vast majority of metabolic energy liberation[185]
 
Figure 6.3: Oxygen kinetics in steady state exercise and exercise beyond the critical power 
 
Steady state VO2 can usually be maintained for 10-60 minutes of submaximal 
exercise. A limit to endurance is imposed by the availability of substrates 
sustaining aerobic metabolism.  
An exercise testing protocol that achieves steady state has the advantages of being 
able to measure endurance time and make serial physiological measurements. The 
percentage of peak work rate corresponding to steady state will vary depending on 
individual levels of fitness; healthy and trained individuals will have a higher VO2 
at AT, therefore the percentage of peak work rate at which they remain in steady 
state will be greater than an untrained or diseased individual. VO2 at AT is 
typically 50-60% of peak VO2[184]. 
 Cardiac output – VO2 relationship 
Cardiac output increases with VO2 in a linear fashion; the increase in cardiac 
output is smaller than VO2 for any given increase in power due to a positive y-axis 
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intercept (Figure 6.4) [185] 
 
Figure 6.4: Cardiac Output (Q) and VO2 relationship in steady state exercise 
 
The slope of the line is equal to the reciprocal of the arterial-venous oxygen 
difference[186]. This relationship is evident in the Fick principle for cardiac 
output: CO is calculated as oxygen consumption divided by the arteriovenous 
oxygen concentration difference.  
VO2 = (CO x Ca) – (CO x Cv) 
Therefore 
CO = VO2 
           Ca-Cv 
 
 Endurance testing in PAH 
Selecting the most appropriate outcome measure to detect meaningful clinical 
change is essential in determining efficacy of exercise interventions. The exercise 
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test must be commensurate with the training modality. The majority of exercise 
rehabilitation programmes across chronic cardiac and respiratory conditions 
employ sub-maximal, aerobic exercise. Endurance tests are generally considered 
to be more sensitive at detecting improvement in functional capacity after 
exercise rehabilitation than 6MWT or maximal exercise tests [187]. In COPD, 
endurance testing has been recognised as a sensitive method for assessing 
treatment response. The endurance shuttle walk test is the most commonly 
employed testing modality, the cycling endurance test (CET) is another validated 
endurance test and in COPD has an MCID of 33% following pulmonary rehabilitation 
[188]  
Endurance tests are not commonly employed end-points in PAH and have not been 
extensively investigated. A small study of 21 PAH patients suggested that 
endurance tests in PAH produced near maximal physiological changes and argued 
that changes in exercise capacity were related to modality (walking versus cycling) 
rather than incremental versus endurance testing protocols [189]. A possible 
limitation of this study is that the critical power may have been lower than 
anticipated, due to low VO2 at AT in PAH and the “steady state” exercise may have 
been actually been anaerobic exercise.  
 Aims 
The aims of this chapter are to determine the impact of exercise training in PAH 
on: 
1. Respiratory physiology at rest and on exercise and explore potential 
mechanisms for these changes 
2. Exercise capacity, utilising both endurance, sub-maximal and maximal exercise 
tests in order to determine the most suitable outcome measure(s) for assessing 
response to the exercise programme.  
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 Methods 
Exercise tests were performed at baseline, at the end of the residential phase of 
exercise and at the end of the study. Pulmonary function tests were performed at 
baseline and after the residential exercise phase was completed.  
 Cardiopulmonary exercise testing  
Spirometry was performed before the test to allow reference values to be obtained 
for ventilatory measurements. Subjects wore a tight fitting mask, connected to the 
spirometer ( 
Figure 6.5). This mask was then used for the subsequent CPET.  
 
Figure 6.5: Spirometry being performed prior to CPET 
 
CPETs were conducted in accordance with ATS guidelines[190] using an 
electromagnetically braked cycle ergometer (Ergoselect 200, Ergoline GmbH, Bitz, 
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Germany). CPETs were carried out by a trained respiratory physiologist with 
medical supervision (AM). The face mask was connected to a metabolic cart for 
breath by breath measurement of VO2 and VCO2 (Medisoft, Sorinnes, Belgium; 
lovemedical, Manchester, United Kingdom). Oxygen saturations were measured by 
finger or ear probe and a continuous 12 lead electrocardiograph (ECG) was 
performed for cardiac monitoring. Systemic blood pressure was measured 
noninvasively by either an automated electronic or a manual sphygmomanometer 
at rest, during exercise and recovery (Figure 6.6). Borg scores for breathlessness 
and leg fatigue were obtained. Capillary blood gases were performed before and 
immediately after exercise 
 
Figure 6.6: Incremental cardiopulmonary exercise test equipment set up 
 
The ramp rate was determined by the physiologist and supervising doctor (AM) 
depending on the individual level of fitness, with the aim of achieving 8 to 12 
minutes of loaded cycling. Saddle height was adjusted for optimal cycling 
mechanics. A two minute period of resting measurements were taken, followed by 
3 minutes of unloaded cycling. A pre-determined progressive ramp rate then 
 152 
commenced until symptom limited cessation of exercise. Verbal encouragement 
was given to the subject in accordance with guidelines.  
Borg breathlessness score was performed before, during and after the test to 
assess breathlessness and leg fatigue, to determine subjective effort and the 
predominant limiting symptom. Capillary blood gases were taken before exercise 
and as close to peak exercise as possible.  
CPET analysis and reporting was performed by AM using Blue Cherry® analysis 
software (Geratherm, Bad Kissingen, Germany). AT and RCP were manually 
determined.  
 Isotime CPET measurements  
Isotime comparisons of CPET variables were performed before and after the 
exercise programme. Ramp rate was kept the same between tests for individual 
subjects, so that isotime corresponded to isowork.  Isotime (and therefore isowork) 
was defined as the time elapsed from the beginning of the ramp to the lowest of 
the two peak work rates between tests. 
 Steady state endurance testing 
Steady state endurance testing was performed at the time of exercise right heart 
catheterisation. The supine endurance exercise protocol is described in Chapter 7: 
Changes in invasively measured haemodynamics in response to exercise therapy in 
PAH. 
 Statistics  
Normally distributed variables are shown as mean (SD) and non-normally 
distributed variables are shown as median (IQR). Categorical variables are 
presented as number (%). Due to the small sample size, non-parametric tests were 
used throughout. Comparison between baseline and follow-up measurements were 
made by Wilcoxon signed rank test. Comparisons of non-paired data were made 
using the Mann-Whitney test. Correlation between two variables was determined 
by Spearman correlation coefficient.  
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 Results  
 CPET 
Baseline characteristics are displayed in  
Table 6.2. The findings were typical of a PAH population, with reduced peak 
aerobic exercise capacity, impaired oxygen delivery and gas transfer. 
Using Jones VO2 % predicted[191], 9 subjects had severely reduced exercise 
capacity (VO2 < 50%), 6 had moderately reduced (51-70%), 4 had mildly reduced 
(<80%) and 9 had normal exercise capacity (>80%). From a prognostic perspective, 
six subjects had VE/VCO2 gradient greater than 45% and 19 had VO2 ml/kg/min < 
15.  
Table 6.2: Baseline CPET characteristics 
N 28 Mean  Range  
Peak WR (%) 65 22-109 
Peak VO2 L/min (%) 61 23-98 
Peak VO2 ml/kg/min 13 7-20 
Peak O2 pulse (%) 77 36-136 
VO2 / WR slope 
(ml/min/W) 
8 3-11 
VE (%) 68 48-98 
TV (L) 1.5 0.7-2.5 
RR (/min) 36 24-50 
VeqCO2 41 29-65 
VE/VCO2 gradient 41 28-73 
PET CO2 (mmHg) 30 17-45 
% signifies percentage predicted 
 
 Change with exercise therapy 
24 patients had full CPET data from baseline to end of study based on previously 
discussed drop-outs (4) and equipment malfunction (1).  Change in CPET 




Table 6.3. Significant improvements are seen in exercise capacity, oxygen 




Table 6.3: Change in CPET parameters from baseline to end of residential phase  
N 27 Baseline (SD) Week 3 (SD) p 
Peak WR (watts) 78.9 (27.6) 88.3 (34.3) <0.001 
WR (%) 65.5 (25.1) 73.3 (29.6) <0.001 
Peak VO2 (L/min) 1.0 (0.3) 1.1 (0.4) 0.003 
VO2 (%) 61.1 (21.2) 69.2 (24.9) 0.002 
Peak VO2 ml/kg/min 12.8 (3.5) 14.4 (4.6) 0.001 
VO2 at AT (L/min) 0.69 (0.16) 0.78 (0.18) 0.001 
VO2 at AT (%) 44.0 (15.6) 49.3 (16.9) 0.003 
Peak HR (BPM) 135 (22) 140 (22) 0.002 
HRR  33 (20) 28 (21) 0.002 
E.E O2 Pulse (ml) 7.3 (1.7) 8.1 (2.0) 0.002 
% O2 Pulse  77.6 (24.7) 84.5 (28.1) 0.005 
VO2/WR (ml/min/W) 8.2 (1.5) 8.6 (1.4) 0.475 
VE (L/min) 54.0 (17.4) 62.1 (21.2) <0.001 
VE (%) 67.7 (19.4) 77.6 (19.4) 0.006 
BR (L/min) 26.7 (14.7) 18.7 (17.0) 0.028 
TV (L) 1.5 (0.5) 1.7 (0.5) <0.001 
RR (/min) 36.7 (7.8) 36.3 (9.3) 0.903 
Peak O2 sats (%) 91.1 (7.9) 90.6 (7.2) 0.371 
Veq CO2 AT  41.5 (8.1) 39.7 (8.9) 0.006 
Veq O2 AT 40.4 (9.0) 38.1 (8.1) 0.036 
VE/VCO2 gradient  40.6 (10.1) 36.9 (9.9) <0.001 
PETCO2 (mmHg) 29.9 (5.9) 29.9 (8.7) 0.976 
Vd/Vt end exercise 0.36 (0.22) 0.14 (0.37) 0.293 
PA-a O2 gradient rest 63.7 (13.8) 48.2 (24.9) 0.043 
 
Change in CPET parameters from baseline to the end of the study are described in  
Table 6.4. A similar pattern is seen to the changes observed from the start of the 
study to end of the residential phase. 
Table 6.4: Change in CPET parameters from baseline to end of study 
N 24 Baseline (SD) End of study (SD) p 
Peak WR (watts) 80.1 (29.0) 89.0 (37.9) 0.007 
WR (%) 66.9 (25) 73.3 (30.3) 0.008 
Peak VO2 (L/min) 0.99 (0.3) 1.07 (0.35) 0.022 
VO2 (%) 61.4 (21.9 ) 66.8 (22.4) 0.037 
Peak VO2 ml/kg/min 12.7 (3.7) 13.7 (4.3) 0.020 
VO2 at AT (L/min) 0.68 (0.2) 0.76 (0.24) 0.030 
VO2 at AT (%) 44.1 (16.1) 47.8 (16.7) 0.077 
Peak HR (BPM) 137 (21) 140 (23)) 0.063 
HRR (/min) 30.5 (19) 27.1 (20.2) 0.034 
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E.E O2 Pulse (ml) 7.2 (2) 7.7 (2.1) 0.032 
% O2 Pulse  76.5 (25.7) 79.5 (25.9) 0.157 
VO2/WR (ml/min/W) 7.89 (2) 8.02 (1.4) 0.702 
VE (L/min) 56.3 (17.6) 59.9 (19.3) 0.048 
VE (%) 69.2 (12.5) 75.3 (15.5) 0.054 
BR (L/min) 25.9 (14.8) 19.1 (15.2) 0.116 
TV (L) 1.55 (0.5) 1.73 (0.5) <0.005 
RR (/min) 37 (7) 35 (9) 0.160 
Peak O2 sats (%) 90 (9) 89 (8.6) 0.072 
Veq CO2 AT 42.7 (8.2) 40.5 (9.6) 0.026 
Veq O2 AT 41.7 (9.1) 39.5 (10.0) 0.044 
VE/VCO2 gradient  43.1 (11.9) 38.1 (10.7) 0.004 
PETCO2 (mmHg) 29.1 (6.2) 29.5 (9.10) 0.047 
 
Change in CPET parameters in the group receiving 15 weeks standard care (Group 
B) were compared to all subjects who completed the exercise training programme 
(Table 6.5). Exercise capacity, peak HR, minute ventilation and tidal volume were 
all significantly improved in the exercise therapy group compared with control, the 
VE/VCO2 gradient just missed statistical significance, with a trend towards 
reduction.  




SD Delta Standard 
Care n 11 
SD P 
Peak WR (watts) 8.8 15.1 -3.5 5.6 0.005 
WR (%) 6.1 11.7 -3.9 5.5 0.002 
Peak VO2 (L/min) 0.08 1.43 0.00 0.12 0.224 
VO2 (%) 5.4 10.8 0.91 9.6 0.252 
Peak VO2 
(ml/kg/min) 
0.97 1.9 0.18 1.9 0.252 
VO2 at AT  0.08 0.14 0.032 0.1 0.409 
VO2 at AT (%) 3.6 9.0 2.1 6.9 0.451 
Peak HR (BPM) 3.2 6.7 -4.5 5.9 0.007 
HRR (/min) -3.4 6.6 4.81 5 0.001 
E.E O2 Pulse (ml) 0.5 0.9 0.2 0.7 0.430 
VO2/WR 
(ml/min/W) 
-0.21 2.3 0.02 1.1 0.958 
VE (L/min) 3.6 9.4 -4.9 6.9 0.004 
VE (%) 6.2 15.4 -9.5 14.1 0.004 
BR (L/min) -6.9 15.6 7.8 12.8 0.040 
TV (L) 0.17 0.19 -0.01 0.3 0.009 
RR (/min) -1.6 4.7 -3.18 5.9 0.687 
Peak O2 sats (%) -1.3 3.8 -0.36 3.6 0.283 
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Veq CO2 AT -2.2 4.9 -0.26 4.3 0.299 
Veq O2 AT -2.2 5.3 -0.15 5.3 0.517 
VE/VCO2 gradient  -5 7.9 -0.2 5.9 0.061 
PETCO2 (mmHg) 0.4 4.8 0.9 2.9 0.740 
 
 Isotime CPET analysis 
Isotime analysis was performed for baseline to week 3 (end of residential phase 
exercise) and baseline to end of study CPET as described in 6.3.1.1. Isotime 
improvements were noted in O2 pulse, TV and gas exchange in both analyses (Table 
6.6 and Table 6.7). There was an improvement in isotime VO2 between baseline 
and week 3. 
Table 6.6: Baseline to week 3 CPET highest isotime comparisons 
n 27 Baseline  SD Week 3 SD P 
Weight 80.7 18.1 80.3 16.9 0.572 
VO2 (L/min) Jones  0.99 0.26 1.1 0.23 0.012 
VO2 (L/min) Jones (%) 59 18 63 19 0.004 
VO2 ml/min/kg 12.7 3.5 13.5 3.8 0.010 
RER  1.15 0.11 1.11 0.09 0.058 
HR (BPM) 134 22 132 20 0.215 
HR % predicted max 85 13 83 12 0.210 
O2 pulse (ml) 7.4 1.5 8 1.7 0.004 
O2 pulse (% predicted)  72.1 16.7 78 19.3 0.003 
VE (L/min) 53.4 17.3 51.1 16.7 0.177 
VE % predicted 68.6 20.8 66.8 24.3 0.393 
TV (L) 1.51 0.45 1.68 0.42 0.001 
RR (/min) 36.3 7.9 30.7 7.8 <0.005 
O2 saturation (%) 90.6 7.7 91.3 7.3 0.197 
VE/VCO2  43.9 11.8 41.2 11 <0.005 
VE/VO2 49.6 13.2 46.7 14.3 0.011 
PetCO2 (mmHg) 28.9 6.8 30 7.4 0.018 
 
Table 6.7: Baseline to end of study CPET highest isotime comparisons 
N 24 Baseline  SD EOS SD P 
VO2 (L/min) Jones  0.98 0.29 1.0 0.3 0.507 
VO2 (L/min) Jones (%) 59.2 19.3 60.2 19.2 0.579 
VO2 ml/min/kg 12.5 3.7 12.9 3.9 0.299 
RER  1.15 0.09 1.14 0.09 0.604 
HR (BPM) 136 22 133 22 0.256 
HR % predicted max 86.6 13 85.2 12 0.349 
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O2 pulse (mL/beat) 7.29 1.68 7.65 2.11 0.087 
O2 pulse (% predicted)  70.9 17.9 74.1 20.1 0.128 
VE (L/min) 54.6 18.3 51.3 15.8 0.140 
VE % predicted 71.5 20.5 67.9 20.7 0.200 
TV (L) 1.54 0.46 1.67 0.49 0.033 
RR (/min) 36.3 8.1 31.2 7.6 0.001 
O2 saturation (%) 90.3 8.2 89.9 8 0.536 
VE/VCO2  45.5 12.6 43.3 12.9 0.046 
VE/VO2 51.2 14.1 48.2 13.8 0.012 
PetCO2 (mmHg) 27.9 7.1 29.3 7.7 0.008 
 
 Endurance time and assessment of exercise capacity  
Four markers of exercise capacity were compared, two maximal (peak WR, peak 
VO2), one sub-maximal (6MWD) and one endurance (cycling endurance time). All 
parameters improved significantly from baseline to the end of the study. Cycling 
endurance improved by 52% (19% greater than the MCID). 6MWD improved by 40m, 
7m beyond the MCID. Proportionate changes are displayed in Figure 6.7 and  
Table 6.8 
Table 6.8: Exercise capacity % changes with exercise therapy 
Group mean Baseline  EOS % change p 
Peak WR (W) 80 (29) 89 (38) 11.3% <0.001 
6MWD (m) 447 (86) 487 (90) 9.0% <0.001 




669 (287) 1018 (437) 52% 0.004 
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Figure 6.7: Endurance time versus conventional markers of exercise capacity 
 
 Pulmonary Function 
Baseline characteristics are displayed in  
Table 6.9 and are typical of a PAH population, with reduced gas transfer. TLCO 
was under 45% in 29% (8/28) of subjects, 32% (9/28) had evidence of airflow 
obstruction, air trapping (RV/TLC > 120%) was present in 18% (5/28), 14% (4/28) 
had ventilatory inhomogeneity (VA/TLC < 0.8). 
Table 6.9: Baseline characteristics PFTs 
N 28 Mean  Range  
FEV1 (L) 2.28 1.11-3.33 
FEV1 (%) 83.7 47-119 
FVC (L) 3.2 1.38-4.39 
FVC (%) 97.2 63-124 
FEV1/FVC (%) 71.2 53-85 
TLC (L) 5.11 2.85-7.90 
RV/TLC (%) 37.37 19-61 
MEP 1s (%) 67.39 18-166 
MIP 1s (%) 64 17-101 
KCO (Si) 1.09 0.29-1.83 
KCO% 67.52 18-103 
TLCO (ml/min/mmHg) 4.72 1.31-8.19 
TLCO % 55.5 18-90 
VA (L) 4.28 2.54-6.2 
































Total lung capacity and gas exchange improved with exercise therapy . 
Table 6.10: Effects of 3 weeks exercise therapy on pulmonary function 
N 28 Baseline  SD Week 3 SD p 
FEV1 (L) 2.28 0.55 2.254 0.586 0.451 
FEV1% 83.7 19.5 82.89 20.02 0.647 
FVC (L) 3.2 0.70 3.214 0.688 0.657 
FVC% 97.2 17.3 93.45 25.32 0.989 
FEV1/FVC 71.2 8.11 70.33 7.442 0.133 
TLC (L) 5.11 1.11 5.263 1.196 0.042 
RV/TLC 37.37 7.64 37.67 7.544 0.604 
KCO (Si) 1.09 0.421 1.144 0.488 0.114 
KCO% 67.52 22.97 71.11 26.93 0.034 
TLCO (ml/min/mmHg) 4.72 1.98 4.92 2.10 0.105 
TLCO % 55.5 21.1 57.5 22.0 0.190 
VA (L) 4.28 1.31 4.40 1.1 0.785 
VA/TLC 0.84 0.18 0.85 0.08 0.362 
 
Expiratory mouth pressures improved following exercise therapy Table 6.11 
Table 6.11: Change in mouth pressures with 3 weeks exercise therapy 
 N 27 Baseline  SD Week 3 SD p 
MEP (1 sec) 65.9 28.5 72.2 21.9 0.150 
MEP (%) 65.6 34.0 72.9 27.0 0.031 
MIP (1 sec) 60.0 23.0 63.6 18.7 0.493 
MIP (%) 63.1 23.3 65.1 25.2 0.486 
MEP (peak) 105.6 38.7 105.8 29.7 0.656 
MIP (Peak) 67.4 21.5 74.5 25.9 0.060 
Maximum expiratory mouth pressure (MEP), Maximum inspiratory mouth 
pressure (MIP) 
 
 Association between CPET and PFTs with prognostic and 
clinically relevant variables  
CPET and PFT variables associated with exercise capacity, gas exchange and 
ventilation were correlated with clinically and prognostically relevant variables 
and are discussed further below.  
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 Exercise capacity  
Baseline markers of exercise capacity correlated with IL-6, PA compliance and gas 
exchange (Table 6.12). The cytokine IL-6 is discussed further in Chapter 9.  
Table 6.12: Baseline exercise capacity correlations 
Baseline Baseline  r p N 
WR (W) IL6 (pg/L) -
0.641 
<0.001 26 
VO2 (L/min) Rca (ml/mmHg) 0.527 0.014 21 
Peak VO2 (%) VeqCO2 -
0.565 
0.006 28 
Peak VO2 (L/min) Rca (ml/mmHg) 0.527 0.014 21 
Peak WR (W) TLCO (%) 0.746 <0.005 27 




Change peak aerobic exercise capacity correlated with quality of life, peak 
exercise oxygen pulse (stroke volume surrogate) and peak minute ventilation 
(Table 6.13) 
Table 6.13: Delta exercise capacity correlations 
Delta Delta r p N 
Peak WR (W) EmPHasis-10 -0.425 0.048 22 
Peak WR (W) Peak O2 pulse 0.603 0.002 24 
Peak WR (W) VE 0.647 0.001 24 
 
 Gas exchange correlations  
Gas exchange at baseline was assessed through a number of parameters. A similar 
pattern was evident between gas exchange variables, of a correlation with 
exercise capacity, mixed venous O2 saturations, pulmonary artery compliance and 
stroke volume (Table 6.14).  
Table 6.14: Baseline gas exchange correlations 
Baseline Baseline  r p N 
VE/VCO2 at AT % WR -0.587 0.001 28 
VE/VCO2 at AT % VO2 -0.565 0.002 28 
VE/VCO2 at AT SvO2 % -0.549 0.012 20 
VE/VCO2 at AT SV mL (RHC) -0.527 0.010 21 
VE/VCO2 at AT Rca 
(ml/mmHg) 
-0.544 0.011 21 
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VE/VCO2 at AT  O2 pulse % -0.643 0.000 28 
VE/VCO2 gradient Rca 
(ml/mmHg) 
-0.684 0.001 21 
VE/VCO2 gradient SV (RHC) -0.545 0.011 21 
VE/VCO2 gradient PVR (WU) 0.621 0.003 21 
PET CO2 at AT PVR (WU) -0.625 0.002 21 
PET CO2  at AT Rca 
(ml/mmHg) 
0.583 0.006 21 
PETCO2 at AT O2 pulse 
(mL/beat) 
0.623 0.000 28 
TLCO(ml/min/mmHg) WR (W) 0.726 <0.001 26 
TLCO(ml/min/mmHg) VO2 L/min 0.703 <0.001 26 
TLCO(ml/min/mmHg) VE (L) 0.528 0.006 26 
TLCO(ml/min/mmHg) RVOPF -0.509 0.022 21 
KCO (si) VO2 at AT  0.584 0.002 26 
KCO (si) VO2 L/min 0.587 0.002 26 
KCO (si) % WR  0.562 0.003 26 
 
Change in gas exchange with exercise therapy correlated with exercise capacity, 
stroke volume, minute ventilation and invasively measures PA pressures ( 
Table 6.15, Figure 6.8, Figure 6.9) 
Table 6.15: Delta gas exchange variables 
Delta Delta r p N 
VE/VCO2 at AT 6MWD (m) -0.507 0.014 23 
VE/VCO2 at AT SV (mL) (MRI) -0.521 0.011 23 
PET CO2 at AT mPAP 
(mmgHg) 
-0.529 0.043 15 
TLCO% VE (L) -0.655 0.006 22 
TLCO % RV SV (mL) 0.535 0.007 24 
VE/VCO2 
gradient 




Figure 6.8: Change in VE/VCO2 gradient and relationship with change in Right Atrial Pressure 
 
Figure 6.9: Change in Ventilatory Equivalent for CO2 and change in 6MWD 
 
 Ventilation correlations  
At baseline, tidal volume ad minute ventilation correlated with IL-6, quality of life 








Table 6.16: Ventilation correlations at baseline 
Baseline Baseline  r p N 
TV (L) (CPET) 6MWD (m) 0.493 0.008 28 
TV (L) (CPET) IL6 (pg/L) -0.559 0.003 26 
VE (L) 6MWD (m) 0.622 0.000 28 
VE (L) IL6 (pg/L) -0.516 0.007 26 
VE (L) EmPHasis-10 -0.529 0.004 28 
 
Change in ventilation with exercise therapy was associated with changes in stroke 
volume, cardiovascular efficiency and gas exchange ( 
Table 6.17) 
Table 6.17: Delta ventilation correlations 
Delta Delta r p N 
VE (L) VO2 % 0.625 0.001 24 
VE (L) WR (W) 0.647 0.001 24 
VE (L) TLCO% -0.566 0.006 22 
VE% RVOPF -0.587 0.021 15 
TV (L)(CPET) SVI (RHC) 0.746 0.001 15 
TV (L)(CPET) SV (mL) 0.589 0.021 15 
TV (L)(CPET) CO (L) (RHC) 0.567 0.028 15 
TV (L)(CPET) O2 Pulse 
(mL/beat)  
0.484 0.017 24 
 
 Relationship with prognosis and treatment response 
 Treatment response 
Comparison between baseline factors in those that improved, versus those who 
demonstrated no change or deteriorated (NC /D) are displayed in Table 6.18 and 
Table 6.19 
Table 6.18: Improved 6MWD versus deteriorated or no change 
Baseline Improved (15) SD NC / D (10) SD p 
Peak WR (W) 85 21 70 36 0.031 
Peak VO2 (L/min) 1.1 0.2 0.9 0.1 0.048 
Peak VO2 (mL/kg/min) 13.5 3.4 11.5 3.7 0.144 
VO2 at AT (L/min) 0.7 0.1 0.6 0.2 0.115 
End ex HR %  83 9 79 13 0.495 
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HRR 28 15 36 23 0.428 
Peak O2 pulse (mL/beat) 7.6 1.4 6.6 2.3 0.196 
VO2/WR 8.4 1.9 7.3 1.8 0.071 
VE (L) 55 11 58 25 0.978 
TV (L) 1.6 0.4 1.5 0.5 0.727 
RR 36 8 39 8 0.311 
Ve/VCO2 at AT 41 6 45 11 0.397 
VE/VCO2 gradient 38 7 49 15 0.036 
PET CO2 at AT  30 4 28 8 0.177 
 









Peak WR (W) 14.7 15.7 2.7 7.5 0.024 
Peak WR % pred  10.5 10.3 2.8 7.7 0.053 
Peak VO2 (L/min) 
Jones  
0.13 9.6 0.01 0.1 0.080 
Peak VO2 (L/min) 
Jones (% pred)  
7.3 9.6 4.1 12.4 0.013 
Peak VO2 ml/min/kg  1.7 2.0 0.0 1.4 0.023 
VO2 at AT  0.11 0.16 0.03 0.08 0.159 
VO2 at AT (% pred)  4.2 10.9 2.8 6.2 0.692 
End exercise HR  3.4 6.2 3.6 7.6 0.956 
End exercise HR (% 
pred) 
2.0 3.8 2.3 4.7 0.860 
HRR  -3.6 6.2 -2.9 7.6 0.918 
End exercise O2 
pulse (mL/beat) 
0.8 1.0 0.3 0.9 0.251 
End exercise O2 
pulse (% pred)  
5.9 9.7 -0.2 7.1 0.100 
VO2/WR  0.16 1.9 -1.0 2.8 0.282 
VE (L) 6.4 10.5 -0.6 4.1 0.104 
VE % predicted  8.0 17.4 5.5 11.6 0.682 
Breathing reserve -7.9 17.0 -7.0 14.0 0.902 
TV (L) 0.2 0.2 -0.2 0.8 0.179 
RR  -1 4.2 -2 5.9 0.269 
O2 Sat rest (%) -0.14 1.3 0.2 4.1 0.812 
O2 Sat peak (%)  -0.9 2.2 -1.2 5 0.841 
VE/VCO2 at AT  -4.2 4.1 0.7 5.4 0.020 
VE/VO2 at AT  -4.0 4.1 0.0 4.4 0.042 
Ve/VCO2 gradient  -3.1 4.1 -3.2 7.5 0.394 
PetCO2 at AT 
(mmHg) 




Those who were dead, transplanted or had dropped out of the study at censoring, 
had lower baseline gas exchange and exercise capacity ( 
Table 6.20)  
Table 6.20: Prognostically relevant CPET and PFT variables at baseline 
Baseline Alive at 
censoring (23) 
Transplant or dead at 
censoring or drop out (7)  
p 
TLCO % 60.2 (19.8) 40.3 (18.9) 0.040 
Peak WR (W) 83 (7) 52 (26) 0.001 
Peak VO2 
(L/min) 
1.0 (0.2) 0.77 (0.2) 0.015 
Peak VO2 
ml/kg/min 
13.3 (2) 9.5 (4) 0.012 
A-a gradient 49 (22) 73 (16) 0.024 
VE/VCO2 39 (7) 52 (19) 0.059 
 
From baseline to the end of study assessment, those who remained alive had 
improved gas exchange and exercise capacity, compared to those who were 
transplanted or had died (Table 6.21) 
Table 6.21: Change in gas exchange variables in relation to transplant free survival 
Delta Alive at censoring 
(23) 
Transplant or dead at censoring 
(7)  
p 
TLCO % 8.0 (11.6) 0.3 (5.6) 0.029 
KCO (si) 0.17 (0.23) 0.02 (0.11) 0.042 
Peak WR (W) 11 (14) -7 (10) 0.045 
Peak VO2 
ml/kg/min 
1.2 (1.9) -0.7 (10.9) 0.035 
 
 Discussion 
Participants in this study displayed typical features of PAH, with reduced exercise 
capacity, impaired gas exchange and impaired of oxygen delivery on CPET. Despite 
being on optimal drug therapy, 68% of participants had peak VO2 under 15 
ml/kg/min and 21% had TLCO under 45%. 
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Wide physiological variation existed in this cohort, ranging from severe 
impairments of gas exchange, airflow obstruction and air trapping, to subjects 
with preserved gas exchange and supranormal lung volumes. This may be explained 
by the heterogeneity of the population both in age, BMI, PAH subtype and 
comorbidity. The second largest group behind IPAH was CTD-PAH, 6 subjects (20%) 
had associated lung disease, 2 subjects (13%) were smokers . It also highlights the 
need to pursue further research of a highly phenotyped population, with more 
specific inclusion criteria or pre-defined subgroup analyses.  
Exercise capacity 
Exercise therapy resulted in significant improvements in peak aerobic exercise 
capacity and endurance exercise capacity. 
All markers of exercise capacity (Peak WR, Peak VO2, cycling endurance time and 
6MWD) improved and all were highly statistically significant. Assessing the varying 
degrees of sensitivity in exercise-based outcome measures may help inform future 
trial design in PH exercise rehabilitation studies. Comparing the performance of all 
parameters of exercise capacity in this study, the largest proportionate change 
was seen in loaded endurance time and this modality reflected the predominantly 
aerobic nature of the exercise programme. Additionally, it allowed serial 
measurements of haemodynamics and oxygen extraction (discussed in Chapter 7). 
The highest degrees of sensitivity from a statistical perspective were seen with 
peak WR and 6MWD. The 6MWT remains an inexpensive and reproducible test to 
perform, without the requirement for specific expertise. Incorporating both sub-
maximal or maximal tests with an endurance testing provided valuable information 
on treatment response and the mechanisms of improvement in this study.  
CPET 
The improvement in exercise capacity was accompanied by a higher VO2 at AT, 
higher peak oxygen pulse, greater peak minute ventilation secondary to greater 
tidal volumes and more efficient gas exchange. The effect was more pronounced 
within the first three weeks of exercise training but maintained at the end of the 
study.  
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In comparison to subjects receiving standard care, those who completed the 
exercise programme had significantly improved exercise capacity and ventilatory 
capacity. There was a signal towards improved gas exchange in the standard care 
versus treatment analysis, however this narrowly missed statistical significance.  
Both at week three and the end of the study, isotime CPET measurements of gas 
exchange, oxygen pulse and tidal volumes were significantly higher and respiratory 
rate was significantly lower. Similar to the peak CPET comparisons, the 
improvement was maintained at the end of the study, but more pronounced within 
the first three weeks of exercise. Of note, VO2 at isotime was higher at the end of 
the study, this may be due to improvements in the VO2/WR relationship.  
Lung function 
Nearly half of participants had severely impaired gas exchange. Abnormalities 
were not restricted to gas exchange however, one third demonstrated airflow 
obstruction, 18% had air trapping and 14% ventilatory inhomogeneity. Despite this, 
the mean FEV1/FVC ratio was low normal as was VA/TLC 
Following three weeks of exercise training, total lung capacity, gas exchange and 
expiratory mouth pressures improved. No significant change was seen in 
spirometry, RV/TLC or VA/TLC. 
Clinical and prognostic relevance of observed changes  
At baseline, a higher peak aerobic exercise capacity was associated with lower Il-
6, greater pulmonary artery compliance and more efficient gas exchange (CPET). 
Improvement in peak WR correlated with improvements quality of life, oxygen 
pulse and minute ventilation.  
The majority of gas exchange variables at baseline, both CPET and PFT, were 
associated with a number of relevant clinical variables. More efficient gas 
exchange was associated with greater exercise capacity, higher stroke volume 
(RHC and oxygen pulse), lower PVR and higher pulmonary artery compliance. 
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Following exercise therapy, improvements in gas exchange were associated with 
higher minute ventilation, improved stroke volume, reduced right atrial pressure, 
lower mPAP and increased 6MWD. 
At baseline lower minute ventilation and tidal volumes were associated with lower 
6MWD and poorer quality of life. Improvements in VE and TV were associated with 
improved exercise capacity, more efficient gas exchange, higher stroke volume 
(CMR , RHC and oxygen pulse) and cardiovascular efficiency (RVOPF).  
In the post hoc analysis, those who improved with exercise therapy appeared to 
have higher baseline peak WR and VO2 in addition to significantly lower VE/VCO2 
gradient. Peak aerobic exercise capacity (VO2 and WR) correlated with 6MWD. In 
those who improved, minute ventilation and tidal volumes increased significantly 
compared to those who derived no benefit.  
Gas exchange and exercise capacity at baseline appeared to be lower in those who 
were transplanted or dead at censoring. The group of subjects who improved, had 
improvements in gas exchange, whereas no change was noted in those 
transplanted or dead at censoring.  
Mechanisms 
This study verified the prognostic roles of exercise capacity and gas exchange in 
PAH, seen in the associations of these parameters with known prognostic markers 
such as PVR and WHO FC[5]. Improvements in exercise capacity were tracked by 
changes in gas exchange; a crucial relationship exists between the two, both at an 
isolated time point and in relation to the response to therapy. Those who did not 
demonstrate improvements in gas exchange were more likely to undergo lung 
transplantation or die and were less likely to improve functionally with exercise 
therapy. This relationship may exist because gas exchange measurements 
encompass many aspects of the pathophysiology of PAH including vascular 
remodelling, microthrombosis with damage to the capillary basement membrane, 
anaemia and low alveolar capillary blood volume. When inspecting the elements of 
physiology contributing to gas exchange, four potential reasons are evident to 
explain the mechanism of improvement 
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1) Improvements in stroke volume accompanied the gas exchange 
improvements occurred in this cohort. This could be explained by a larger 
alveolar capillary volume secondary to the higher cardiac output observed 
during exercise. The changes seen in TLCO were due to improved KCO 
rather than VA, this would be in keeping with improved alveolar capillary 
blood volume.  
2) Tidal volume improved and correlated with gas exchange and peak 
expiratory mouth pressured improved. This may be secondary to recruited 
lung through increased respiratory muscle strength therefore improving V/Q 
matching 
3) Minute ventilation increased due to increased tidal volume, with reduced 
respiratory rate à reduced hyperventilation and improved work of 
breathing / ventilatory efficiency secondary to lung recruitment and 
improved respiratory muscle strength.  
4) Reduced atrial stretch and improved pulmonary artery compliance à 
Reduction in RAP correlated with reduced VE/VCO2 gradient following 
exercise therapy. Additionally, a strong and clear relationship existed 
between pulmonary artery compliance and gas exchange, with higher 
pulmonary artery compliance being associated with better gas exchange 
across a number of variables. In keeping with this, higher RVOPF (i.e. a less 
efficient pulmonary circulation), correlated significantly with lower TLCO. 
Chapter 7 discusses the possible reasons for improved pulmonary artery 
compliance with exercise therapy. In reviewing the literature, animal 
models have demonstrated a close relationship between the RV, RAP and 
the ventilatory response. Pressure-related stimulation of mechanoreceptors 
in the right atrium and right ventricle result in an aggravated sensation of 
dyspnoea that increases ventilation[192]. RAP also has a strong negative 
association with exercise  capacity and is linked to the afterload faced by 
the right ventricle[193]. 
There was no change in haemoglobin with exercise therapy and it is unlikely in the 
short time frame of the study, that there was a change in structure to the capillary 
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basement membrane. Therefore, the key mechanisms in gas exchange 
improvements appear to be: Lung recruitment secondary to strengthened muscles, 
reduced hyperventilation, improved stroke volume and improved pulmonary artery 
compliance, the latter two factors leading to increased capillary blood volume.  
Subjects with improved 6MWD, had higher exercise capacity and more favourable 
prognostic markers at baseline. Those who deteriorated or did not improve, clearly 
had markers of more severe PAH at baseline. This group of “non-responders” with 
severe PAH are more difficult to analyse, it is unclear whether exercise therapy 
will slow an inevitable progression in this group of patients with severe PAH or will 
not impact on the disease course. No evidence from this data suggests the exercise 
therapy or testing caused harm. There were not enough participants in this study 
to perform an analysis of exercise therapy versus standard care those who did not 
improve, this would be a useful consideration for future studies to help clarify the 
role of exercise therapy in severe PAH.  
Future research avenues to explore the improvements seen with gas exchange 
could include lung perfusion imaging to determine flow mediated contributions, 
exercise cardiac MRI to assess dynamic right atrial volume and the potential 
contribution of RA stretch, studies of respiratory muscle strengthening in isolation, 
to determine the impact of improved inspiratory muscle strength and lung 
recruitment and assessment of autonomic regulation, particularly of the pulmonary 
circulation, before and after exercise therapy.  
 Conclusions  
Exercise therapy resulted in significant improvements in exercise capacity. Both 
endurance and incremental exercise tests were sensitive means of detecting 
treatment response and provided valuable and different information regarding the 
exercise response in PAH.  
A significant proportion of subjects on optimal drug treatment had severe 
reductions in aerobic exercise capacity and gas exchange. These subjects were less 
likely to show a favourable response to exercise therapy. Lung function 
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abnormalities were common and suggest more specific inclusion criteria may be of 
benefit in future studies of exercise therapy.  
Gas exchange and lung volumes improve with exercise therapy. These changes are 
associated with a number of relevant prognostic markers. The improvements in gas 
exchange are likely multifactorial, with lung recruitment, improved alveolar 
capillary blood volume and potentially reduced atrial stretch.  
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Chapter 7 Changes in invasively measured 
haemodynamics in response to exercise therapy 




 Normal anatomy and physiology of the pulmonary circulation  
The healthy adult human pulmonary circulation is a high flow, low pressure circuit 
[194], the function being defined by the pressure-flow relationship. Flow and 
pressure in the pulmonary circulation are pulsatile. Low pressure prevents fluid 
moving out of the pulmonary vessels into the interstitial space and allows the right 
ventricle to operate at minimal energy cost. In contrast to the systemic 
circulation, the arteries in the pulmonary circulation are thin walled, highly 
compliant vessels [195]. The pulmonary circulation is characterised by an inflow 
pressure (pulmonary artery pressure) and an outflow pressure (left atrial pressure), 
the difference between which is the transpulmonary pressure gradient (TPG). 
The right ventricle pumps deoxygenated blood into the pulmonary arteries (Figure 
7.1). The pulmonary arteries divide into pulmonary arterioles and then to the 
capillary bed, which supplies the deoxygenated blood to the alveoli, where gas 
exchange occurs (Figure 7.2).  
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Figure 7.1 General anatomy of the human circulatory system – blue, deoxygenated blood; red, 
oxygenated blood. 
 
Figure 7.2: Alveolar gas exchange 
Blood then drains into pulmonary venules, then veins, which transport blood to the 
left ventricle, allowing oxygenated blood to be delivered to the body via the 
systemic circulation.  
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 Normal values and measurement of right heart and pulmonary artery 
pressures 
Right heart catheterisation is the gold standard for assessment of the pulmonary 
circulation. A fluid filled, balloon tipped thermodilution catheter (Figure 7.3) with 
a pressure transducer is inserted into the systemic venous circulation via a central 
vein, allowing real time pressure wave monitoring. Vascular pressures are 
measured using a zero-levelled external manometer at the mid thoracic level (the 
hydrostatic indifferent point) [196] In the supine position, this is 5cm below the 
sternal angle [196]. 
   
Figure 7.3: Swan Ganz thermodilution catheter 
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Once inserted into a central vein, the catheter is advanced into the right heart and 
pulmonary circulation under fluoroscopic guidance. With the balloon tip inflated, 
the catheter is then advanced to the most distal point of the pulmonary circulation 
that can be reached until the pulmonary artery is occluded. A wedged or occluded 
pulmonary artery pressure, is an acceptable estimate of left atrial pressure [197]. 
The pulmonary artery wedge pressure (PAWP) is obtained from the pulmonary 
pressure decay curve after a single arterial balloon occlusion. Measurements are 
performed at end expiration so as the lungs are at functional residual capacity ( 
Figure 7.4). At higher lung volumes, increased alveolar vessel resistance can cause 
an increase in PVR and at lower lung volumes, extra-alveolar vessel resistance rise, 
resulting in increased PVR. [198]
 
Figure 7.4: Pulmonary artery (top image)) and pulmonary arterial wedge (lower image) wave 
forms during right heart catheterisation 
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Table 7.1 covers the standard measurements made at right heart catheterisation 
and their normal range. Additional calculations that inform on pulmonary vascular 
function made at time of RHC using direct measurements. These calculations are 
displayed in Table 7.1 and are discussed in further detail below. 
Table 7.1 Normal Pulmonary Artery and Right Heart Pressures [126] 
 Measurement Normal reference range 
RAP (mmHg) Direct  1-8 
RVSP (mmHg) Direct  15-30 







mPAP (mmHg) 2/3 DPAP + 1/3 SPAP 8-20 
PAWP (mmHg) Direct  5-12 
CO (L/min) Measured by thermodilution 4.5-8.5 
CI CO/Body Surface Area 2.5-4.0 
PVR (WU) mPAP-PAWP/CO 0.25-1.6 
SvO2 (%) Direct – blood sampled from 






 Pulmonary Vascular Resistance 
Resistance across the pulmonary vasculature consists of venous and arterial 
components. The site of most pulmonary vascular diseases is the resistive 
arterioles. 
The Hagen-Poiseuille law is used to describe resistance in the pulmonary 
circulation. It is the physical law defining laminar flow of Newtonian fluid through 
non-distensible, straight, cylindrical tubes. It is governed by the following factors  
• The viscosity of the fluid (n)  
• The pressure gradient across the circuit (Δ P) 
• The length (l) of the tubing 
• radius (r) of the tubing 
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The law can be extrapolated to calculate the resistance in the pulmonary 
vasculature as the pressure gradient to flow (Q) ratio: 
R = (l.n.8)/(π.r4) 
= Δ P /Q 
= mPAP – PAWP / CO 
The fact that r in the equation is to the fourth power explains why resistance is 
exquisitely sensitive to small changes in calibre of these small vessels. 
 Pulmonary artery compliance (capacitance)  
Pulmonary artery compliance (Pca) provides a measure of the ability of the 
pulmonary circulation to stretch in response to an applied pressure (cardiac 
output). It has the units mmHg.mL-1 is calculated by the formula: 
Stroke Volume 
Pulmonary Artery Pulse Pressure 
 
 Haemodynamic changes in PAH 
In PAH, as the vascular stiffness rises and luminal narrowing occurs, the PVR 
increases. This leads to increased PA pressure and RV afterload.[194]. Initially, 
cardiac output is maintained; heart rate rises and the right ventricle compensates 
for the increased afterload through right ventricular hypertrophy. As the afterload 
progressively increases, the right ventricle begins to fail, with both volume and 
pressure overload. This affects the left ventricle due to septal bowing and the 
interdependence of RV and LV function and reduced cardiac output to the systemic 
circulation (Figure 7.5). 
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Figure 7.5: Change in cardiac dimensions in PAH 
Changes that are seen in invasive measurements of the pulmonary circulation in PH 
are summarised in Table 7.2 
Table 7.2: Haemodynamic changes in PAH 
 Normal reference range Pulmonary Arterial Hypertension 
RAP  
(mmHg) 
1-8 Normal or raised  
 
RVSP (mmHg) 15-30 Raised  
RVEDP (mmHg) 2-8 Normal or Raised  
SPAP (mmHg) 13-26 
 
Raised  
DPAP (mmHg) 6-16 Raised  
mPAP (mmHg) 8-20 Raised  
PAWP (mmHg) 5-12 Normal or Low             
                     
CO  
(L/min) 
4.5-8.5 Normal or Low  
 
CI 2.5-4.0  









Normal or Low 




3.8-12 Reduced  
 
Abbreviations: RAP: Right Atrial Pressure 
RVSP: Right Ventricular Systolic Pressure 
RVEDP: Right Ventricular End Diastolic Pressure 
mPAP: Mean Pulmonary Artery Pressure 
PAWP: Pulmonary Artery Wedge Pressure 
CO: Cardiac Output 
CI: Cardiac Index 
PVR: Pulmonary vascular resistance 
SvO2: Mixed Venous Oxygen Saturations  
 
 
There is a negative correlation between Pca and mortality in PAH [199]. Although 
PAH is classically viewed as a disease of the distal resistive vessels leading to 
increased PVR, it also results in a reduction in compliance, and both contribute to 
RV afterload. Right ventricular afterload is a key determinant of RV function, 
which is strongly related to patient survival in PAH.  
 Right ventricular afterload 
Pulmonary Vascular Resistance has traditionally been used to characterise 
pulmonary haemodynamics, however it does not take into consideration pulsatile 
flow or arterial stiffness [200]. The proximal pulmonary arteries also play an 
important role in buffering pulsatile RV ejection and in RV-PA coupling. This is 
reflected in the finding that RV dysfunction is independently related to PA 
stiffness. There are two key components to right ventricular afterload [201]: 
1. Pulmonary Vascular Resistance 
2. Pulmonary Arterial Compliance  
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 Relationship between components of RV afterload 
In the pulmonary circulation, resistance and compliance are coupled in an inverse 
hyperbolic relationship, resulting in a constant product known as the RC time 
(Figure 7.6).  
 
Figure 7.6: Relationship between compliance (mmHg.mL) and resistance (WU) in the 
pulmonary circulation  
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The Pulmonary Arterial time constant (RC time constant) represents the 
exponential pressure decay in the pulmonary artery during diastole. Units are in 
seconds. It is calculated as follows: 
RC time constant =  PVR x Pca. 
 
Figure 7.7: Pulmonary Artery Time Constant (Rc) 
   
For any given resistance, a shorter time constant translates to faster diastolic 
pressure decay and a higher pulse pressure. It is independent of right ventricular 
function[199].  
Unlike the systemic circulation, where RC time is highly variable, the RC time of 
the pulmonary circulation has traditionally been proposed to be constant in health 









Figure 7.8: RC constant: The relationship between compliance and resistance in health and 
pulmonary vascular disease  
 
This constancy implies that compliance cannot change independently from 
resistance and the two are tightly bound [205] . The proposed reasons for this 
fixed relationship [206] are: 
1. The main pulmonary arteries account for only 15-20% of total pulmonary 
arterial compliance; the majority of vascular compliance is determined by 
vessels in the lung periphery; these vessels also account for the majority of 
pulmonary vascular resistance, meaning there is a tight anatomical 
correlation between the two.  
2. Due to the anatomical and physiological properties of arterial vessels, 
elevations in PVR increase pressure within the vascular lumen leading to 
higher vessel wall tension and therefore increased vascular stiffness, as per 
the Law of Laplace.  
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Exceptions to this rule have been documented in a fairly large body of evidence, 
suggesting this relationship is not always fixed as has been previously thought. In 
studies of CTEPH [207], and left heart disease with high PAWP [208] RC time was 
reduced compared to normal; in a study of IPAH patients with cardiovascular risk 
factors versus those without cardiovascular risk factors, RC time was also 
significantly reduced[209]. Additionally, in an unselected population of pulmonary 
hypertension patients with a PAWP under 15mmHg, higher heart rate was 
associated with lower RC time independently of mPAP, PAWP and age[206].  More 
recently, in a large cohort of IPAH patients (717) versus those with no pulmonary 
hypertension (156), RC time was found to be significantly lower in the IPAH group 
and correlated with RV oscillatory power fraction [210].  
Few studies have assessed dynamic changes in RC time in the pulmonary 
circulation on exercise. In healthy older exercising adults, reductions in RC time 
and compliance can occur during exercise, despite small reductions in pulmonary 
vascular resistance [211].  
 Right Ventricular Oscillatory Power Fraction 
The right ventricular oscillatory power fraction (RVOPF) provides a measure of the 
efficiency of the pulmonary circulation. There are two components to the RVOF, 
reflecting the two key properties of the pulmonary arterial tree that determine 
afterload [212]: 
Mean Power: energy per unit time expended to produce steady (non-pulsatile) net 
forward flow, calculated as the product of SPAP and mean flow (CO). The mean 
power is influenced by the calibre of small distal resistive arteries as reflected in 
the pulmonary vascular resistance 
Oscillatory Power: The energy used in the production of the pulsatile component 
of flow and pressure. This estimates the contribution from elastic properties of the 
pulmonary arterial tree, which can be estimated by the total arterial compliance 
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Figure 7.9: Oscillatory power fraction in healthy vessel (left) and stiff vessel (right)  
(Blue = mean power, yellow oscillatory power) 
 
The sum of the mean power and oscillatory power is the total external hydraulic 
power generated by the ventricle. 
Mean flow determines transport, therefore the mean power may be considered 
useful and oscillatory power wasted. The normal ratio is around 23-25% [213], with 
the lower the fraction, the more efficient the circulation. RVOPF can be calculated 
by the formula  
1- mPAP 
SPAP 
The formula is based on the following derivation [213].  
Power (oscillatory) / (Power oscillatory + Power mean). 
à ((sPAP x CO) – (mPAP x CO) )/ (SPAP x CO) 
à 1 – (mPAP / sPAP) 
Similarly to RC time constant, it has been proposed that the RVOPF remains 
constant in health and disease[213], this constant fraction being explained by the 
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proportionality in mPAP and SPAP under all conditions [214]. In larger more recent 
studies, this concept has not held, with RVOPF being higher in patients with IPAH 
[210].  
 Haemodynamic responses to exercise  
 Physiology of exercise in the healthy human pulmonary circulation 
The lungs receive the entire cardiac output with every stroke [202]. In young 
adults, the pulmonary circulation has an average resistance of 1mmHg.min.L-1 
increasing to 2.5mmHg.min L-1 by the age of 60.  
In health, mPAP and PAWP increase on exercise. mPAP rises approximately 0.5 – 3 
mmHg per litre, per minute increase [215] with a smaller rise seen in PAWP [216]. 
The rise in mPAP is predominantly due to increases in Cardiac Output, which can 
be up to 6 fold at maximal exercise. This is to match the twenty fold increase in 
oxygen uptake and carbon dioxide output required to meet the convective 
transport needs of O2 and CO2 to and from the exercising muscle. In the elderly 
and in heart and lung disease, increasing filling pressures of the left ventricle and 
air trapping provide increasing contributions to the rising PAP during exercise. 
 Pulmonary Circulation and RV response to exercise in PAH 
In PAH there is a steep rise in mPAP with a smaller increment in CO than is seen in 
health. The cardiac output response to exercise is blunted due to the failure of the 
RV to augment SV on exercise. This is due to impaired RV contractile reserve in the 
face of increasing RV afterload as exercise progresses. With increasing RV 
afterload, RV-PA uncoupling occurs, contributing to reduced SV .In severe PAH RV-
PA uncoupling can be present at rest[217].  
During exercise, the mPAP/CO gradient can be taken as a surrogate of TPR. The 
large increase in mPAP and relatively small increase in CO leads to a steeper 
mPAP/CO relationship with exercise. 
Chronotropic incompetence also occurs, with a blunted heart rate response to 
exercise. In PAH, peak CO has been found to be related to both decreased peak SV 
and chronotropic incompetence.   
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 Haemodynamic responses to exercise therapy in PAH 
Limited data exist on the effects of exercise therapy on the pulmonary circulation 
in PAH. In the one controlled study to date assessing the impact of exercise 
therapy on invasive haemodynamics in PAH, a significant reduction in mPAP and 
PVR occurred, with improvement in CO at rest, however there was no significant 
change seen during exercise, on a standard 25 watt supine ergometer step wise 
protocol. No assessment was made of Pca, RC time or RVOPF[218].  
 Aims 
The aims of this chapter are  
1. Determine the impact of exercise training on resting pulmonary arterial 
haemodynamics in optimally treated pre-capillary PH patients 
2. Assess the impact of exercise therapy on measures of RV-PA efficiency 
a. Right ventricular oscillatory power fraction 
b. Resistance-compliance time constant  
3. Explore the change in invasively measured exercise haemodynamic before 
and after exercise therapy  
 Methods  
 Study population 
The right heart catheterisation exploratory sub-study involved an opt in or opt out 
section in the consent form for the study “The effect of adding exercise training to 
optimal therapy in pulmonary arterial hypertension”. Ethics, recruitment, consent 
and study intervention are described in the study protocol in Chapter 2. Separate 
written consent was performed for all right heart catheterisation procedures as is 
done in normal clinical practice. Local guidelines on anticoagulation were 
followed. Subjected who were anticoagulated were bridged with low molecular 
weight heparin until 24h prior to the RHC.  
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 Protocol 
Right heart catheterisation with exercise was performed before and after the study 
intervention (exercise therapy). There was a window of at least 24 hours between 
other exercise tests (6MWT and CPET) to allow sufficient time for recovery. 
 Right heart catheterisation 
Resting right heart catheterisation 
Resting right heart catheterisation was performed under full aseptic conditions, in 
the supine position via the left or right internal jugular vein. An 8Fr sheath was 
inserted under direct ultrasound visualisation, with fluoroscopic guidance. A 
balloon-tipped, flow-directed pulmonary arterial Swan-Ganz catheter was inserted 
through the introducer sheath and into the venous system. Under fluoroscopic 
screening, the catheter was passed into the right atrium, right ventricle and 
pulmonary artery. Standard pressure measurements were performed as discussed 
in section 7.1.1.1. Cardiac output was quantified by the thermodilution method 
[219] with the transducer zeroed at the mid thoracic point. Although the direct 
Fick method of cardiac output measurement is the gold standard, the 
thermodilution method has been accepted as a more practical alternative and has 
shown good agreement with the direct Fick method in patients with pulmonary 
hypertension, even in the context of low cardiac output or severe tricuspid 
regurgitation [110]. Cardiac output measurements were repeated until three 
readings were obtained with variability of ≤10% and the mean of these three 
readings was recorded as the CO. Measurements were captured and recorded using 
GE© digital healthcare software, UK. Mixed venous oxygen saturations (SvO2) were 
measured by withdrawing 3ml of blood from the distal pulmonary arterial port of 
the catheter into a heparinised blood gas syringe (BD, Oxford, United Kingdom). 
This sample was immediately processed in a blood gas analyser (RAPIDLab 1265, 
Siemens Healthcare, Germany). To obtain an estimate of the relative oxygen 
extraction at peak exercise, the difference between the arterial and mixed venous 
saturations was expressed as a proportion of the arterial saturation. No systemic 
arterial blood sampling was undertaken as part of this study, therefore the 
peripheral arterial oxygen saturation as measured by pulse oximetry was used. 
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Following completion of resting measurements, subjects then went on to perform 
exercise (discussed below). 
Exercise right heart catheterisation 
 
As part of the study protocol described in Chapter 2, all subjects performed an 
initial standard increment cardiopulmonary exercise test. For the exercise RHC 
protocol, a constant work rate was used in order to achieve steady state exercise 
and allow serial measurements to be made. As discussed in Chapter 4, exercise 
capacity is significantly reduced in the supine compared to upright position during 
moderate to high intensity cycling and this is most marked during constant work 
rate exercise[113]. The supine constant work rate was calculated as 50% of the 
peak work rate achieved in the initial maximal upright cardiopulmonary exercise 
test.  
An electromagnetically braked cycle ergometer (Corival Supine, Lode, Groningen, 
Netherlands) was placed on the cardiac catheterisation table and its position 
adjusted to allow comfortable supine cycling for each patient. The ergometer was 
secured to the table by bolts attaching it to the table’s side rails to maintain its 
position during cycling. The patient’s feet were then strapped to the pedals. This 
led to an elevation of the legs compared with the fully supine resting RHC.  
Subjects were asked to start cycling, initially with zero resistance, at a cadence of 
60 revolutions per minute for 3 minutes (unloaded cycling) as a warmup. The 
resistance was then increased to 50% of the peak WR achieved on erect 
incremental CPET. Subjects were asked to cycle until exhaustion. The following 
measurements were made: Total exercise time, Heart Rate, SpO2, mPAP, Cardiac 
Output and SvO2. It was not possible to reliably measure PAWP every two minutes 
due to lack of fluoroscopy during exercise and subject movement. Measurements 
were made at the following time points: 
• At rest with the feet in pedals 
• After 2min 30 of unloaded cycling 
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• After 3 min of loaded cycling 
• Every 2 min thereafter until end exercise. 
At the end of exercise, the pulmonary artery catheter was removed from the 
pulmonary arterial system under fluoroscopy screening. The introducer sheath was 
removed, firm pressure was applied and an occlusive dressing after bleeding had 
stopped. Subjects were observed for one hour after test completion with 
measurement of BP, HR and SpO2 and review of puncture site.  
 
Figure 7.10: Exercise RHC protocol 
 
As measurement of PAWP was not possible during exercise, the total PVR (TPR) 
was calculated as mPAP/CO. Despite not characterising the flow-resistive 
properties of the pulmonary circulation as accurately as PVR, TPR may be a more 
realistic estimate of right ventricular afterload, as the right ventricle is exposed to 
the mean pulmonary artery pressure and not to the difference between mPAP and 
PAWP. 
 Statistics 
Normally presented data are presented as mean (SD), non-parametric data are 
presented as median and interquartile range (IQR). The Wilcoxon Sign rank test 
was used for paired data and Mann-Whitney U test for independent samples.  
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 Results  
 Resting RHC 
21 subjects had baseline right heart catheterisation performed. All were optimally 
treated; 48% (10/21) were on triple therapy and the remainder were on dual oral 
therapy. 
The majority of the subjects were female; 62% (13/21). IPAH/HPAH was the most 
common diagnosis 61% (13/21). 5% (1/21) had CTD-PAH, 24% (5/21) CHD-PAH, 5% 
(1/21) POPH and 5% (1/21) residual CTEPH. The median age was 48 (34-74) 
At rest 19% (4/21) had mPAP <25mmHg, these subjects all had PVR of 3.5 or less, 
indicating a good response to optimal drug therapy. 81% (17/21) had a normal CI 
(greater or equal to 2.5). 29 % (6/21) had an SvO2 equal to or greater than 75% 
(Table 7.3) 
Table 7.3: Resting RHC data at baseline 
 Mean SD Range 
BMI (kg/m2) 30.29 7.54 23-47 
Sats (%) 93.24 4.72 83-100 
HR (BPM) 77.05 12.55 56-107 
SBP (mmHg) 119.38 17.85 97-177 
DBP (mmHg) 71.57 9.92 51-87 
RAP mean (mmHg) 4.95 3.68 0-11 
RVP (mmHg) 61.76 18.89 30-85 
SPAP (mmHg) 63.62 18.88 32-91 
DPAP (mmHg) 23.33 9.91 6-39 
MPAP (mmHg) 39.33 12.34 17-57 
PAWP (mmHg) 7.48 4.68 1-17 
CO (L/min) 6.22 1.62 3.3-9.4 
CI (L/min/m2) 3.22 0.78 1.8-4.4 
PVR (WU) 5.50 2.70 2.3-13.2 
PVRI (L.min-1.m2) 10.59 5.20 3.9-25.9 
TPR (WU) 6.72 2.91 3.3-16 
SV (mL) 81.95 21.55 33.3-120 
SVI (ml/m2) 41.68 10.78 17-61 
SvO2 (%) 69.89 8.05 49-82 
Rca (ml/mmHg) 2.20 0.81 0.74-3.4 
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RVOPF 0.38 0.05 0.32-0.47 
RC time (sec) 10.30 2.18 6.8-15.1 
 
 RHC at rest pre and post exercise therapy 
Of the 21 subjects who had initial RHC, 16 completed end of study RHC. Reasons 
for the 5 subjects not completing follow-up RHC: 2 study dropouts, 1 subject 
transplanted, 1 subject declined repeat RHC, 1 subject had venous stenosis of left 
internal jugular vein and hickman line in the right internal jugular vein; 
advancement of the Swan-Ganz catheter into the right atrium was not feasible on 
the return visit.  
Paired analysis in the 16 subjects who had pre and post exercise RHC revealed no 
significant differences in invasively measured haemodynamics at rest (Table 7.4) 
Table 7.4: Baseline and End of Study Resting RHC data 
 Baseline  SD EOS  SD p 
HR (BPM) 74.2 10.6 76.1 12.2 0.269 
SBP (mmHg) 119.6 19.5 107.1 11.9 0.012 
DBP (mmHg) 72.1 8.5 70.2 7.9 0.311 
RAP mean (mmHg) 4.9 3.8 4.4 4.3 0.639 
RVP (mmHg) 54.4 17.6 53.2 19.2 0.522 
SPAP (mmHg) 57.3 16.9 57.4 20.6 0.945 
DPAP (mmHg) 20.8 9.3 21.5 8.8 0.551 
MPAP (mmHg) 35.3 11.2 35.5 11.9 0.858 
PAWP (mmHg) 6.6 4.6 7.19 4.7 0.318 
CO (L/min) 6.3 1.5 6.7 2.2 0.284 
CI (L/min/m2) 3.3 0.7 3.6 1.1 0.211 
PVR (WU) 4.8 2.2 4.7 2.5 0.701 
PVRI (L.min-1.m2) 9.2 4.1 8.8 4.8 0.474 
TPR (WU) 5.9 2.0 5.8 2.7 0.894 
SV (mL) 84.1 16.7 87.7 22.9 0.547 
SVI (ml/m2) 42.8 7.9 46.3 12.1 0.264 
SvO2 (%) 69.8 6.3 70.1 7.1 0.879 
Rca (ml/mmHg) 2.44 0.7 2.8 1.4 0.184 
RVOPF 0.38 0.05 0.38 0.05 0.436 
RC time (sec) 10.5 2.34 10.5 2.34 0.994 
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Those with paired resting RHC data who improved (11) versus those who had an 
unchanged or deteriorated 6MWD (5) were compared using a Mann-Whitney U test. 
There was a significant improvement in delta stroke volume, cardiac output and 
pulmonary artery compliance in those who had improved 6MWD versus those who 
did not (Table 7.5).  
Table 7.5: Changes in haemodynamics in subjects with improved 6MWD vs those without 
 Improved  SD Deteriorated SD p 
HR (BPM) 0.0 5.9 6.2 7.1 0.145 
SBP (mmHg) -10 19 -17 14 0.743 
DBP (mmHg) -1 4 -5 4 0.320 
RAP mean (mmHg) -1 3 0 4 0.661 
RVP (mmHg) -12 25 -13 31 0.583 
SPAP (mmHg) 0.2 7.4 0.0 7.5 0.661 
DPAP (mmHg) 0.8 5.0 0.5 5.1 0.913 
MPAP (mmHg) 0.2 3.8 0.2 5.3 0.913 
PAWP (mmHg) 0.4 2.2 1.2 3.0 0.583 
CO (L/min) 1.0 1.7 -0.8 1.0 0.038 
PVR (WU) -0.4 1.0 0.6 1.1 0.115 
TPR (WU) -0.4 1.2 0.8 1.7 0.090 
SV (mL) 12 21 -16 13 0.005 
SvO2 (%) -0.6 6.3 2.1 2.8 0.221 
Rca (ml/mmHg) 0.7 1.2 -0.3 0.5 0.05 
RVOPF -0.01 0.06 -0.01 0.04 1.00 
RC time (sec) 0.35 2.9 -0.8 1.4 0.267 
 
 Exercise RHC 
Comparison of standard haemodynamic variables at rest and throughout 
progressive stages of exercise are summarised in Table 7.6 pre and post exercise 
therapy. Lowest isotime was the earliest loaded measurement comparable at the 
same time on both tests, highest isotime was determined by the test of shortest 
duration; the time of last measurement before cessation of exercise in the shortest 
duration test was compared between both tests.  
Table 7.6: Baseline and end of study exercise right heart catheterisation  
Change haemodynamics following exercise therapy. 
 Baseline End of Study P 
mPAP (mmHg) 
Rest 36 (11) 36 (12) 0.950 
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Unloaded 50 (9) 48 (13) 0.330 
Lowest isotime 57 (12) 55 (16) 0.210 
Highest isotime 66 (18) 60 (20) 0.02 
End exercise 68 (18) 62 (20) 0.04 
CO (L/min) 
Rest 6.3 (1.5) 6.7 (2.2) 0.280 
Unloaded 8.9 (2.0) 8.7 (2.8) 0.630 
Lowest isotime 10.7 (2.7)) 10.9 (3.7) 0.730 
Highest isotime 12.2 (3.7) 12.3 (4.2) 0.760 
End exercise 12.2 (3.7) 12.5 (4.1) 0.630 
CI 
Rest 3.3 (0.7) 3.6 (1.1) 0.210 
Unloaded 4.6 (0.9) 4.5 (1.3) 0.690 
Lowest isotime 5.5 (1.2) 5.6 (1.7) 0.680 
Highest isotime 6.2 (1.7) 6.4 (2.0) 0.580 
End exercise 6.4 (1.9) 6.7 (2.0) 0.530 
SvO2 (%) 
Rest 69.8 (6.3) 70.1 (7.1) 0.880 
Unloaded 58.0 (6.6) 58.4 (8.5) 0.780 
Lowest isotime 45.8 (7.8) 45.8 (10.2) 0.990 
Highest isotime 44.6 (7.6) 44.3 (8.0) 0.820 
End exercise 42.9 (6.6) 42.2 (7.1) 0.650 
HR (BPM) 
Rest 75 (11) 76 (12) 0.269 
Unloaded 89 (10) 90 (11.0) 0.710 
Lowest isotime 105 (14) 103 (15) 0.570 
Highest isotime 127 (37) 119 (23) 0.01 
End exercise 131 (27) 128 (25) 0.450 
PCa (mmHg.mL) 
Rest 2.4 (0.7) 2.8 (1.4) 0.180 
Unloaded 2.0 (0.7) 2.1 (1.0) 0.300 
Lowest isotime 1.8 (0.7) 2.3 (1.4) 0.100 
Highest isotime 1.5 (0.6) 2.4 (1.6) 0.02 
End exercise 1.4 (0.5) 2.1 (1.2) 0.03 
SV (mL) 
Rest 84 (17) 88 (23) 0.547 
Unloaded 100 (19) 96 (26) 0.410 
Lowest isotime 104 (27) 105 (31) 0.910 
Highest isotime 96 (24) 104 (31) 0.110 
End exercise 92 (22) 97 (24) 0.410 
Pca; Pulmonary artery compliance.  CI; Cardiac Index. SvO2; Mixed venous 
oxygen saturation. HR; Heart Rate 
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 Pulmonary artery pressure 
At rest, SPAP was unchanged pre and post exercise therapy. During progressive 
exercise, there was a significant reduction in SPAP at lowest and highest isotime 
point (Figure 7.11).  
 
Figure 7.11: Pre and post exercise therapy changes in systolic PAP 
 
mPAP displayed the same pattern in the pre and post exercise groups; At highest 
exercise isotime point and peak exercise, mPAP was significantly lower following 
exercise therapy (Figure 7.12). 
  
P0.09 P <0.05 
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Figure 7.12: Pre and post exercise therapy changes in mPAP 
 
There was no significant change in resting diastolic pulmonary artery pressures nor 
diastolic pulmonary artery pressures during exercise following the exercise 
programme.  
 Stroke volume, heart rate and cardiac output 
Change in cardiac output during exercise is show in Figure 7.13. No statistically 
significant difference was seen in CO changes during exercise before and after the 




Figure 7.13: Pre and post exercise therapy changes in CO 
 
Cardiac index was higher in the post exercise therapy group at higher stages of 
exercise, however this did not reach statistical significance (Figure 7.14)  
 
Figure 7.14: Pre and post exercise therapy changes in Cardiac Index 
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Following completion of the exercise programme, heart rate was lower at highest 
isotime exercise than at baseline (Figure 7.15).  
 
Figure 7.15: Pre and post exercise therapy changes in Heart Rate 
 
SV improved at highest exercise isotime following exercise therapy, although 
missing statistical significance. SV can be seen to plateau and fall at an earlier 




Figure 7.16: Pre and post exercise therapy changes in Stroke Volume 
 
The changes in relative contributions of HR and SV to cardiac output pre and post 
exercise therapy can be seen in Figure 7.17, with improved SV and a lower HR 
during later stages of exercise in the post exercise therapy group. Indicative of a 
reduced reliance on chronotropic function to maintain CO.  
 
 





































 Pressure – Flow relationship 
The gradient between cardiac output and mean pulmonary artery pressure was 
taken as a surrogate of pulmonary vascular resistance. Total pulmonary resistance 
(mPAP/CO) provides an accurate reflection of the work faced by the right 
ventricle. The relationship between cardiac output and mPAP (TPR) was plotted at 
each exercise time point and the mean for the population was then plotted at 
baseline and the end of study (Figure 7.18,  
 
Table 7.7). Linear trendlines were selected to best fit the progressive increase of 
mPAP with CO, with R2 values close to 1 for both trendlines (equation shown in 
figure 7.18).  
 
Figure 7.18: mPAP-CO gradient - change with exercise therapy 
 
Table 7.7: Change in total pulmonary resistance with exercise therapy  
TPR baseline SD TPR EOS SD p 
Rest 5.77 1.99 5.75 2.79 0.97 
Feet in pedals 6.43 2.49 6.90 3.35 0.41 
Unloaded 5.94 2.24 6.31 3.14 0.30 
Lowest isotime 5.82 2.69 5.81 3.01 0.97 
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Highest isotime 6.27 3.80 5.77 3.39 0.18 
Peak 6.56 4.02 5.89 3.49 0.11 
 
For individual participants, the gradient was calculated for the mPAP-CO 
relationship throughout exercise at baseline and at the end of the study. Individual 
responses are shown in Figure 7.19 along with the population mean. The mean 
mPAP-CO gradient fell from 4.8 (2.2) to 3.8 (1.8), p 0.035. 
 
Figure 7.19: Individual changes in mPAP-CO gradient 
 
 Pulmonary Artery Compliance  
Pulmonary artery compliance was measured at rest and during progressive 
exercise. Pulmonary artery compliance was significantly higher at highest isotime 
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Figure 7.20: Changes in Pulmonary Artery Compliance 
 
Pulmonary artery compliance is directly proportional to stroke volume, therefore 
the lower the PA compliance, the greater the increase in pressure for a given 
stroke volume and the more work required of the RV to maintain CO. This 
proportionate relationship can be seen in Figure 7.21 during progressive stages of 
exercise. 
  
Rest Feet inpedals Unloaded Lowest Highest Peak
Baseline 2.4 2.2 2.0 1.8 1.5 1.4

























Figure 7.21: Stroke volume and PA Compliance relationship during progressive exercise 
 
 RC time constant  
The time constant (in seconds) of a resistance compliance (RC) circuit is equal to 
the product of the circuit resistance and the circuit capacitance (compliance), 
called the RC time.  
Resistance and compliance in the pulmonary circulation exhibit an inverse 
hyperbolic relationship, and therefore substantial declines in pulmonary artery 
compliance occur before increases in PVR or TPR. The further to the left of the 
inverse hyperbolic curve, the improved the relationship is i.e. a high compliance, 
low resistance circuit.   
When measured following exercise therapy, the compliance - resistance 
relationship appeared to improve at rest, however not reaching statistical 
significance, p 0.609 (Figure 7.22). A power trendline was selected for both 






































Figure 7.22: Change in compliance - resistance relationship at rest between baseline and end 
of study tests.  
 
Combined curves of compliance and total pulmonary resistance are shown in Figure 
7.23 and  
Figure 7.24. During progressive exercise, the inverse hyperbolic relationship 
remained, however the curve shifted down and subjects are seen to move further 
to the right along the inverse hyperbolic curve, representing a deterioration in the 
efficiency of the pulmonary circulation during progressive exercise.  
Following exercise therapy, subjects moved further to the left of the curve, with 
an improved compliance – resistance relationship. A Freidman repeated measures 
test was performed due to the non-parametric nature of the data to compare the 
different time points measured during exercise (Rest, unloaded, lowest isotime, 
highest isotime). This was performed at baseline and at the end of study (EOS), 
with the difference between exercise time points reaching statistical significance 
in both assessments. 
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Figure 7.23: Baseline RHC. Compliance-Resistance curves during progressive stages of 
exercise 
 
Figure 7.24: End of Study RHC. Compliance-Resistance curves during progressive stages of 
exercise 
P < 0.005 
P 0.005 
 207 
At highest isotime and peak exercise, there was a significant improvement in the 
resistance – compliance relationship (Figure 7.25) with more subjects towards the 
left of the curve. This corresponded with a longer Rc time at highest isotime point 
and peak exercise (Figure 7.26) 
 




Figure 7.26: Progressive exercise change in RC time pre and post exercise therapy 
 
 Right Ventricular Oscillatory Power Fraction 
At rest in the population studied, the mean baseline RVOPF was higher than in 
health at 38% (32-47%), with no subjects being within the normal range (20-25%). 
In later stages of exercise, the ratio of mean power to oscillatory power improved 
following exercise therapy in keeping with previously discussed invasively 
measured PA haemodynamic variables and improved efficiency of the pulmonary 





Figure 7.27: Pre and post exercise therapy right ventricular oscillatory power fraction during 
progressive exercise 
 
 Mixed venous oxygen saturation 
As expected, during exercise, oxygen extraction increased and mixed venous 
oxygen saturation reduced. There was no significant difference in mixed venous 
oxygen saturation or oxygen extraction at any stage of exercise (Table 7.8,Figure 
7.28). At baseline and at the end of exercise programme, O2 extraction did not 
reach maximal expected values that would occur in health (0.8)[220].  
Table 7.8: Oxygen extraction and mixed venous oxygen saturations during exercise RHC 
Oxygen extraction   
Baseline mean SD EOS mean SD p 
Rest 0.24 0.05 0.24 0.05 0.84 
Feet in pedals 0.25 0.06 0.27 0.05 0.21 
Unloaded 0.36 0.06 0.35 0.07 0.74 
Lowest isotime 0.50 0.08 0.49 0.11 0.74 
Highest isotime 0.51 0.07 0.50 0.08 0.73 
Peak 0.52 0.06 0.52 0.07 0.74 
SvO2 (%) 
Rest 69.97 6.56 69.91 5.99 0.96 
Feet in pedals 69.22 7.55 66.78 5.95 0.13 
Unloaded 57.95 6.59 58.43 8.48 0.78 
Lowest isotime 45.83 7.82 45.81 10.27 0.99 
< 0.05 0.01 
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Highest isotime 44.58 7.58 44.30 7.99 0.82 
Peak 42.89 6.62 42.18 7.11 0.65 
 
 
Figure 7.28: Pre and post exercise therapy SvO2 during progressive exercise 
 
 Endurance time  
Supine exercise time was measured at baseline and the end of the study. 
Endurance time improved significantly following exercise therapy from a baseline 
of 669 seconds (287) to 1018 seconds (437) at the end of study, p 0.004. 
Comparison of endurance time to other markers of exercise capacity is discussed in 
Chapter 6. 
 Discussion 
Haemodynamics in this cohort were typical of a pre-capillary PH population, with 
raised mPAP and reduced SvO2. All patients were clinically stable at study entry on 
optimal drug therapy; this was reflected in the normal mean RAP, CO and CI. A 


























 Resting haemodynamics 
There were no significant changes in resting invasively measured haemodynamics 
pre and post exercise therapy, however a trend to improved PA compliance and 
stroke volume occurred. In those who had improved 6MWD, there was a significant 
improvement in stroke volume, cardiac output and PA compliance in comparison to 
the group who did not improve.  
 Exercise haemodynamics 
Exercise therapy resulted in a similar pattern of improvement in all invasively 
measured exercise haemodynamics. Little or no change occurred at rest but as 
exercise progressed the majority of haemodynamic parameters improved following 
exercise therapy, with the most striking change occurring at peak exercise.  
Following exercise therapy, significantly lower SPAP and mPAP were noted at later 
stages of exercise, along with lower heart rate and higher PA compliance. The 
mean mPAP-CO gradient was significantly lower, indicative of a reduced PVR 
during exercise. Although not reaching statistical significance, there was a trend to 
improved stroke volume and cardiac output. Pre- exercise therapy, there was an 
earlier and more pronounced fall in stroke volume during exercise, with a higher 
heart rate at equivalent stages of exercise, compared to SV and HR measurements 
post-exercise therapy.  
 Cardiovascular efficiency 
The relationship between compliance and resistance deteriorated throughout 
progressive exercise. Exercise therapy resulted in improvements in this 
relationship, with a left and upwards shift of the inverse hyperbolic curve.  
Contrary to literature on PA RC time, the RC time did not appear to be constant 
during dynamic measurements. As exercise progressed, the RC curve shifted 
downwards, meaning RC time was shorter for any given PVR. Exercise therapy 
resulted in improvements in RC time at later stages of progressive exercise.   
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At study entry, right ventricular oscillatory power fraction was elevated, in 
keeping with a high resistance, low compliance circulation. Following exercise 
therapy, the RVOPF improved in later stages of exercise, in keeping with a more 
efficient circulation and less wasted oscillatory power expenditure.  
 Mechanisms for improvement 
Logically, increases in flow in the pulmonary circulation result in increases in PA 
pressure. Exercise therapy resulted in reductions in mPAP in the face of unchanged 
or improved cardiac output and lower heart rate. This maintenance or reduction in 
mPAP in the face of higher flow, is likely to be due to improvements seen in 
pulmonary artery compliance. These improvements are reflected in the assessment 
of the efficiency of the pulmonary circulation, with improved RC time and RVOPF, 
translating to reduced afterload and less wasted energy for the RV. The change in 
pulmonary artery compliance is probably the most striking of the changes seen 
following exercise therapy, along with improvements in endurance time – a clinical 
measure of the effects of the improved haemodynamics. It is unclear what is 
responsible for this improvement in PA compliance. Possibilities may include: 
1. Recruitment of capacitance vessels; this may occur due to lung recruitment 
and / or improved flow secondary to improved cardiac output. Recruitment 
of capacitance vessels would fit with the variable RC time constant 
observed in this study. In the current literature, the constancy has been 
assumed to be due to the fact that the resistance in PAH is largely due to 
the smaller resistive vessels, and this is felt to be relatively fixed. Lung 
perfusion imaging may help to answer this question in future studies. 
2. Improved endothelial health resulting in endogenous vasodilation. Exercise 
induced improvement in endothelial function and release of vasoactive 
mediators such as Nitric Oxide is a well-established phenomenon in the 
systemic circulation, both in health and disease states. This phenomenon 
would be difficult to study in the pulmonary circulation due to the lack of 
ability to biopsy the pulmonary artery. Consideration could be given as to 
whether changes in NO production and endothelial function in the systemic 
circulation would serve as a surrogate in future research[221]  
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3. Autonomic function : A number of studies have demonstrated evidence of 
autonomic nervous system disturbance in PAH. Wensel et al demonstrated 
reduced heart rate variability and blunted baroreceptor sensitivity 
associated with a reduction in peak VO2[100]. Ciarka et al found that 
sympathetic nervous system activation in PAH was associated with lower 
6MWD and NYHA FC[222]. In an animal model, pulmonary artery dilatation 
has also been shown to be induced by vagal stimulation[223]. More recently 
attempts to modulate the autonomic nervous system have been made with 
intravascular ultrasound pulmonary artery denervation; Rothman et al 
demonstrated improved mPAP and pulmonary artery compliance, associated 
with improvements in 6MWD[224]. Exercise training has been shown to 
improve autonomic regulation in a number of conditions including chronic 
heart failure[225], COPD[226] and coronary artery disease[227]. It is 
therefore possible that exercise improves autonomic regulation in PAH and 
reduces pulmonary arterial vasoconstriction, thus improving pulmonary 
arterial compliance. Further studies to look at the impact of exercise 
training on autonomic function in PAH would be of great interest.  
No changes were seen in oxygen extraction or mixed venous oxygen saturation. 
One may have expected improvements in oxygen extraction with improved muscle 
blood flow and potentially improved skeletal muscle cellular function (Discussed in 
Chapter 9).  Two possible explanations exist for this lack of change in oxygen 
extraction  
1. Oxygen delivery (DO2) proportionately rises with the improvements in 
oxygen uptake (VO2), therefore the oxygen extraction ratio (O2ER) remains 
the same 
O2ER =  VO2 
            DO2 
As discussed in chapter 6, peak VO2 measured during CPET increases. CO 
also shows a trend to increase, in addition to improvements seen in O2 pulse 
on CPET measurements. Therefore, it may be that delivery of oxygen 
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proportionately rises with oxygen consumption as the subjects’ 
cardiovascular efficiency improves.  
2. There may be additional pathophysiological factors that are unmodified with 
exercise therapy and contribution to impaired O2 diffusion, local tissue O2 
delivery or O2 extraction. Examining the Fick equation for diffusion of 
oxygen, this could be due to  
a. O2 gradient. A smaller difference in O2 gradient – i.e. patients with PAH 
are more prone to arterial hypoxaemia due to V/Q mismatch, therefore 
the concentration gradient is smaller.  
b. Diffusion distance. Increased diffusion distance in the alveolus; 
microvasculature disease with increased wall thickness.  
c. Flow. Although it appears that global blood flow improves there could be 
an unmodified problem with regional blood flow at a muscle level. 
d. Oxygen extraction at a local muscle level may be impaired 
(mitochondrial disease or cellular enzymatic dysfunction).  
It Is clear from this data, that exercise therapy results in beneficial effects on the 
pulmonary circulation during exercise. The lack of change seen in resting figures 
supports the theory that the improvement in exercise capacity is multifactorial (as 
discussed in Chapter 6). The small population size means that this study may not 
be sufficiently powered to detect more subtle differences in invasive 
haemodynamics.  Further research, with larger numbers of patients will help 
further characterise the nature of the improvements seen.  
Assessment of resting haemodynamics only in this population could have led to 
inaccurate conclusions on the effects of exercise therapy on the pulmonary 
circulation. This should prompt further research into selecting the best outcome 
measures for PH trials and specifically for trials of exercise intervention.  
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 Conclusions 
Patients with pre-capillary pulmonary hypertension, treated with optimal drug 
therapy, can achieve satisfactory improvements in resting PA haemodynamics, as 
reflected in a sub-set of the population with normal mPAP and CO prior to 
embarking on exercise therapy. Exercise haemodynamics are crucial in the 
assessment of the pulmonary circulation and determining the response to an 
intervention; despite reassuring resting PA pressures, significantly abnormal 
exercise haemodynamic responses can occur, in keeping with impaired exercise 
capacity. These changes are responsive to exercise therapy. 
In this study, exercise therapy resulted in reductions in mPAP during progressive 
exercise in the face of unchanged or improved cardiac output and lower heart 
rate. This is likely to be due to improvements in pulmonary artery compliance. 
These improvements are reflected in improved efficiency of the pulmonary 
circulation following exercise therapy, with improved RC time and RVOPF, 
translating to reduced afterload and less wasted energy for the right ventricle. The 





Chapter 8 Non-invasive assessment of the 
cardiovascular response to exercise therapy in 
PAH 
 Introduction 
Assessing the response of the right ventricle to exercise in PAH is essential, as it is 
RV function, rather than pulmonary artery pressure, that determines survival. To 
study the response of the right heart to exercise in PAH, the pathophysiology of RV 
failure in PAH must first be understood. Additionally, it is important to understand 
what modalities best assess right ventricular structure and function in relation the 
effect of exercise.  
The gold standard for the diagnosis of PAH is right heart catheterisation[228]. This 
has disadvantages as a tool for follow up due to its invasive nature, requirement 
for a high level of operator expertise and lack of information on cardiac structure 
and volumes. Non-invasive, reproducible means of assessing cardiac status in PAH 
are desirable; CMR and NTproBNP are two of the most comprehensive and simple 
methods of doing so respectively. Their role as a means of assessing the response 
to exercise therapy in PAH has not been studied. 
 Pathophysiology of right ventricular failure in PAH 
In PAH, RV failure is a late sign, after a long period of adaptation. Four stages 
occur in the adaptation and failure of the right ventricle [229]  
1. Reduction in the calibre of blood vessel and increased resistance in the 
pulmonary vasculature, leading to increased right ventricular afterload 
2. Right ventricular adaptation by increasing contractility (up to five fold) and 
RV hypertrophy  
3. RV dilatation and increased heart rate to maintain cardiac output. Increased 
wall tension and oxygen consumption occur and leftward septal bowing 
occurs  
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4. “Uncoupling” occurs when the RV can no longer overcome the afterload 
resulting in a falling stroke volume and increasing RV end diastolic volume. 
In very late stages of the process, the mPAP can then fall as cardiac output 
falls  
 
Figure 8.1 Coupling in PAH 
 
In health and stable pulmonary arterial hypertension, RV-arterial coupling 
describes the matching of RV contractility to afterload[230]. Uncoupling only 
occurs in late stages of PAH, when the ventricle fails, or during exercise[231]. 
Cardiac output and stroke volume therefore provide prognostic information, 
however, are not sufficiently sensitive in identifying early signs of deterioration. 
Assessing earlier components of the RV adaptive pathway may facilitate earlier 
disease intervention and provide higher sensitivity for change in clinically stable 
patients.   
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The right ventricle is not the only important ventricle in PAH. Ventricular 
interdependency is a pathophysiological phenomenon and plays an important role 
in the pressure overloaded RV. Ventricular interdependency between the RV and 
LV in PAH can be due to 
1. Parallel interaction: Leftward septal bowing, hampering filling of the LV. 
This is primarily due to a prolonged contraction time of the RV with respect 
to LV contraction time 
2. Series interaction: decreased filling of the LV due to lowered RV SV (lower 
LV preload).  
Chronic underfilling of the LV results in atrophy of the cardiac myocytes[232]. The 
importance of the LV in PH is underlined by the fact that stroke volume is closely 
related to LV end diastolic volume (LVEDV), but not to mPAP or RV end-diastolic 
volume[233] 
 The role of cardiac magnetic resonance imaging in PAH 
Cardiac MRI is a non-invasive imaging modality that provides high resolution, three 
dimensional images, allowing assessment of cardiac structure, function and 
volumes[234]. Decreased RV ejection fraction is the strongest predictor of 
mortality in PAH meta-analyses [235], with RV end systolic volume (RV ESV) and LV 
End Systolic Volume (LV ESV) also providing useful prognostic information. Studies 
have also demonstrated that RV mass index of greater that 59gm-2 is associated 
with poorer survival, however this appears to have a weaker prognostic signal that 
end diastolic volumes and stroke volume.[236, 237] 
Limited data exist on the use of CMR as a follow up tool to determine treatment 
response in PAH. From the limited data, low or falling RVEF appears to relate to 
treatment failure and poor prognosis and can occur in the face of falling PVR on 
treatment[238]. This highlights the pivotal role of the RV in determining survival 
and that the RV may not respond to treatment induced reductions in PVR. In 
patients with PAH and CTEPH, 1 year of treatment with PAH-specific therapy 
resulted in significant improvements in stroke volume which correlated with an 
increase in 6MWD and led to the calculation of a minimal clinically important 
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difference in SVI of 10 mL [237]. This MCID for SVI requires validation in larger 
cohorts.  
 Cardiac MRI normal reference ranges 
The standard ventricular references ranges for structure and function have been 
extensively analysed in a number of studies[239], including 804 Caucasian males 
and females in the UK biobank study (Table 8.1) [240]  
Table 8.1: CMR normal reference ranges 
 Male Female 
Left ventricle 
LVEDV (ml 109-218 88-121 
LVESV (ml) 39-97 31-68 
LVSV (ml) 59-132 49-100 
LV mass (g) 64-141 46-93 
LVEF % 48-69 51-70 




RVEDV (mL) 124-248 85-168 
RVESV (mL) 47-123 22-77 
RVSV (mL) 62-131 48-99 
RVEF % 45-65 47-68 
RV mass (g) 25-57 21-49 
 
 Changes in cardiac structure and function with exercise 
In health and athletes, changes in cardiac structure are specific to the type of 
exercise performed. Strength training (isometric exercise), involves short 
repetitive bursts of high-intensity muscle contraction and causes significant 
increases in systolic blood pressure with little effect on cardiac output. This 
affects mainly the left ventricle and aorta and leads to increase in left ventricular 
wall thickness without change in chamber size, resulting in concentric left 
ventricular hypertrophy (LVH). Endurance training (isotonic exercise) results in a 
high metabolic demand from exercising muscle, requiring a more persistent 
elevation in cardiac output; this functions as a volume load on all four cardiac 
chambers, with resultant biatrial and biventricular dilation. LV chamber size 
increases without increase in wall thickness, consistent with eccentric LV 
remodelling[241]. Exercise that has both high isotonic and isometric stresses result 
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in four chamber dilation with balanced increase in LV size and wall thickness 
consistent with eccentric LVH[242] 
The majority of studies looking at changes in cardiac structure and function in 
athletes have underrepresented females. It appears that the male and female 
heart adapt differently to exercise therapy and gender appears to be an important 
modifier of the relationship between exercise and associated cardiac 
remodelling.[243]. Gender differences in the cardiac response to exercise in PAH is 
an unstudied, but relevant area, due to the “oestrogen paradox” in PAH, where a 
female preponderance exists, but with a less severe phenotype than men .  
Evidence is sparse in relation to the effect of exercise therapy on the structure and 
function of the heart in PAH. In children and young adults with corrected tetralogy 
of Fallot or Fontan circulation, a 12 week aerobic exercise training programme 
resulted in improvements in peak aerobic exercise capacity, but no significant 
changes in cardiac structure or function[244]. In left ventricular systolic heart 
failure, endurance exercise can reverse LV remodelling with improvement of 
systolic and diastolic LV function and reduction of LV end-diastolic diameters. The 
reverse remodelling is a consequence of peripheral training effects and direct 
cardiac effects[245] 
Exercise MRI is an emerging and potentially valuable tool to assess dynamic 
structural and functional cardiovascular changes in PAH, such as RV-PA uncoupling 
during exercise[246]. It has the advantage of recreating the environment in which 
the patient is most symptomatic (exertion) in order to delineate the changes from 
the resting state likely to be contributing to symptoms and identify features of RV 
dysfunction at an early stage in the disease process.  
 The role of NTproBNP in PAH 
Brain Natriuretic Peptide (BNP) is secreted by ventricular cardiomyocytes in 
response to increased ventricular stretch, as a result of cardiac wall stress. N-
terminal pro Brain Natriuretic Peptide (NTproBNP) is an inactive fragment of a 108 
amino acid peptide. The 108 amino acid peptide is also metabolised to the active 
fragment BNP; BNP is less stable than NT-proBNP and therefore is a less convenient 
biomarker [247]. Serum levels of NT-proBNP correlate with mPAP, TPR and RV mass, 
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and inversely correlate with cardiac output and RV ejection fraction [128]. High 
plasma levels have a strong, independent association with mortality, however 
absolute values have not been shown to effectively predict treatment response. 
 Aims 
The aim of this chapter is to determine the efficacy of non-invasive means of 
assessing the cardiac response to exercise therapy in PAH, specifically looking at 
changes in 
1. Cardiac MRI: Structure and function  
2. NTproBNP 
3. How these parameters relate to invasively measured haemodynamics 
 Methods 
As discussed in Chapter 2, General Methods, assessments were performed, pre and 
post exercise. Group B (control) subjects, had an additional assessment before and 
after 15 weeks of standard care, prior to entry to the exercise programme.  
 NT proBNP  
N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured on venous 
blood, sampled by venepuncture and collected in vacuum tubes containing 
ethylenediaminetetraacetic acid (EDTA). NT-proBNP was sampled prior to the 
exercise therapy sessions or testing. Samples were processed in the Golden Jubilee 
Hospital Laboratory as per standard clinical practice.  
 Cardiac MRI 
CMR imaging was performed as per standard clinical practice at the Golden Jubilee 
Hospital, in the supine position on a 1.5-T magnetic resonance imaging scanner 
(Sonata Magnetom, Siemens, Erlangen Germany) and images were analysed Circle 
Cardiovascular imaging, version 5.1 (Calgary, Canada). 
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CMR reporting was performed by a doctor (MMcG) trained in the analysis of cardiac 
MRI. The reporting Doctor was blinded to the subject number and assessment time 
point of the subject. All anonymised, blinded CMR scans were analysed twice and 
intra-observer agreement was calculated as discussed in 8.3.3. 
RV and LV volumes and mass were determined by manual tracing endocardial and 
epicardial borders of end diastolic and end systolic images on the short axis stack 
obtained during breath-hold [248].  
Stroke volumes (RVSV & LVSV) were calculated by EDV-ESV. Stroke volume and 
cardiac output were also measured using flow mapping using techniques previously 
described in publications from the SPVU [249]. Right ventricular SV was measured 
using MR phase-contrast flow quantification in an image plane positioned 
perpendicular to the main pulmonary artery. Left ventricular SV (aortic flow) was 
also measured, approximately 2–4 cm above the aortic valve and distal to the 
coronary arterial ostia. 
Right and left ventricular mass (RVM and LVM) were determined as the product of 
myocardial volume for each ventricle and the quoted density of cardiac muscle 
(1.05 g/cm3). RV mass was determined as RV free wall mass, while the 




Ejection fraction (RVEF and LVEF) was determined as a percentage (%) using 
planimetry derived stroke volume measurement: 
RVEF = (RVEDV-RVESV)/RVEDV x100 
LVEF as LVSV/LVEDV x100. 
 Statistics  
Data was assessed for normality using the Shapiro-Wilk test due to the small 
sample size. For cardiac MRIs, scans were blinded and analysed twice by the same 
operator (MMcG), the mean being taken. Intra observer variability was determined 
using Cohen’s Kappa. NTproBNP values were transformed to Log NTproBNP due to 
its non-normal distribution. Correlations were performed using Spearman’s 
correlation coefficient. Multiple linear regression was performed to identify 
significant relationships between cardiac MRI variables and NTproBNP as dependant 
variables with clinically relevant parameters. Normally distributed data are 
presented as mean +/- SD, non-normally distributed are presented as median + 




In the full cohort of subjects who completed the exercise programme, NTproBNP 
did not change following exercise therapy. At baseline Log NTproBNP was 2.28 
(0.54) and at the end of the study, LogNTproBNP was 2.25 (0.54), p 0.296, N 25. 
There was no significant change in NTproBNP in the exercise therapy group versus 
control group: Delta Control Log NTproBNP -0.11 (0.20), N 12, Delta treatment -




 Relationship with treatment response and prognosis 
Treatment response 
In subjects with improved 6MWD, baseline NTproBNP was significantly lower ( 
Table 8.2). At the end of study, the NTproBNP remained lower in the improved 
group, however not reaching statistical significance. There was no rise in 
NTproBNP in the group that deteriorated.  
Table 8.2: NTproBNP in subjects who improved versus deteriorated with exercise therapy 
NT pro BNP Mean improved (N 15) Mean deteriorated (N 9) p 
Baseline 2.07 (0.4)  2.59 (0.6) 0.019 
End of study 2.18 (0.4) 2.48 (0.7) 0.201 
Transplant free survival 
In those who had died or undergone lung transplantation at censoring, NTproBNP 
was significantly higher at baseline (N 7) and follow-up (N 3), compared to those 
who were alive (N 21) (Table 8.3) 
Table 8.3: NTproBNP in subjects who were alive versus deceased or transplanted 
NT pro BNP Mean dead or transplant Mean alive (N 21) p 
Baseline  2.95 (0.5) 2.10 (0.4) <0.005 
End of Study  2.97 (0.6) 2.18 (0.5) 0.014 
 
Association with relevant clinical variables 
At study entry, a number of relevant clinical and prognostic variables correlated 
with baseline NTproBNP (Table 8.4) 
Table 8.4: Baseline NTproBNP significant correlations 
Variable Spearman’s R p N 
TLCO (ml/min/mmHg) -0.538 0.005 26 
VO2/WR -0.504 0.007 27 
mPAP (mmHg) 0.577 0.008 20 
PVR (w.u) 0.552 0.012 20 
TPR 0.681 0.001 20 
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RAP (mmHg) 0.516 0.012 20 
 
Multiple regression analysis was performed for variables with significant 
spearman’s correlation coefficient. TLCO, mPAP, PVR and TPR remained 
significantly associated with baseline NTproBNP, whereas VO2/WR and RAP did not 
(Table 8.5). 
Table 8.5: Multiple regression analysis for NTproBNP at baseline 
Variable B Std. Error Beta t p 
(Constant) 1.97 0.596  3.306 0.006 
TLCO 
(ml/min/mmHg) -0.153 0.036 -0.507 -4.252 0.001 
VO2/WR -0.041 0.063 -0.089 -0.646 0.530 
MPAP (mmHg) 0.018 0.008 0.38 2.252 0.044 
PVR (WU) -0.264 0.121 -1.233 -2.19 0.049 
TPR 0.325 0.114 1.636 2.846 0.015 
RAP mean 
(mmHg) -0.009 0.026 -0.059 -0.354 0.730 
 
TLCO and TPR showed the stronger correlations with NTproBNP (Figure 8.2, Figure 
8.3) 
 




Figure 8.3: Correlation between NTproBNP and Total Pulmonary Resistance 
 
End of study assessment 
At the end of study assessment, NTproBNP correlated with biomarkers relating to 
exercise capacity, gas exchange and cardiovascular function. Multiple regression 
analysis was performed for the three domains.  
Exercise capacity correlations are shown below and multiple regression analysis in   
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Table 8.6: 
• 6MWD R2 -0.564, p 0.005, n 23 
• End exercise WR R2 -0.606, p 0.004, N21 
• Peak VO2 ml/kg/min R2 -0.662, p 0.001, N 21 
• VO2 at AT R2 -0.483, p 0.026, N 21  
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Table 8.6: NT pro BNP linear regression with exercise capacity variables 
 Beta Std. Error 
Adjusted 
Beta t p 
(Constant) 3.324 0.587  5.662 <0.005 
End exercise WR 
EOS (W) 0.002 0.006 0.109 0.285 0.779 
Peak VO2 
ml/mi/kg EOS -0.11 0.047 -0.905 -2.328 0.033 
VO2 at AT EOS -0.042 0.646 -0.017 -0.065 0.949 




Figure 8.4: Correlation between end of study 6MWD and NTproBNP 
 
Gas exchange (Table 8.8):  
• O2 saturations at rest R2 -0.493, p 0.023, N 21 
• Vd/Vt end exercise R2 0.762, p 0.028, N 8 
  
R -0.564 
p 0.005N 23 
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Beta t p 
(Constant) 4.52 1.739  2.599 0.048 
O2 Saturation 
rest (%) -0.023 0.018 -0.347 -1.275 0.258 
Vd/Vt end 
exercise 0.254 0.11 0.628 2.307 0.069 
 
Cardiovascular variables (Table 8): 
• VO2/WR R2 -0.512, 0.018, N 21 
• Right Atrial Pressure R2 0.597, p 0.040, N 12 
 
Table 8.8: NTproBNP and cardiovascular variables linear regression 
 
Unstandardized 
beta Std. Error 
Standardized 
Beta t p 
(Constant) 3.105 2.037  1.524 0.171 
RAP mean 
(mmHg)15 0.018 0.066 0.161 0.274 0.792 
VO2/WR 15 -0.114 0.211 -0.318 -0.539 0.606 
 
Delta NTproBNP 
Change in the primary outcome measures of 6MWD QOL and RVEF showed no 
significant correlation with change in NTproBNP, nor did change CMR variables or 
invasively measured haemodynamics. Significant variables are shown below (Table 
8.9) 
Table 8.9: Significant Spearman's correlation coefficients with change in NTproBNP 
Variable R p N 
TLCO (ml/min/mmHg) 0.586 0.004 22 
Delta VE (L) 0.482 0.02 23 
RC time (sec) 0.48 0.044 18 
 
Multiple regression model showed moderate correlation, with an adjusted R2 of 
0.444. TLCO remained the only significant variable (Table 8.10) 
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Beta t p 
(Constant) -0.678 0.235  -2.887 0.014 
TLCO 
(ml/min/mmHg) 0.065 0.021 0.6 3.05 0.010 
RC time (sec) 0.035 0.021 0.334 1.666 0.122 
VE delta (L) 0.009 0.011 0.166 0.83 0.423 
 
 Cardiac MRI 
Cardiac output and stroke volume measured by flow map improved significantly in 
the entire population who completed the exercise programme ( 
Table 8.11) 




SD / IQR Mean / 
Median 
EOS 
SD / IQR p 
LVEF % 62.5 10.4 64.7 11.4 0.140 
LV EDV** 
(mL) 
120 37.0 124 36.0 0.517 
LV ESV (mL) 46.2 19.3 44.2 20.8 0.330 
RV SV** 
(mL) 
79.0 27 80.2 19.0 0.226 
LV SV** 76.7 26.5 79.7 25.2 0.101 
CO flow 
map (L/min) 
5.9 1.7 6.3 1.73 0.040 
LV Mass (g) 87.7 19.2 90.4 19.6 0.260 
RV EF (%) 44.6 13.3 47.5 13. 0.100 
RV EDV 
(mL) 
180 56 179 62 0.450 
RV ESV** 
(mL)  
104.3 58.8 99.0 58.7 0.230 
RV Mass** 
(g) 
57.0 19.0 54.5 25.9 0.530 
SV flow map 
(mL) 
76.2 23.8 80.9 22.9 <0.005 
Abbreviations and units: Left Ventricle (LV), Right ventricle (RV), Ejection fraction (EF, %), End 
systolic volume (ESV, mL), End diastolic volume (EDV, mL), Stroke volume (SV, mL), Mass (g) 
** Non-parametric data; median / IQR values displayed  
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In both males and females, RV mass was greater than the normal range, in keeping 
with RV hypertrophy. In females, RV end systolic volume was greater than normal 
and in males, RV ejection fraction was lower than normal. In the female 
population, a significant improvement was seen in stroke volume. 
Statistically significant differences between male and female CMR values were 
found in baseline LV mass: 83.9g (16.6) females, 103g (18.8) males, p 0.019; end of 
study RV mass, p 0.026; and end of study LV mass p 0.002; signified by (*) in Table 
8.12. These values remained significantly different when indexed for BSA. 














LVEF (%) 63.9 (9.2) 65.8 
(12.1) 
0.162 59.5 (12.8) 62.1 (9.9) 0.502 
LVEDV 
(mL) 
121 (39) 123 (34) 0.620 116 (29) 129 (42) 0.403 
LVESV 
(mL) 
44.0 (17.2) 41.9 
(18.7) 
0.227 51.3 (23.7) 49.5 (25.6) 0.754 
RVSV 
(mL) 
80.9 (26.8) 76.8 
(17.4) 
0.549 76.9 (26.5) 88.1 (21.5) 0.250 
LVSV 
(mL) 
77.4(27.8 ) 80.4 
(24.5) 
0.177 75.0 (26.3) 78.0 (28.5) 0.585 
CO 
(L.min) 







0.609 103 (18.8)* 109 (16.7)* 0.330 
RVEF (%) 45.7 (12.6) 50.2 
(14.3) 
0.112 39.2 (12.7) 41.5 (8.8) 0.543 
RVEDV 
(mL) 
181 (66) 169 (64) 0.616 197 (31) 200.7 (62.8) 0.500 
RVESV 
(mL) 









70.6 (21.8)* 0.823 
SV (mL) 74.9 (25.2) 80.0 
(23.9) 
0.002 79.0 (21.7) 82.9 (21.8) 0.174 
Bold italics signifies values out-with the normal reference range 
(*) signifies values that are significantly different between males and females.  
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 Exercise therapy versus standard care  
Change in cardiac MRI variables in all subjects (N 26) who completed the exercise 
programme, were compared to changes in control arm CMR following 15 of 
standard care (N 11) (Table 8.13) 
Table 8.13: Control Group (B) Versus Exercise Therapy (A+B) 
 Mean (26) SD Mean (11) SD p  
LVEF (%) 2.1 7.1 -0.19 8.51 0.319 
LVEDV (mL) 1.6 13.7 0.15 21.7 0.273 
LVESV (mL) -2.0 10.1 -0.92 12.98 0.642 
RVSV (mL) 3.2 19.8 -0.15 38.90 0.485 
LVSV (mL) 3.0 10.6 1.06 17.57 0.115 
CO (L/min)(Flow Map) 0.4 0.0 -0.02 0.6 0.384 
LV Mass (g) 2.7 11.7 2.6 18.59 0.883 
RV EF (%) 2.9 8.6 -1.13 13.91 0.496 
RV EDV (mL) -1.5 19.6 -0.25 21.0 0.909 
RV ESV (mL) -5.7 17.3 -0.31 32.47 0.595 
RV Mass (g) -0.63 12.0 2.4 29.56 0.335 
SV (Flow Map) (mL) 4.7 6.2 -0.30 11.19 0.058 
Change in the individuals in Group A (N14, active intervention) versus Group B (N 
11, standard care) are shown in  
Table 8.14 
Table 8.14: Group A (Exercise therapy) versus Group B (Control) changes in MRI variables 
variable Mean (14) SD Mean (11) SD p  
LV EF (%) 3.65 8.42 -0.19 7.1 0.189 
LV EDV (mL) -5.1 8.20 0.15 21.7 0.784 
LV ESV (mL) -6.64 9.48 -0.92 12.98 0.106 
RV SV (mL) -0.39 21.70 -0.15 38.90 0.893 
LV SV (mL) 0.46 10.48 1.06 17.57 0.784 
CO (L)(Flow Map) 0.37 0.95 -0.1 0.60 0.139 
CO (L)(short axis) 0.36 1.32 -0.02 1.35 0.443 
LV Mass (g) 5.38 12.36 2.56 18.59 0.784 
RV EF (%) 2.35 9.92 -1.13 13.91 0.547 
RV EDV (mL) -9.21 17.3 -0.25 21.0 0.274 
RV ESV (mL) -9.50 20.33 -0.31 32.47 0.274 
RV Mass (g) 0.19 16.01 2.92 29.56 0.609 
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SV (mL)(Flow Map) 2.98 5.01 -0.30 11.19 0.317 
 
 Responders and non-responders to exercise therapy. 
Responders to exercise therapy were defined, as previously discussed, as subjects 
who had a 30m or greater improvement in 6MWD. In this sub-group, change in left 
ventricular ejection fraction and cardiac output were significantly greater in the 
responder group ( 
Table 8.15, Figure 8.5, Figure 8.9).  
Table 8.15: Delta CMR variables in responders versus non-responders to exercise therapy 
 
Responders 




mean / Median 
SD / 
IQR p 
LVEF (%) 4.70 7.40 -1.52 5.74 0.04 
LV EDV** 
(mL) 0.70 19.6 1.78 11.5 0.94 
LV ESV (mL) -4.15 11.98 0.33 6.73 0.30 
RV SV(mL) 4.31 24.56 -4.61 23.11 0.29 
LV SV(mL) 5.83 9.78 -2.22 11.00 0.07 
CO (L) 0.67 1.17 -0.35 0.84 0.02 
LV Mass (g) 3.22 14.47 1.85 8.22 0.79 
RV EF (%) 3.67 9.35 0.77 7.57 0.42 
RV EDV** 
(mL) -7.5 40.3 -0.3 16.5 0.37 
RV ESV (mL)  -6.88 19.97 -2.21 17.15 0.46 
RV Mass (g) 2.79 13.35 -5.82 9.32 0.10 
SV (mL) 5.33 7.62 3.64 4.46 0.53 




Figure 8.5: Change in cardiac output in responders versus non responders to exercise therapy 
 









Below are two examples of subjects participating in the exercise programme with 
CMR before and after, with one improvement and one with no change in 6MWD. 
The first subject (Figure 8.7) was a 33y old female on triple therapy for IPAH and 
had been diagnosed 1y and 8 months prior to embarking on the exercise 
programme. Her baseline 6MWD was 510m and end of study 6MWD was 610m. At 
baseline her LVEF was 65%, with an LV stroke volume of 75mls; at the end of study, 
LVEF was 67% with an LV stroke volume of 85mls and a 1.5L improvement in 
cardiac output. A clear improvement can be seen in RV morphology. 
 
Figure 8.7:CMR before (left) and after exercise therapy (right) in a 33y old female subject with 
IPAH and improved exercise capacity 
 
The second subject (Figure 8.8) was a 38y old female, also on triple therapy for 
IPAH. She was diagnosed 12y and 6 months prior to the exercise programme and 
was undergoing work up for lung transplantation at time of enrolment. Her 
baseline 6MWD was 468m, at the end of study 6MWD was 470m. Despite no change 
in exercise capacity, this subject demonstrated a drop in LVEF from 41% to 33% at 
the end of the study, with an increase in RV end systolic volume from 312ml to 
318ml and clear evidence of septal bowing and a “D-shaped” left ventricle. This 
subject was accepted for lung transplantation shortly after the exercise 
programme and went on to have a successful lung transplant in 2018. 
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Figure 8.8 CMR before (left) and after exercise therapy (right) in 37y old female with IPAH and 
deterioration in 6MWD following exercise therapy. 
 Transplant free survival  
At censoring, 7 study participants had been transplanted (2) or had died (5). These 
subjects had poorer RV function both at baseline and the end of the study. They 
also had poorer LV function at the end of the exercise programme, compared to 
those who remained alive ( 
Table 8.16).  
Table 8.16: Significant differences in CMR variables in those alive versus those dead or 
transplanted at censoring 
 Dead or 
transplanted (7) 
Alive (22) p 
LV EF EOS % 51 (15) 67 (9) 0.028 
LV SV EOS  mL 54 (25) 84 (23) 0.039 
RV EF baseline % 32 (9) 48 (12) 0.008 
RV EDV baseline 
mL 
238 (71) 162 (51) 0.012 
RV ESV baseline 
mL 
169 (66) 89 (35) 0.001 
RV ESV EOS mL 184 (92) 84 (36) 0.009 
RV mass g 83 (33) 54 (18) 0.023 
RV EF EOS % 30 (12) 51 (11) 0.012 
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Figure 8.9: LV ejection fraction at the end of study in alive subjects versus transplanted or 
deceased 
 
Figure 8.10: RV ejection fraction at study entry in alive subjects versus transplanted or 
deceased 
0 = Alive,  




0 = Alive,  






Figure 8.11: RV ejection fraction at the end of study in alive subjects versus transplanted 
 
Figure 8.12: RV end diastolic volume at baseline in alive subjects versus transplanted 
 
0 = Alive,  
1 = Deceased / Transplant 
0 = Alive,  








 Relationship between cardiac structure and function 
The relationships between Cardiac MRI measurements pre and post exercise in PAH 
and a number of invasive and non-invasive measures of cardiorespiratory function 
were explored. Specifically, cardiac function (flow and ejection fraction) and 
cardiac structure (mass and volumes). 
Function 
In keeping with ventricular interdependence and the impact of RV volume on LV 
function, a strong correlation was seen between RV and LV ejection fraction; R 
0.727, p <0.005 and also between LV ejection fraction and RV end systolic volume; 
R -0.604, p 0.001. 
CMR Measures of cardiac output showed good agreement with invasively measured 
CO by thermodilution during right heart catheterisation (Figure 8.13). CMR Stroke 
volume correlated with surrogates of SV on CPET and invasively measured SV and 
CO (Table 8.17).  
Table 8.17: CMR CO and SV correlates 





CMR CO flow map (L) CO (RHC) 0.608 0.003 21 
CMR CO flow map (L) Delta O2pulse 
(mL/beat) 
0.573 0.003 24 
CMR stroke volume 
(mL) 




Figure 8.13: Correlation between Cardiac Output measured by RHC and CMR 
 
Baseline CMR Stroke volume, measured by flow map also correlated strongly with 
peak aerobic exercise capacity and change in invasively measured pulmonary 
artery pressures following exercise therapy (Table 8.18).  
Table 8.18: CMR stroke volume correlations 
CPET variable  Spearman R p n 
Peak VO2 (L/min) 0.637 0.001 24 
Delta SPAP (mmHg) -0.639 0.008 16 
Delta mPAP (mmHg) -0.590 0.016 16 
 
Change in SV on CMR correlated with gas exchange on CPET and change in SPAP 
measured during RHC (Table 8.19). 
Table 8.19: Change in Stroke Volume correlations 
Correlate  Spearman R p n 
VE/VCO2 -0.521 0.011 23 
Delta SPAP (mmHg) -0.639 0.008 16 
  
Left ventricular stroke volume correlated with pulmonary artery compliance at 
baseline: R2 0.619, p 0.003, N 21. (Figure 8.14) 
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Figure 8.14: LV stroke volume and PA compliance correlation 
Mass 
LV mass demonstrated a moderate correlation with CO and SV as measured by RHC 
(Table 8.20, Figure 8.15) 
Table 8.20: Correlations with LV mass 
Correlate  Spearman R p n 
CO (L) (RHC) 0.546 0.01 21 







Figure 8.15: LV mass and cardiac output correlation 
 
RV mass correlated with invasively measured pulmonary artery pressures at 
baseline and with change in RVOPF, Rca, SPAP and PAWP following exercise 
therapy (Table 8.21, Table 8.22). 
Table 8.21: Correlation of RV mass with baseline invasive haemodynamic variables 
Correlate  Spearman R p n 
Baseline mPAP (mmHg) 0.627 0.002 21 
Baseline SPAP (mmHg) 0.655 0.001 21 
 
 
Table 8.22: Correlation of RV mass with change in invasively measured haemodynamics 
Delta PAWP 0.602 0.014 16 
Delta SPAP (mmHg) 0.547 0.028 16 
Delta RVOPF (mmHg) 0.696 0.003 16 
Delta Rca (ml/mmHg) -0.559 0.024 16 
 
There was no significant change in RV mass with exercise therapy and delta RV 






Right ventricular end diastolic volume (RVEDV) correlated with CO, PVR and 
invasively measured PAPs (Table 8.23) 
Table 8.23: RVEDV correlations with invasive haemodynamic measurements  
 
Multiple regression analysis was performed for RVEDV. Adjusted R2 for this model 
was 0.873, p 0.005. Cardiac Output and PVR remained significantly associated with 
RVEDV (Table 8.24).  
Table 8.24: Multivariate analysis of RV end diastolic volume correlations  
B Std. Error Beta t p 
(Constant) -340.496 101.001 
 
-3.371 0.005 
PVR (WU) 55.915 12.305 2.118 4.544 0.000 
CO (L/min) 64.698 20.051 1.466 3.227 0.006 
SV (mL) 0.424 1.028 0.128 0.412 0.686 
MPAP (mmHg) 4.874 7.767 0.843 0.628 0.540 
SPAP (mmHg) -4.624 3.253 -1.224 -1.421 0.177 
DPAP (mmHg) -5.058 4.806 -0.702 -1.053 0.310 
 
RV end systolic volume also correlated with invasively measured pressures, 
however less strongly that RVEDV (Table 8.25).  
  
  Spearman R p n 
PVR (WU) -0.504 0.02 21 
CO RHC (L) 0.697 <0.005 21 
SV RHC (mL) 0.642 0.002 21 
mPAP (mmHg) 0.635 0.002 21 
SPAP (mmHg) 0.65 0.001 21 
DPAP (mmHg) 0.529 0.014 21 
SPAP (mmHg) 0.65 0.001 21 
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Table 8.25: Correlation with RV end systolic volume 
Variable  Spearman R p n 
mPAP (mmHg) 0.57 0.007 21 
SPAP (mmHg) 0.605 0.004 21 
delta PAWP (mmHg) 0.62 0.010 16 
 
LV end diastolic volume correlated strongly with both SV measured on CMR and 
RHC (Table 8.26,Figure 8.16). The relationship between stroke volume was 
stronger than that seen with RV volumes.  
Table 8.26: Correlation between LV Volumes and Stroke Volume 
Variable 1 Variable 2  Spearman R p n 
MRI SV baseline (mL)  LVEDV 
Baseline 
0.614 <0.005 29 
RHC SV baseline (mL) LVEDV 
Baseline 
0.783 0.003 21 
MRI SV EOS (mL) LVEDV EOS 0.852 <0.005 26 









No change in NTproBNP was noted with exercise therapy. NTproBNP was higher at 
baseline in those who did not improve with exercise therapy; there was no 
significant rise noted in this group. In smaller studies assessing treatment response 
in PAH, NTproBNP appears to show little or no change. Larger scale 
pharmacotherapy studies have demonstrated that changes can be detected 
following treatment [250, 251]; NTproBNP therefore appears to be a less sensitive 
biomarker for assessing treatment response or identifying a deteriorating patient 
who may require treatment escalation or cessation of the exercise programme.   
Although NT pro BNP did not provide sensitive information about treatment 
response in isolation, the prognostic value of absolute NTproBNP was clear. 
NTproBNP was lower in those who were alive and untransplanted at censoring at 
baseline and follow up. Additionally, it correlated with a number of relevant 
prognostic variables at baseline and follow up relating to exercise capacity, 




It is possible that the small sample size in this study limited the usefulness of the 
test. 
 CMR 
 Baseline characteristics  
The population in this study had increased RV mass, however ventricular volumes 
and function were relatively preserved, despite impaired exercise tolerance. This 
is in keeping with previously published data, showing that RV ejection fraction can 
be maintained or even improve with drug therapy in the face of deteriorating 
haemodynamics and clinical condition[238].  
Invasively measured Cardiac Output and stroke volume showed good agreement 
with CMR measures, highlighting the contribution that CMR can provide in the non-
invasive assessment and following up cardiac function.  
 Changes in the right heart with exercise therapy 
Function 
With exercise therapy, cardiac output and stroke volume improved significantly in 
those who completed the exercise programme. CMR stroke volume correlated with 
exercise capacity (peak VO2) and changes in pulmonary artery pressures, therefore 
demonstrating the use of non-invasively measured SV as a clinically relevant 
marker relating to invasive haemodynamics and disease severity. There was a 
trend towards improvement in RV ejection fraction, however this did not reach 
statistical significance.  
Volumes 
As previously published, ventricular volumes hold important prognostic value in 
PAH and can indicate deteriorating clinical status in the face of preserved 
RVEF[238]. Data from this study are in keeping with the published literature, with 
RVEDV correlating with CO, SV and invasively measured haemodynamics. RV end 
systolic volume also correlated strongly with invasively pressures. RVEDV and 
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RVESV were significantly higher in those that were transplanted or died in 
association with a lower RV ejection fraction. 
Mass 
RV mass correlated with pulmonary artery pressures and correlated with changes in 
PA compliance and right ventricular oscillatory power fraction. This is in keeping 
with the known pathophysiology of right heart failure in PAH; RV hypertrophy is an 
adaptive response to overcome increased RV afterload and the reduced efficiency 
of the RV-PA relationship, as reflected in the RVOPF. Exercise therapy did not 
appear to influence RV mass. It is possible that changes in RV mass may take longer 
to reverse than 15 weeks. Additionally, there may be counter effects of isometric 
exercise which would work to increase ventricular mass, whilst the presumed 
reduction in afterload would contribute to a reduction in ventricular mass. 
 Relationship between the Left Ventricle and the Right Ventricle-
Pulmonary Circulation 
The role of the left ventricle in pulmonary hypertension and its close relationship 
with the RV is important and clearly demonstrated in this study.  
The impact of a volume overloaded RV on biventricular function was highlighted in 
the strong correlation between RV and LV function, as well as RV end systolic 
volume and left ventricular ejection fraction. There was a strong correlation 
between LV end diastolic volume and stroke volume both at baseline and at the 
end of the study. 
LV stroke volume improved following exercise therapy and correlated with 
pulmonary artery compliance, therefore, the more compliant the pulmonary 
circulation, the higher the LV stroke volume. As discussed in Chapter 7, PA 
compliance seems to be a key marker of response to treatment and a more 
sensitive marker than invasive pressure or volume measurements. In subjects who 
died or were transplanted at censoring, LV ejection fraction and LV stroke volume 
were significantly lower.  
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LV mass showed moderate positive correlation with SV and CO (RHC); the latter 
observation would fit with the “deconditioned” and atrophic LV that occurs in 
more severe PAH due to reduced filling.  
Interestingly, there seems to be scope to improve LV function without seeing 
significant improvements in RV function or RV volumes. It may be that the 
“deconditioned” LV is responsive in its own right to exercise training, as is seen in 
health and other medical conditions such as left ventricular systolic failure, where 
reverse remodelling can occur. It could also be that improvements in the LV are 
one of the earlier signs of positive change with exercise therapy. 
In subjects with improved 6MWD, left ventricular ejection fraction and cardiac 
output were significantly higher than those who deteriorated or did not improve. 
In those who were alive and untransplanted at censoring, LV and RV function were 
significantly higher and ventricular volumes were significantly lower. 
 Influence of gender 
Analysis of gender difference was performed in a post hoc analysis, therefore these 
data are exploratory as the study was not powered to detect a between group 
difference in response to exercise therapy between males and females. Gender 
differences appeared to exist both in baseline cardiac structure and function and 
in the response to exercise therapy in this study. In male subjects, RV ejection 
fraction was lower than normal. Female subjects appeared to have less severe 
haemodynamic impairment, however the only statistically significant differences 
between groups were in RV and LV mass, which may be expected given the 
naturally higher RV and LV mass in males. It is well established that PAH is more 
common in females[252], however a more severe clinical phenotype manifests in 
male patients; the so called oestrogen paradox[253]. Post hoc analysis showed 
trends to poorer indices of cardiac function in males. The exercise responses 
between male and female with PAH warrants further investigation.  
 Future research and limitations 
Going forwards, research should focus on developing more sensitive methods of 
detecting treatment response and predicting RV failure. Given the changes seen in 
 249 
Chapter 7, exercise CMR may capture earlier changes in dynamic RV function and 
may be more sensitive at detecting treatment response. This study may be limited 
by small sample size, therefore restricting evaluation of the role of CMR in follow 
up. Gender differences and associations with other clinical variables were post hoc 
and exploratory, future larger prospective studies would be useful to characterise 
the gender differences in cardiac structure and function PAH and response to 
exercise therapy. 
 Conclusions  
PAH specific exercise therapy improves cardiac function, with improved cardiac 
output and stroke volume measured by MRI.   
Cardiac MRI and NTproBNP provide useful and reliable non-invasive information 
regarding cardiac structural and functional changes with exercise therapy in PAH.  
Both modalities correlate with invasively measured haemodynamic variables and 
provide good surrogates for invasive measurements of cardiac function and disease 
severity. In isolation, NTproBNP is not sufficiently sensitive in detecting treatment 
response, however changes can be detected with Cardiac MRI. 
Gender difference exist in cardiac structure, function and response to exercise 




Chapter 9 Changes in muscle function, systemic 
inflammation and metabolism in response to 
exercise therapy in PAH.  
 Introduction 
In PAH, improvements in exercise capacity occur with pulmonary arterial 
vasodilators, however a high degree of morbidity and exercise tolerance persist, 
despite optimal drug therapy.  The pulmonary vasculature in PAH exhibits a 
cancer-like phenotype that promotes cell proliferation and resistance to apoptosis. 
Beyond the pulmonary circulation, it is well established that abnormalities in 
metabolic and muscle function exist and patients demonstrate a pro-inflammatory 
phenotype [254]. These changes have been associated with poorer RV function and 
survival[255] . This has led to an ongoing search for new therapies beyond the 
prostacyclin, nitric oxide and endothelin pathways 
 Metabolic function in PAH 
The molecular origins of PAH promote remodelling of the pulmonary vasculature, 
characterised by hyperproliferation and increased cellular survival. Metabolic 
dysregulation has emerged as a candidate molecular driver of PAH pathogenesis 
[4]. Metabolic changes have been documented in the pulmonary arteries, right 
ventricle, skeletal muscle and serum of patients with PAH [256]. These changes are 
noted in the initial development of disease and early stages through to the end 
stages [5, 6].  
 BMPR2 
The BMPR2 mutation is the most common genetic mutation in PAH, seen in up to 
70% of heritable cases and 20% of idiopathic cases [257]. In metabolomic studies, it 
has been linked to downstream reprogramming in multiple independent metabolic 
pathways, with changes being more extensive in patients with higher disease 
severity [258].  In animal models and human PAECS, reduced BMPR2 expression 
resulted in pulmonary artery endothelial cell (PAEC) mitochondrial dysfunction, 
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promoting a pro-inflammatory or pro-apoptotic state and was associated with 
reduced microvessel density in pulmonary arteries[259] 
 Insulin resistance 
Insulin resistance is a state in which a given concentration of insulin is associated 
with a sub-normal glucose response. The Homeostasis Model Assessment (HOMA) 
estimates steady state beta cell function (%B) and insulin sensitivity (%S), as 
percentages of a normal reference population, using fasting plasma glucose and 
fasting plasma insulin. As insulin sensitivity decreases, insulin production increases 
to compensate for decreasing beta cell function. The HOMA-IR model measures this 
relationship; as the HOMA-IR value increases, so does insulin resistance[260]. The 
original HOMA-IR relationship is described as below:  
HOMA1-IR = FPI x PFG 
                      22.5 
HOMA1-5B =   20 x FPI 
  FPG – 3.5 
FPI: Fasting plasma insulin, FPG: Fasting plasma glucose 
 
An updated non-linear model was developed in 2004 to account for alterations in 
hepatic and peripheral glucose resistance, increases in the insulin secretion curve 
for plasma glucose concentrations greater than 10 mmol/L and the contribution of 
circulating proinsulin[261]. This model allows use of C-peptide in place of plasma 
insulin concentration. C-peptide is released from pancreatic beta-cells during 
insulin cleavage and has the reference range 0.26-1.03 nmol/L. 
Metabolic profiling in advanced PAH lung tissue at time of transplant has 
demonstrated disrupted glycolysis in the cytoplasm, altered glucose metabolism 
through the TCA pathway in the mitochondria, and altered fatty acid metabolism 
through beta-oxidation in the smooth endoplasmic reticulum in addition to β-
oxidation in the mitochondria in the progression of severe PAH [262]. In animal 
models, insulin resistance (IR) rather than elevated lipid content is associated with 
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the presence of pulmonary hypertension in animal models. Insulin resistance has 
been documented in up to 45% of patients with IPAH compared with age, sex and 
BMI matched controls and has been associated with circulating markers of 
inflammation and vascular dysfunction. Insulin resistance has been associated with 
poorer 6 month event free survival (79% vs 58%) risk in IR versus insulin sensitive 
patients with PAH [263].  
 Effects of exercise on metabolic function  
In health, exercise training enhances insulin sensitivity and induces increased 
expression of several key proteins involved in insulin-stimulated 
glucose metabolism, such as the glucose transporter GLUT4, Hexokinase-II, and 
glycogen synthase[264]. In a wide range of chronic health conditions, exercise 
therapy has been shown to improve metabolic function. In dialysis dependent 
chronic kidney disease, exercise training improved insulin sensitivity, associated 
with improvements in systemic blood pressure, without change in body 
weight[265]. Physical training improved hyperinsulinaemia and insulin resistance in 
patients with chronic left ventricular failure[266]. The effects of exercise have not 
been specifically studied in relation to metabolic function in PAH.  
 Muscle Function 
 Skeletal muscle changes in PAH  
Skeletal muscle dysfunction in IPAH is well documented [267]. Clinically, leg 
fatigue and dyspnoea during exercise are potential indicators. Maximal volitional 
and non-volitional strength of both the quadriceps as well as the inspiratory 
muscles are reduced in PAH-patients and are closely correlated to exercise 
capacity[268]. Controversy exists as to whether PAH myopathy is due to the 
atrophying effects of low cardiac output, deconditioning or an independent 
systemic process (Figure 9.1).  
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Figure 9.1: Potential mechanisms of skeletal muscle myopathy in PAH 
 
At a physiological level, attempts have been made to study oxygen delivery and 
extraction balance in IPAH using near infrared spectroscopy at rest and on 
exercise. In PAH patients with higher PVR, the change in deoxygenated muscle 
haemoglobin on exercise was faster than the change in VO2 (a so called 
“overshoot” phenomenon), suggesting a delivery – utilisation mismatch, with 
extraction being sufficient but delivery inadequate [269].  
At a histological level, there is a shift from highly oxidative, fatigue resistant slow-
twitch type I muscle fibres to fast twitch type II muscle fibres and reduction in 
peripheral skeletal muscle capillarisation occurs. Reduced skeletal muscle 
capillarisation correlates with markers of exercise capacity such as VO2 and 6MWD 
[270].  
At a cellular level, the Warburg effect describes the shift from oxidative 
phosphorylation to glycolysis in the presence of adequate oxygen tension[271, 
272]. This phenomenon has been observed in the pulmonary circulation, RV and 
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skeletal muscle in PAH. There is a reduction in skeletal muscle oxidative enzyme 
capacity and reduced function and numbers of mitochondria, resulting in a higher 
potential for anaerobic metabolism compared with aerobic metabolism [267]. 
Importantly, these changes, correlate with exercise capacity and muscle strength, 
but are independent of the severity of pulmonary haemodynamics, suggesting a 
mechanism other than the atrophying effect of low cardiac output [273]. BMPR2 
mutations, may again explain this phenomenon; in normoxia, reductions in BMPR2 
are associated with increased ATP production, glycolysis, mitochondrial fission and 
a pro inflammatory, catabolic state[259].  
 Skeletal muscle changes in deconditioning and chronic health 
conditions 
Deconditioning results in a number of structural and biochemical changes in 
skeletal muscle. Muscle mass decreases and type IIa fibres (fatigue resistant, high 
oxidative and glycolytic capacity) tend to convert to type IIb (low oxidative and 
high glycoloytic capacity; fatigue rapidly). There is a decrease in oxidative enzyme 
concentration, the number and density of mitochondria, and the number of 
capillaries. In other health conditions such as left ventricular failure, it has been 
demonstrated that in age, and VO2 matched individuals, deconditioning did not 
account for changes in skeletal muscle oxidative capacity[274]. The contribution of 
deconditioning to myopathy in PAH has not been studied, however it is unlikely to 
be the sole driver for myopathy, given skeletal muscle changes are present in 
subjects with relatively preserved exercise tolerance.  
 Potential pathways and biomarkers in PAH myopathy 
Micro-RNAs (miRs) are small, non-coding RNA molecules that are involved in post-
transcriptional regulation of gene expression. Gene expression control by miRs is 
an important mechanism for maintenance of cellular homeostasis in response to 
different stimuli including exercise.  
Specific pathways have been identified in the pathogenesis of myopathy in PAH. In 
skeletal muscle biopsies of patients with PAH, miR-126 expression was reduced by 
60% compared with healthy controls and SPRED (a target of miR126) was 
upregulated [103], resulting in a downstream reduction in effectors of the VEGF 
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pathway. miR-126 expression correlated with capillary density and peak VO2 in 
PAH, suggesting a role in angiogenesis in PAH. In this study, 3 patients had skeletal 
muscle biopsies before and after an exercise training programme with no 
significant difference in miR-126 expression. Systemic angiogenic defects may 
therefore contribute to skeletal muscle microcirculation rarefaction and exercise 
intolerance in PAH and appear to be unrelated to haemodynamic severity in this 
small study. A number of other miRs have been identified in relation to skeletal 
muscle function, blood vessel formation and inflammation in PAH, these are 
summarized in Table 9.1. 
Table 9.1: Micro-RNA associations with muscle function and PAH 
Function Specific miR 


































 Exercise training and skeletal muscle effects in chronic 
cardiorespiratory conditions  
The effects of physical exercise on skeletal muscle are in many cases associated 
with changes in gene expression. The characteristics of exercise (intensity, 
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duration, frequency, modality, trained level) and age, play a central role in the 
regulation of gene expression. Physical exercise modulates expression of several 
miRs involved in protein synthesis, such as miR-26a, miR-29a, miR-378 and miR-
451. In health, change in expression of miRs such as miR-20a correlate with 
changes in VO2 following exercise training[104]. In health, miR-761 is related to 
skeletal muscle mitochondrial oxidative capacity and biogenesis via inhibition of 
p38 mitogen-activated protein kinase (MAPK) signalling pathway[281]; inhibition of 
this pathway is of relevance in PAH as expression of p38 MAPK is increased in 
animal models of the hypertrophied RV and in human pulmonary arteries[282]; 
inhibition of MAPK leads to diminished RV fibrosis and improved RV function in 
animal models[283]. 
The AKT pathway stimulates skeletal muscle growth via the pro anabolic peptide 
insulin-like growth-factor 1 (IGF-1)[284]. In left ventricular failure (LVF) and 
cancer cachexia, down regulation of the AKT pathway is linked to skeletal muscle 
atrophy. In LVF, this is predominantly due to a flow related decrease in blood and 
nutrient supply to the highly oxidative, fatigue-resistant type I muscle fibres, with 
exercise training exerting positive effects [285]. In a monocrotaline PAH rat model, 
the AKT pathway was unchanged in control versus PAH rats, whilst significant 
skeletal muscle loss and increased circulating inflammatory biomarkers (IL-1beta, 
CRP, myostatin) and local catabolic markers (MAFbx/atrogin-1 and protease) were 
noted [286]. The changes in PAH do not mirror the changes in left heart failure, 
therefore suggesting a different pathogenesis of myopathy and in keeping with 
changes not being solely flow related.  
 Exercise training and effects on PAH skeletal muscle 
Studies with combined aerobic and resistance training in PAH have demonstrated 
improvements in quadriceps strength and peak aerobic exercise capacity [149]. 
Limited data exist on the effects of exercise and skeletal muscle at a histological 
level in PAH. In a small study of 5 IPAH patients, skeletal muscle biopsies pre and 
post exercise training resulted in a reduction in the proportion of type IIx fibres, 
this was associated with improved 6MWD and improved ventilatory efficiency on 
CPET [78].  
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Several studies have used less intensive exercise programmes. A Dutch study of 12 
IPAH patients found that low intensity rehabilitation resulted in improved 
quadriceps strength and endurance time, with increased muscle capillarity and 
improved oxidative capacity, but importantly, no change in exercise capacity or 
prognostic variables [63]. Further studies utilising existing cardiac rehabilitation 
programmes achieved improvements in quadriceps strength and endurance, with 
increased capillarity density, improved succinate dehydrogenase activity and 
increased numbers of fast twitch fibres. The latter two changes being associated 
with quadriceps endurance [63], however no change was noted in exercise 
capacity. 
From the existing evidence, it seems clear that exercise can induce positive 
effects in PAH myopathy, however the mechanisms in which to most effectively 
improve muscle function remain unclear. 
 
 Inflammation 
Inflammation is an essential immune response and plays an important role in tissue 
repair. However, a persistence of inflammation beyond the initial repair, leading 
to chronically elevated levels of pro-inflammatory markers, exerts deleterious 
effects[287]. 
There is a pro-inflammatory phenotype in PAH. Increased circulating levels of 
monocyte chemo attractant protein-1, tumour necrosis factor- (TNF-α), interleukin 
(IL)-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70 and IL-64 in both PAH animal 
models and patients have been demonstrated [288]. Inflammatory infiltrates are 
also seen in plexiform lesions in pulmonary arteries. In animal models of PAH, 
over-expression of IL-6 leads to severe pulmonary hypertension in mice and under-
expression provides a protective effect from experimental hypoxia driven PH [289].  
Pro-inflammatory cytokines have detrimental effects on skeletal muscle through 
damage to contractile proteins and stimulation of proteolysis [290]. Furthermore, 
elevated levels of pro-inflammatory cytokines (interleukin-6, 8, 10, and 12p70) are 
associated with poorer survival in IPAH, irrespective of haemodynamics [291]. In a 
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study of chronic thromboemolic pulmonary hypertension (CTEPH) patients, IP-10 
negatively correlated with cardiac index and 6mwd[101].  
 Composite serum marker of inflammation 
The potential use of routinely measured, non-invasive serum measurements as 
biomarkers for systemic inflammation in PAH is appealing, particularly when 
assessing the response to therapy. Three scoring systems, discussed below, have 
been widely validated in prognostication of a wide range of cancers. Given the 
parallels between cancer and PAH pathobiology these scoring systems have 
potential to inform on levels of inflammation in PAH and have yet to be studied in 
this condition.  
Modified Glasgow Prognostic Score 
The modified Glasgow prognostic score (mGPS) is a simple scoring system 
combining serum CRP and Albumin. One point is allocated for a CRP greater than 
10 mg/L, one point is allocated if the Albumin is under 35 g/L, with the possible 
scores ranging from 0 to 2. The mGPS was initially validated in colonic cancer, 
providing independent prognostic information. It has since been found to be 
associated with prognosis across a wide range of malignancies. It is also associated 
with muscle loss, poor performance status, increased comorbidity, increased pro-
inflammatory and angiogenic cytokines[292].  
Neutrophil to Lymphocyte Ratio 
In several forms of cancer, neutrophilic inflammation has been associated with 
poorer prognosis. The Neutrophil to Lymphocyte Ratio (NLR) captures subclinical 
inflammation and is a marker of impaired cell-mediated immunity associated with 
systemic inflammation. The normal range is 1 to 3. [293] 
Platelet to Lymphocyte Ratio 
The platelet to lymphocyte ratio (PLR) has been extensively examined in cancer 
studies and out with oncology, in rheumatology and cardiovascular studies, PLR has 
been shown to correlate with the severity of inflammation and is helpful in 
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predicting infection and severe organ damage in SLE [294], the normal range is 
around 50-200[295]. 
 Exercise therapy and inflammation 
The effect of exercise on the pro-inflammatory cytokine profile has not yet been 
investigated in PAH. In health, the anti-inflammatory effects of exercise have been 
described for many years and are proposed form part of the protective mechanism 
against developing conditions such as type II diabetes[296]. Chronic inflammation 
underlies a variety of seemingly unrelated disease processes. In left ventricular 
failure, cytokines such as TNF-alpha reduce with exercise training and correlate 
with improved exercise capacity [102]. In type II diabetes, exercise training 
reduced high sensitivity CRP and pro-inflammatory cytokines[297] 
 Aims  
The aims of this chapter are to explore the effect of exercise training in PAH on  
1. Systemic inflammation: IL-6 and composite scores mGPS, NLR and PLR 
2. Metabolism: Assessing insulin resistance through the HOMA2 score 
3. Muscle function: Looking at clinical parameters of muscle function 
(myometry) and potential pathways - miRs involved in myogenesis (miR 21), 
angiogenesis (miR 126) and specific to PAH (miR 1). 
 Methods  
30 PAH patients participating in an exercise rehabilitation study at the Scottish 
Pulmonary Vascular Unit were included. Those who had known diabetes (7) were 
excluded from metabolic function assessment. Fasting serum was taken before, 
during and after a 15 week aerobic and resistance PAH specific exercise 
programme, along with standard tests to assess PAH severity (described in Chapter 
2). Serum and muscle biomarkers were correlated with standard clinical and 
prognostic variables and are described in more detail below.  
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 Metabolic function 
Insulin resistance was assessed by measuring fasting glucose, fasting C-peptide and 
calculating the HOMA2 score, insulin sensitivity (%S) and beta cell function (%B), as 
described in the introduction section: Metabolic function in PAH  
Fasting whole blood samples were taken in a heparin plasma blood bottle for C-
peptide and kept on ice until analysis. Fasting glucose samples were taken in a 
serum separator blood bottle. Serum glucose samples were analysed at the GJNH 
laboratory and C-peptide was analysed at the Queen Elizabeth University Hospital 
(QEUH) laboratory, as per standard clinical practice.  
 
 Serum markers of inflammation 
 Serum IL-6 
Whole blood samples were taken in a serum separating blood tube and left for 30 
min. Samples were then centrifuged at 3000 rpm for 10 minutes. Serum was 
pipetted into eppendorfs and frozen at -80C.  
Samples were analysed in batch and thawed to room temperature. The Merck 
millipore SMCä Human Interleukin-6 immunoassay kit was used to quantify plasma 
concentration of IL-6 according to manufacturer’s instructions. The immunoassay 
was performed at the University of Glasgow ICAMS laboratory with the assistance 
of EB and JC.  
Materials 
Assay buffer, IL-6 coated beads, IK-6 standard diluent, IL-6 detection antibody, 




1. Jitterbug™ Microplate incubator / shaker  
2. ALPS™ 50V microplate heat sealer (Thermo Fisher)  
3. Centrifuge  
4. 12-channel pipettes capable of transferring 20 µL - 250 µL  
5. 8- or 12-channel pipette capable of transferring 15 µL  
6. Rotisserie rotator  
7. Microcentrifuge  
8. MultiScreenHTS BV 96-Well Filter Plate (EMD Millipore)  
9. 96-well V-bottom polypropylene plate, 500 µL (Axygen)  
10. 384-well round bottom polypropylene plate, 120 µL (Thermo Fisher)  
11. 0.2 µm syringe filter (EMD Millipore)  
12. Universal plate cover (Thermo Fisher)  
13. Sealing tape (Thermo Fisher)  
14. Heat sealing plate foil (EMD Millipore)  
15. 12-channel reagent reservoirs for preparing standards  
16. 5 mL syringe  
17. Microcentrifuge tubes  
18. Container capable of holding 300 mL  
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19. 500 mL graduated cylinder  
20. SMCxPRO™ 384–well Senso plate, sterile, flat bottom with lid 
21. SMCxPRO™ Plate Holder (EMD Millipore)  
22. Senso plate adhesive sealer (Thermo 276014) 23. SMCxPRO™ plate w/seals and 
holder (EMD Millipore PN 02-1003-00)  
Process 
1. All reagents and the standard curve were prepared according to the 
manufacturer’s instructions  
2. 75 µL of standard and samples and 100 µL of capture beads coated in 
antibody specific for IL-6 were pipetted to plate 1 
3. The plate was covered and incubated for 2 hours at 25C on the microplate 
incubator/shaker to allow IL-6 present in the sample to bring to the capture 
antibody on the coated beads. 
4. A post capture wash performed of plate 1 to wash away unbound molecules 
5. The plate was removed from the magnet and 20µL of detection antibody 
was added to each well to recognize and bind to IL-6 captured on the beads  
6. The place was covered and incubated for 1 hour at 25C on the microplate 
incubator/shaker. 
7. The pre-transfer / post-detection was wash then performed on plate 1 to 
remove the unbound detection molecules 
8. Manual plate transfer occurred to plate 2 
9. Final aspiration was performed on plate 2  
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10. The magnet was removed and 10µL of Elution buffer was added to each well 
to dissociate the bound protein sandwich from the bead surface, releasing 
the labelled antibodies 
11. Plate 2 was covered and incubated for 10 minutes at 25C on the microplate 
incubator/shaker 
12. 10 µLL of buffer was added to each well in Plate 3 
13. The contents of Plate 2 were transferred to Plate 3  
14. Plate 3 was loaded onto the SMCxPRO™ system where the labelled molecules 
were detected and counted. The amount of flour-labelled detection 
antibodies counted was directly proportional to the amount of IL-6 present 
in the sample 
 Composite markers of inflammation from whole blood 
Blood was drawn in ethylenediaminetetraacetic acid (EDTA) and serum separating 
blood tubes at baseline, the end of the residential phase of exercise, the end of 
the study, and in the control arm group before and after usual care. A standard 
panel of routinely measured laboratory tests were taken including: Full Blood 
Count (FBC), Urea and Electrolytes (U&E), Liver Function (LFT), Iron Studies, C-
reactive Protein (CRP). 
Samples were analysed in the GJNH laboratory in line with standard clinical 
practice and used to calculate  
• mGPS: Score 1 for Albumin < 35 g/L, score 1 for CRP > 10 
• PLR: Platelet to Lymphocyte Ratio  
• NLR: Neutrophil to Lymphocyte Ratio  
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 Muscle Biopsy  
 Biopsy Technique 
A needle biopsy of the vastus lateralis was performed at baseline and at the end of 
the study. Biopsies were performed at Gartnavel General Hospital (GGH) and 
Glasgow Royal Infirmary (GRI) Radiology Departments. Ultrasound was used to 
identify the vastus lateralis muscle of the dominant leg, 3 cm proximal to the 
patella with the subject in the lateral decubitus position. The skin was prepared 
with chlorhexidine and anaesthetised with 2-5ml of 2% lidocaine. A 1cm skin 
incision was made. A size 14 Gauge, 9cm coaxial Achieveä biopsy needle (Merit 
Medical, Jordan UT, USA) was used to take 2 to 3 biopsies to obtain roughly 200mg 
of skeletal muscle (Figure 9.2) with the assistance of, or by a musculoskeletal 
radiologist (MM or DR). Fat and hair were dissected off muscle samples prior to 
sample storage.  
 
Figure 9.2 Muscle Biopsy Equipment 
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The muscle sample was transferred immediately to 5mLs RNAlater aqueous 
solution (Thermofisher Scientific) for RNA stabilization and storage. Samples were 
transported to the SPVU laboratory at Glasgow University and placed on a rocker 
for 6 hours at 20 rpm in a cool room, they were then frozen at -20C for one week 
and thereafter stored at -80C. The samples stored in RNA later were used for 
assessment of miR expression. 
 Micro RNA experiments 
 RNA extraction 
RNA extraction experiments were performed at the University of Glasgow ICAMS 
laboratory with the assistance of KP.  
Apparatus  
• Chloroform  
• Ethanol (70% and 96–100%) 
• Sterile, RNase-free pipet tips  
• 2 ml microcentrifuge tubes 
• 2 x Microcentrifuge for centrifugation at 4°C and at room temperature  
• Disposable gloves  
• Blunt-ended needle and syringe  
• RNase-Free DNase Set (Qiagen, Switzerland) 
• Qiagen TissueLyser II Machine, Figure 9.3 
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Figure 9.3: Tissue lyserQIAshredder disposable homogenizer tubes (Qiagen, Switzerland)  
 
Muscle procedure  
The experiment area was thoroughly cleaned with RNAse ZAP (Qiagen, 
Switzerland) to ensure an RNA free environment; sterile RNase-free water, 
collection tubes and pipet tips were used. Pre-prepared C. elegans miR-39 miRNA 
mimic (Qiagen, Switzerland) was used for the control.  
1. 700 µ L of QIAzol Lysis Reagent was added to the skeletal muscle, tissue was 
disrupted and homoginized using 3mm stainless steel balls.  
2. The homogenate was incubated at 15-25°C for 5 minutes 
3. 140 µ L of chloroform was added and the sample vigorously shaken for 15 
seconds  
4. The sample was then incubated at room temperature for 2-3 minutes  
5. Centrifuged for 15 minutes at 12,000g at 4°C 
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6. The upper aqueous phase was transferred to a new RNA free collection tube 
using a pipette. 
7. 1.5 x  the volume of the sample (~ 525 µL) of 100% ethanol and  was mixed 
with the sample thoroughly by pipetting  
8. 700 µL of the sample (including precipitate) into an RNA mini column in a 
2mL collection tube. Centrifuge for 15 seconds at 10000G 
9. Qiagen DNAse was used according to manufacturer’s instructions, in order to 
remove genomic DNA (KP) 
10. 700 µL of Buffer RWT was added to the RNeasy Mini Column and centrifuged 
for 15s at 10000G. Flow through was then discarded  
11. 500 µL Buffer RPE was pipetted onto the RNeasy Mini column and 
centrifuged for 15s at 10000g and flow through was discarded  
12. 500 µL Buffer RPE was added to the RNeasy Mini column and centrifuged for 
2 min at 10000G 
13. The RNeasy Mini column was placed in a new 2mL collection tube and 
centrifuged for 1 min at full speed to further dry the membrane  
14. The RNeasy mini column was transferred to a new 1.5mL collection tube. 30 
µL RNase-free water was pipetted directly onto the RNeasy Mini column 
membrane, then centrifuged for 1 min at 10000g to elute (Figure 9.4).  
15. Purity and concentration were quantified using nanodrop technology. 
Between 200ng and 1000ng of RNA was obtained per sample 
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The miRNeasy Serum/Plasma kit (Qiagen, Switzerland), was used. The protocol was 
similar for muscle RNA extraction, the notable differences being in tissue 
homogenization and the DNAse step: 
The procedure was as follows: 
1. Serum samples were thawed in 37C water bath and immediately used  
2. 500 µl of QIAzol Lysis Reagent was added to 100 µl of serum and kept at room 
temperature for 5 minutes 
3. 3.5 µl miRNeasy control was added  
5. 100 µl Chloroform was added to the tube and placed in the vortex for 15 
seconds to allow phase separation; the tube was then kept at room temperature 
for 2-3 minutes.  
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7. The sample was centrifuged for 15 min at 12,000G (4°C). To allow separation 
into 3 phases: an upper, aqueous phase containing RNA; a white interphase; a 
lower, organic phase.  
8. The upper aqueous phase was transferred to a new collection tube and 450 µl of 
100% ethanol was added and mixed thoroughly 
9. 700 µl of the sample was added to a RNeasy MinElute spin column in a 2 ml 
collection tube and centrifuged at 10,000 G for 15 s at room temperature. The 
flow-through was discarded. This step was then repeated for the remainder of the 
sample.  
11.  700 µl of Buffer (supplied with the kit) was added to the RNeasy MinElute spin 
column and then centrifuged at 10,000 G for 15 seconds to wash the column, this 
process was repeated.  
12. 500 µl of 80% ethanol (100% ethanol prepared with RNase free water) was 
added to the RNeasy MinElute spin column and then centrifuges 2 min at 10,000G 
to wash the spin column membrane. The flow through was discarded.  
14. The spin column was placed in a new collection tube and centrifuged at full 
speed for 5 min to dry the membrane. The collection tube with the flow-through 
was discarded.  
15. 14 µl RNase-free water was pipetted directly onto the center of the spin 
column membrane then centrifuge for 1 min at full speed to elute the RNA.  
16. RNA quantification and purity were determined using nanodrop technology 
yielding a range of 580ng – 1270ng between serum samples 
 miRNA PCR 
Qiagen miR RT kit was used to perform quantitative reverse transcription PCR on 
the extracted muscle and serum RNA, taqman probes were selected for miR1, miR 
21 and miR 126. Housekeeping genes were used to normalize the mRNA levels of 
the genes of interest in serum and muscle samples before the comparison between 
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different samples by the real time PCR in triplicate. This experiment was 
performed by KP at the University of Glasgow, with assistance from AM.  
miR-1, -21 and -126 were selected based on the following: 
• miR-1 is involved in the development and physiology of muscle tissue, 
including cardiac muscle. High levels of circulating miR-1 have been used as 
a biomarker to identify cardiac ischaemia and miR-1 is down regulated in 
skeletal muscle following endurance exercise training programmes. In PAH, 
miR-1 has been associated with vascular remodelling[298].  
• miR-21 is upregulated in the pulmonary vasculature of PAH patients and is 
also involved in control of skeletal muscle development[299]. Elevated 
levels of miR-21 have been found in a number of myopathies and also 
increased levels of circulating miR-21 have been found in a number of 
cancers, relating to inhibition of apoptosis. Long term inhibition of miR-21 
has been associated with reduction in obesity in animal models and 
inhibition of tumour immune responses[300]. Endrunance training in healthy 
males was associated with downregulation of serum miR-12 after a 12 week 
endurance training programme.  
• miR-126 has reduced expression in PAH skeletal muscle and is associated 
with impaired angiogenesis in PAH muscle and a number of other conditions 
such as retinopathy. It has pro-angiogenic and also pro-proliferative effects; 
it’s role therefore remains controversial.   
 Muscle Function 
Muscle function was assessed using a digital myometer and clinical analysis 
software (CAS) (MIE medical, Leeds, UK) (Figure 9.5). Hand grip and quadriceps 
strength and endurance were assessed at baseline, at the end of three weeks of 
exercise therapy and at the end of the study. 
 271 
 
Figure 9.5: Myometer with pinch grip analyser 
Muscle strength was determined by measuring the peak force (maximum voluntary 
contraction, Newtons (N)), the best of three attempts being taken.  
For assessment of muscle endurance, the subject first performed 2 maximum 
contractions (MVC). The higher of the two contractions was used to perform the 
endurance test. The subject was asked to maintain 50% of their MVC for as long as 
possible (Figure 9.6) with real time audiovisual feedback via the CAS software. The 
total time, time within target range and total area under the curve were used as 
measures of Endurance (Figure 9.7). 
 
Figure 9.6: Digital display for endurance test 
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Figure 9.7: Result output example for endurance test 
 
 
 Pinch grip testing 
Pinch grip testing was performed using an adjustable handle that connected to the 
myometer and measured force in newtons (N). The distance between two bars 
(cm) was measured at which a comfortable grip was produced. The test was 
performed in a seated position with the elbow resting on a table. The dominant 
hand was tested.   
 Quadriceps testing  
Testing was performed with the subject seated with knees flexed at 90 degrees. 
The dynamometer shin strap was positioned to sit comfortably on the lower 1/3 of 
the tibia. MVC of Quadriceps was tested by knee flexion. A totally of 3 tests were 
performed on the dominant leg for strength and two for endurance. 
 
 Statistics  
Normality was assessed using Shapiro Wilk. Normally distributed data are 
presented as mean (SD) and non-parametric data as median (IQR). All paired 
analyses were performed using the Wilcoxon test and non-paired data using Mann-
Whitney due to the small sample sizes in this study. Spearman’s correlation 
coefficient was used for correlation of variables. In IL-6 analysis, outliers were 
 273 
identified using a box plot and analyses were performed with an without outliers 
present.  
 miR statistics  
The ddcT (threshold cycle) method was used to calculate reverse transcription PCR 
(RT-PCR) results normalised to the housekeeper gene. For an individual subject 
ddC was calculated as follows:  
ddC(t) = dCt(t) - dCt(c) 
ddCt(c) = dCt(c) - dCt(c) 
Where dCt was threshold cycle difference, dCt(c) was dCt of the control condition 
and dCt(t) was dCt of the tested condition 
For groups, the average dCT(c) and dCT(t) were used to calculate the ddCt.  
The Relative Quotient (RQ) was then calculated as 2-ddCt  
Data were compared using the Wilcoxon test for paired data and Mann-Whitney for 
unpaired data. Correlations were performed using Spearman’s.  
 Results  
23 subjects were included without diabetes.  
Population characteristics  
• BMI 29.7 (19-41) 
• Age 50.2y (34-74) 
• Gender 22% Male (5/23) 
• Pre-capillary PH population: 26% (6/23)  CTD-PAH, 4% (1/23) Inoperable 
CTEPH,66% (15/23) IPAH, 4% (1/23) POPH  
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At baseline, a significant proportion of subjects had evidence of metabolic 
dysfunction and inflammation (Table 9.2, non-diabetic patients, N 23) 
Table 9.2: Baseline profile of metabolism and inflammation 
N 23 Mean  Median Range  Normal 
Range  
%  of cohort 
Abnormal. 
NLR 3.4 3.2 1.2-6.8 0.58-3.53 52% above 
PLR 164 143 68-271 75-119 74% above 
mGPS 0.13 0 0-1 ≤1 14% above 
CRP 5 4 1-16 ≤ 10 14% above 
Albumin 
(g/L) 
43 43 34-50 35-55 3% below 
Neutrophil 
(109/L) 
4.1 3.8 2.1-9.2 2.5-7.5 6% above 
Lymphocytes 
(109/L) 
1.3 1.3 0.8-2.6 1.5-4.0 69% below 
C-Peptide 
(ng/mL) 
1.01 0.96 0.24-2.14 0.26-1.03 43% above 
IL-6 (pg/mL) 3.52 2.38 0.7-11.6 ≤6 23% above 
Transferrin 
sat (%) 
22 24 7-36 20-50 40% below 
Serum iron 14 15 5-26 10-30 18% below  
 
 Metabolic function 
10/23 (43%) had fasting C-peptide above the normal range.   Median HOMA-IR score 
was 2.1 (range 0.5-4.65). (Table 9.3) 
Table 9.3: Metabolic function pre and post exercise therapy 
 Mean / 
Median 
Baseline 
SD Mean / 
Median EOS  
SD N   p 
C-Peptide  * 
(ng/mL) 
0.94 0.81 0.92 0.86 15 0.938 
%S* 46 40 53 61 15 0.820 
%B* 133 92 157 125 15 0.570 
HOMA-IR* 1.98 1.61 1.81 1.66 14 0.820 
Glucose 
(mmol/L) 
5.0 0.8 4.9 0.7 13 0.900 
Total Chol 
(mmol/L) 
4.1 1 4.3 0.9 13 0.670 
Triglyceride 
(mmol/L) 
1.2 0.4 1.4 0.6 13 0.326 
HDL 
(mmol/L) 




2.1 0.7 2.2 0.7 12 0.726 
VLDL 
(mmol/L) 
0.6 0.2 0.6 0.3 12 0.157 
Chol:HDL 
ratio* 
3.9 1.9 3.6 2.1 12 0.187 
*Median / IQR displayed 
 
Exercise therapy versus standard care  
In the exercise therapy group, there were no significant changes compared to the 
standard care group, Table 9.4 
Table 9.4: Treatment versus control changes in metabolism  
Mean Exercise 
group change  
SD Mean standard 
care change 
SD p 
Glucose (mmol/L) -0.83 3.48 0.53 1.01 .226 
Total Chol (mmol/L) 0.09 0.58 0.06 0.37 1.00 
Triglycerides 
(mmol/L) 0.14 0.36 -0.05 0.05 
.230 
HDL (mmol/L) -0.07 0.29 -0.04 0.08 .444 
LDL (mmol/L) 0.01 0.36 0.30 0.73 .622 
VLDL (mmol/L) 0.08 0.15 0.09 0.20 .687 
cholesterol:HDL 
ratio -0.24 1.11 0.39 0.79 
.968 
 
Those with elevated baseline C-peptide had poorer exercise capacity, higher 
symptom burden and higher levels of inflammation,  
Table 9.5. 






BMI 32 7 28 5 0.151 
WHO FC  2.7 0.5 2.2 0.5 0.044 
Peak CPET WR 
(W) 
65 12 87 34 0.123 
PEAK CPET VO2 
L/min 
55 20 68 34 0.08 
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PEAK CPET HR 75 11 85 12 0.021 
6MWD (m) 396 83 456 85 0.091 
CRP (mg/L) 7 4.2 3 3.2 0.023 
NLR 4.4 1.9 2.5 1.3 0.016 
PLR 186 82 144 57 0.134 
NTproBNP 
(pg/mL) 
625 1293 273 285 0.449 
 
 Serum markers of inflammation 
 Routinely measured biomarkers 
Neutrophil to lymphocyte ratio (NLR), Platelet to lymphocyte ratio (PLR) and 
modified Glasgow Prognostic Score (mGPS) were assessed at baseline, at the end 
of the residential exercise (week 3) and end of the exercise programme (EOS). 
Routinely measured variables including full blood count and iron studies were also 
measured.    
27 subjects had complete baseline and week 3 data. Between baseline and week 3, 
the CRP reduced significantly. There were no other statistically significant 
variables, but there appeared to be a trend to reduced NLR and PLR  (Table 9.6) 
Table 9.6: Change in profile of inflammation from baseline to week 3 of exercise 
N 27 Baseline  SD Week 3 SD mean delta  p 
Hb (g/dl) 13.2 3.2 12 4.5 1.17 0.123 
Hct (L/L) 0.39 0.09 0.36 0.13 0.03 0.123 
MCV (fl) 84 16.7 78.7 27.2 5.32 0.203 
WCC* (g/L) 6.2 2.2 5.1 2.6 0.54 0.275 
Plt (109/L) 193 65 180 89 13.00 0.312 
Neutrophil (109/L) 3.9 1.9 3.5 2.2 0.37 0.344 
Lymphocyte* (109/L) 1.37 0.49 1.3 0.39 0.06 0.121 
Creatinine (mmol/mL) 74 28 68 34 6.43 0.461 
EGFR (mL/min) 56 12 51 21 5.07 0.092 
Albumin* (g/L) 41.6 8.7 37.1 15.3 4.50 0.087 
CRP (mg/L) 5.13 4.5 2.53 2.6 2.60 0.001 
NLR 3.18 1.77 2.94 1.95 0.25 0.427 
PLR 155 71 144 75 10.87 0.322 
*Median / IQR displayed 
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No significant differences were noted in the 24 subjects with complete baseline to 
end of study data (Table 9.7) 
Table 9.7: Change in profile of inflammation from baseline to end of study 
N 24 Mean / 
Median 
Baseline 
SD Mean / 
Median EOS  
SD p 
Hb (g/dl) 13.7 2.1 13.6 2.2 0.303 
Hct (L/L) 0.4 0.06 0.4 0.06 0.686 
MCV (fl) 86.7 4.8 88.0 4.1 0.080 
WCC* (g/L) 5.9 2.4 5.6 2.6 0.685 
Plt (109/L) 205 56 199 57 0.157 
Neutrophil (109/L) 4.1 1.9 4.1 1.9 0.861 
Lymphocyte* 
(109/L) 
1.2 0.6 1.2 0.5 0.647 
Creatinine 
(mmol/mL) 
81 23 80 19 0.475 
EGFR (mL/min) 59 3.5 60 1.6 0.070 
Albumin* (g/L) 42 2 43 6 0.834 
CRP (mg/L) 5.3 3.9 4.5 4.4 0.569 
Transferrin sat 
(%)  
22 10 25 14 0.872 
Serum Iron 14.6 7 16.3 8.3 0.773 
Transferrin  2.8 0.4 2.8 0.5 0.300 
NLR 3.3 1.7 3.1 1.3 0.424 
PLR 160 50 152 44 0.362 
*Median / IQR displayed 
 
Standard care versus exercise therapy 
There were no significant changes following standard care (control group) versus 
exercise therapy (ET) (Table 9.8) 
Table 9.8: Control versus treatment change in routinely measured blood tests and serum 
markers of inflammation  
N Mean  
ET group 
change 




Hb (g/dl) 24 -0.10 1.30 11 0.03 0.99 .390 
Hct (L/L) 24 0.00 0.03 11 0.00 0.03 .540 
MCV (fl) 24 1.51 4.88 11 -2.82 5.99 .072 
WCC* (g/L) 24 0.13 1.83 11 -0.19 0.83 .687 
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Plt (109/L) 24 -10.37 34.25 11 -11.10 34.40 .847 
Neutrophil 
(109/L) 24 0.06 1.75 11 -0.24 0.79 .687 
Lymphocyte* 
(109/L) 24 0.01 0.28 11 0.05 0.21 .958 
Creatinine 
(mmol/mL) 24 -0.17 11.92 11 -1.27 10.77 .766 
EGFR (mL/min) 24 0.79 2.62 11 0.09 1.14 .587 
Albumin* (g/L) 24 0.04 3.32 11 -0.18 2.36 .687 
CRP (mg/L) 24 -0.75 3.71 11 0.00 1.89 .820 
NLR 23 -0.25 1.2 9 0.69 2.30 .273 
PLR 23 -8.1 37.2 9 -6.3 58.9 .930 
 
 Interleukin-6  
Normal Interleukin-6 (IL-6) serum concentration is under 6. IL-6 was non-
parametrically distributed, therefore data are presented as Median (IQR). Table 
9.9 demonstrates the scatter. Four subjects dropped out (as discussed in Chapter 
5). 22 subjects had baseline to week 3 data and 21 subjects had baseline to end of 
study data. 41% (9/22) subjects had IL-6 concentrations greater than 6pg/mL 
Table 9.9: IL-6 values at different time points in the exercise programme 
 Mean Median IQR Range N 
Baseline  7.5 3 6 0.7-49 27 
End residential Phase 4 3.4 3.5 0.7-16 25 
EOS 7.3 3.6 4 0.7-65 22 
Control 3.4 2.9 2.6 1.7-6.3 10 
 
 Change with exercise therapy 
IL-6 was measured at baseline and compared to serum IL-6 concentration at the 
end of residential (ER) phase exercise (Table 9.10) the end of the study (EOS) 
(Table 9.11). Group B subjects had IL-6 measurements performed pre and post 15 
weeks of standard care (Table 9.12) 
Table 9.10: Change in exercise therapy following 3 week residential phase exercise 
Baseline 
Median  
IQR ER Median IQR P  N 
2.7 4.1 3.6 3.1 0.848  22 
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IQR P  N 
2.4 4.9 3.6 4.4 0.339 21 
 
Table 9.12: IL-6 concentration with standard treatment (Group B) 
Baseline IQR Entry to 
exercise 
programme 
IQR P  N 
2.3 8.8 2.3 2.1 0.953 9 
 
 IL-6 Outliers  






Figure 9.8: Serum IL-6 concentrations (pg/mL) at different time points during the study 
  
1 Baseline  
2 End Residential 
3 End of Study  
4 Control 
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Table 9.13: IL-6 concentration (pg/mL) outliers  
Subject Start 
Residential 
Phase (1)  
End Residential 
Phase (2)  
End of study  
(3) 
Control  (4) 
A1 49.5 6.06  n/s  
A2 1.18 3.57 64.824 
A3 3.47  n/s 5.68 
A4 4.77 3.43 7.45 
A5 1.91 2.88 2.52 
A6 20.8 4.99 5.13 
A7 8.14 9.67 7.69 
A8 2.15 0.82 0.74 
A9 4.51 3.85 5.73 
A11 11.6  n/s 18.4 
A12 5.33 4.8 8.4 
A13 2.22 5.33 1.38 
A14 5.14 16.1  n/s 
A15 1.87 5.17 3.64 
A16 4.17 4.76  n/s 
B1 0.7 0.7 0.82 
B2 7.84 1.44  n/s 
B3 1.12 1.36 1.73 
B4 2.21 6.72 5.76 5.73 
B5  n/s 2.91 2.43 n/s 
B6 33.91  n/s 5.78 4.36 
B7 2.44 2.75 2.7 4.00 
B8 2.31 2.43 3.07 2.02 
B9 1.47 1.29  n/s 2.2 
B10 1.62 2.23 2.21 2.9 
B11 n/s n/s n/s 6.1 
B12 3.04 3.65 2.22 2.98 
B13 18.0 1.75 3.5 2.15 
B14 1.77 1.34  n/s 1.73 
 
Outliers identified above, were analysed separately to look for any common factors 
to determine whether these results were a true reflection of serum IL-6 or error in 
the experimental process. Of the outliers, four were in the baseline samples. 
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These subjects had the following characteristics: One CHD-PAH, two CTD-PAH, one 
IPAH with autoimmune hepatitis. In relation to exercise capacity and metabolic 
function, they appeared to have a lower baseline exercise capacity and higher 
degree of metabolic dysfunction in comparison to the entire study population, 
none of these results were statistically significant due to the small numbers. 
(Table 9.14) 
Table 9.14 Comparison of high IL6 concentration (pg/mL) baseline outliers to study population 
 IL-6 Outliers Study Population  
Baseline  EOS Delta Baseline EOS  Delta 
Baseline 
6MWD (m) 
385 455 70 438 477 39 
C-peptide 
(ng/mL) 
1.8 1.36 -0.44 1.03 1.02 -0.01 
HOMA-IR 3.85 2.83 -1.02 2.23 2.19 -0.04 
 
 IL-6 change with outliers out (Standard care v exercise therapy) 
Paired analyses were performed with the outliers removed. There was no 
significant change in IL-6 following residential exercise phase ( 
Table 9.15), however a significant increase was seen following completion of the 
15 week exercise programme (Table 9.16).  






IQR P N 
2.2 2.9 3.4 3.6 0.156 21 
 
Table 9.16: Change in IL6 following 15 week exercise programme (pg/mL) 
Baseline 
Median  
IQR End of 
study 
Median 
IQR P  N 
2.3 2.8 3.1 4.6 0.031 17 
 
Change in individual IL-6 concentration before and after exercise therapy can be 
found in Figure 9.9. 
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Figure 9.9: Individual changes in IL-6 concentration before and after exercise 
 
In the control arm versus the treatment arm, there was a significant increase in 
serum IL-6 concentration with exercise therapy (Table 9.17, Figure 9.10) 
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Figure 9.10: Change in IL-6 standard care versus exercise therapy with outliers removed  
 
 Treatment response and prognosis 
Those who improved 6MWD (15 of 25) had a more favourable baseline metabolic 
and inflammatory profile, Table 9.18 
Table 9.18: Differences in baseline metabolic function and inflammation in those with 
improved 6MWD versus no change or deteriorated (NC / D)  
Improved SD NC / D  SD p 
Hb (g/dL) 13.6 2.2 13.9 1.9 0.730 
WCC (g/L) 5.4 1.5 7.2 2.4 0.026 
Plt (109/L) 185 59.8 225 36.5 0.042 
Neut (109/L) 3.6 1.2 5 2.5 0.063 
Lymph (109/L) 1.3 0.5 1.5 0.4 0.204 
Creat 
(mmol/mL) 
81 24 66 26 0.131 
eGFR (mL/min) 59 4 56 11 0.375 
Albumin (g/L) 42.6 3.3 43.7 4.8 0.508 
CRP (mg/L) 5.3 4.1 5.8 5.5 0.805 
Transferrin sat 
(%) 
26.2 18.9 25.9 13.8 0.969 
Serum Iron 16.8 13.6 15.8 6.7 0.829 





5.2 0.9 6.4 3.9 0.284 
Total Chol 
(mmol/mL) 
4 0.7 5.2 1.5 0.014 
TG (mmol/mL) 1.2 0.42 1.8 0.85 0.045 
HDL (mmol/mL) 1.2 0.3 1.7 1.2 0.157 
LDL(mmol/mL) 2.2 0.7 2.7 1.3 0.237 
VLDL(mmol/mL) 0.56 0.19 0.74 0.34 0.139 
Cholesterol:HDL 3.4 0.89 3.7 1.6 0.543 
mGPS 0.11 0.32 0.22 0.44 0.428 
NLR 3.18 1.4 3.64 2.3 0.516 
PLR 162 77 157 44 0.860 
IL-6 (pg/mL) 6.4 8.9 5.6 6.5 0.675 
C-Peptide 
(ng/mL) 
1.08 0.62 1.00 0.59 0.025 
HOMA2 1.69 1.54 1.72 1.04 0.961 
 
Prognostic role  
Those who were dead or transplanted (D/T) at censoring had higher baseline IL6 
and higher baseline CRP than those who were alive (A). Although not reaching 
statistical significance, there was a trend to higher neutrophils, lower lymphocytes 
and higher HOMA2 score in those who had not survived or had been transplanted at 
censoring.  
Table 9.19: Alive versus transplant / deceased at censoring 
 Mean D/T (7) SD Mean A  (22) SD P 
Hb (g/dL) 14.7 2.0 13.4 2.1 0.217 
Plt (109) 184 58 205 55 0.354 
Neut (109) 5.0 1.7 3.7 1.7 0.070 
Lymph (109) 1.2 0.5 1.4 0.5 0.304 
Albumin (109) 43 5.1 43 3.3 0.980 
CRP (mg/L) 7.9 5.4 4.5 4.0 0.055 
Transferrin sat (%) 21 5.4 27 20 0.409 
Serum iron 13 2.6 17 13 0.409 
Glucose (mg/dL)) 5.3 1.1 5.7 2.7 0.910 
Total Chol (mmol/mL) 4.4 1.8 4.5 0.9 0.431 
TG(mmol/mL) 1.5 1.1 1.5 0.5 0.392 
HDL(mmol/mL) 1.3 0.4 1.4 0.8 0.940 
LDL(mmol/mL) 2.3 1.6 2.4 0.6 0.319 
VLDL(mmol/mL) 0.6 0.4 0.7 0.2 0.101 
Cholesterol:HDL ratio 3.6 2.1 3.6 0.9 0.940 
NLR 4.3 1.6 3.0 1.6 0.078 
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PLR 155 46 162 72 0.784 
IL6 (pg/ml) 6.4 1.9 4.5 5.5 0.047 
C-peptide (ng/mL) 1.0 0.8 0.9 0.4 0.971 
HOMA2 1.9 2.0 1.5 1.2 0.798 
 
Clinical relevance of IL-6  
Baseline IL-6 correlated negatively with 6MWD (Figure 9.11), end exercise WR 
(Figure 9.12), VO2 (CPET) and quadriceps muscle strength and positively with 
NTproBNP. No significant correlations with metabolic parameters HOMA-IR and C-
peptide were noted (Table 9.20) 
Table 9.20: Correlations between baseline IL-6 and relevant clinical and prognostic variables 
 Spearman’s coefficient P N 
Baseline 6MWD (m) -.534** 0.004 27 
Age (y) 0.123 0.55 26 
End exercise  (WR) -.641** <0.005 26 
Peak VO2 (L/min) Jones -.510** 0.008 26 
Ve/VCO2 gradient -0.023 0.912 26 
MPAP (mmHg) 0.156 0.523 19 
PVR (WU) 0.008 0.974 19 
Rca (mL/mm Hg) -0.216 0.375 19 
02 extraction (%) 0.214 0.379 19 
RV SV (mL) 0.067 0.756 24 
C-peptide (ng/mL) 0.345 0.136 20 
Log NTproBNP .569** 0.002 26 
NLR 0.244 0.22 27 
PLR 0.057 0.776 27 




Figure 9.11 Correlation between baseline walk distance and serum IL6 concentration 
 
 







 Muscle Function 
Muscle function was assessed at baseline, after 3 weeks of residential exercise and 
at the end of the study. Grip function and Quadriceps function were both assessed.  
 Grip Strength and endurance  
Both grip maximum voluntary contraction force (strength) and grip endurance time 
improved significantly following three weeks of residential exercise therapy (Table 
9.21). This improvement in endurance was maintained at the end of study visit. 
Grip strength remained higher than at baseline, but not reaching statistical 
significance (Table 9.22) 
Table 9.21: Change in grip strength and endurance baseline to week 3 
N 23 Mean 
Baseline  
SD Mean Wk 3 SD p 
MVC Grip (N) 197 60 226 63 0.002 
AUC MVC Grip 1009 316 1224 350 0.001 
Grip Endurance Time 
(sec)  
102 63 143 103 0.053 
Endurance time AUC  8701 4596 14210 11766 0.001 
 
Table 9.22: Change in grip strength and endurance baseline to end of study 
N 17 Mean Baseline SD Mean EOS SD p 
MVC Grip (N) 194 59 223 56 0.196 
AUC MVC Grip (N) 1012 342 1173 326 0.179 
Grip Endurance Time (sec)  93 61 134 71 0.049 
Endurance time AUC  8256 4436 11794 4860 0.044 
 
 Quadriceps strength and endurance  
Quadriceps function improved significantly in the first 3 weeks of the exercise 
programme (Table 9.23) with quadriceps strength improvements being maintained 
at the end of study (Table 9.24) 





week 3  
SD 
P  
Quads diameter (cm) 50 10 51 10 0.42 
MVC Quads (N) 256 115 355 176 <0.005 
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AUC MVC Quads 1332 639 1717 770 0.015 
Quads Endurance 
Time (Sec) 157 139 215 
175 
0.024 
Endurance time AUC  19705 18995 25751 20417 0.052 
 
Table 9.24: Quadriceps function baseline to end of study 
N 17 Mean Baseline SD Mean EOS  SD P  
Quads diameter (cm) 52 10 50 10 0.230 
MVC Quads (N) 252 123 295 120 0.049 
AUC MVC Quads 1396 724 1456 578 0.523 
Quads Endurance Time (sec)  154 142 134 71 0.653 
Endurance time AUC (sec) 20216 21035 31619 29635 0.088 
 
No significant correlations were found with muscle endurance or strength with 
markers of exercise capacity.  
 Micro-RNA 
 Serum miR 
20 subjects had pre and post exercise training complete serum miR values. There 
was a trend to down regulation of miR-1, -21 and -126, however statistical 















p 0.970  p 0.296  p 0.191 
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Figure 9.13: Change in serum miR expression with exercise therapy 
With standard care, no significant differences were seen in serum miR-1, -21 and -
126 (Figure 9.14).  
 
Figure 9.14: Change in serum miR with standard care 
 Muscle miR 
19 subjects had baseline muscle biopsies and 10 had follow up biopsies. Of the 9 
who did not have follow up biopsy, 4 were drop-outs from the study, 3 declined 
repeat biopsy and 2 subjects were unwell at the time of scheduled biopsy. 
Unpaired comparison of the whole population and paired comparisons in those who 
had pre and post exercise biopsies revealed very similar results, therefore paired 
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Figure 9.15: miR-1 expression pre and post exercise therapy 
 
































































Figure 9.17: miR-126 skeletal muscle expression pre and post exercise therapy  
 
Clinical improvement and transplant free survival 
Muscle miR-126 expression increased significantly in those who deteriorated or did 
not improve with exercise therapy compared with those who did improve (Figure 
9.18). A similar pattern was seen in those who were alive without transplant at 




Figure 9.18: Differences in miR-126 skeletal muscle expression in improved versus 
deteriorated subjects 
 
Figure 9.19: Difference in miR-126 muscle expression in relation to transplant free survival 
 
There were no statistically significant differences in miR-1 and miR-21 in relation 
to transplant free survival or clinical improvement with exercise therapy.  
Association with clinically relevant variables 
Changes in miR-1, -21 and -126 expression correlated with prognostically relevant 
clinical variables such as 6MWD, mixed venous oxygen saturation and PVR (Table 
9.25), however numbers were small. 








Baseline NC/D EOS NC/D Baseline Improved EOS Improved
miR 126 expression in improved (n 5)  and 









Baseline D/T EOS D/T Baseline Alive EOS Alive
miR 126 expression in dead/transplanted (n 3) 






Spearman’s R p N 
miR 1  6MWD (m) -0.750 0.020 9 
miR 21 SvO2 (%) -0.857 0.007 9 
miR 21  RV Mass (g) 0.703 0.035 9 
miR 126 IL-6 (pg/L) 0.833 0.005 9 
miR 126 PVR (WU) 0.833 0.010 9 
miR 126 mPAP (mmHg) 0.714 0.047 8 
miR 126 NLR 0.750 0.020 9 
miR 126 Log NTproBNP 0.850 0.004 9 
miR 126 KCO (%) -0.929 0.001 8 
 
 
Figure 9.20: Log NTproBNP and miR126 muscle expression at baseline 
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Figure 9.21: KCO (%) and muscle expression of miR-126 
 
 
Figure 9.22: PVR (WU) and muscle expression of miR-21 
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Figure 9.23: 6MWD and muscle expression of miR-1 
 
Due to the small numbers, limited correlations were possible for tests of muscle 
function, however miR-126 at baseline and at the end of the study negatively 
correlated with grip endurance  











-0.867 0.002 9 
miR 126 (EOS) Grip 
Endurance 
EOS (sec) 
-0.821 0.023 7 
 
 Discussion 
In keeping with published literature, this cohort of PAH patients displayed high 
rates of insulin resistance and systemic inflammation. As discussed in Chapter 7, a 
large proportion of subjects at baseline had normal cardiac output at rest and no 
change was seen in SvO2 at rest or on exercise following exercise therapy, despite 
evidence of skeletal muscle myopathy and inflammation being present in baseline 
tests. These findings make flow driven causes of myopathy and inflammation less 
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likely and support the hypothesis of these changes being a reflection of the 
systemic nature of PAH as a pro-inflammatory condition.   
 Effects of exercise therapy on metabolism 
There was a trend towards improved insulin sensitivity and beta-cell function, 
however these changes did not reach statistical significance. No changes were 
noted in serum lipid profile. The finding observed of improved insulin sensitivity 
with exercise, without changes in BMI or lipid profile has been noted in previously 
published studies [263]. Subjects with insulin resistance had lower exercise 
capacity, higher levels of systemic inflammation and poorer functional class. In 
those who improved with exercise therapy, lipid profile was more favourable at 
baseline however no other markers of metabolism were significantly different. 
Despite the high prevalence of insulin resistance within this cohort and the 
benefits of exercise on metabolic function being well established in other 
conditions, exercise did not have a powerful impact on insulin resistance. It 
possible that there are other, more sensitive biomarkers that may more accurately 
reflect metabolism in PAH. Bioinformatics studies my help to identify the most 
appropriate biomarkers moving forwards.  
 Muscle function and mechanistic pathways  
Exercise therapy improved clinical measures of muscle function, with improved 
strength and endurance in both quadriceps and hand grip.  
From a mechanistic perspective, the most striking change in circulating and muscle 
miRs was in the down regulation of miR-126.  In a post hoc analysis, a higher 
expression of miR-126 was noted in subjects with a poorer clinical course. In this 
exploratory analysis, miR-126 also negatively correlated with several prognostic 
markers such as mPAP, NTproBNP, IL-6 and positively correlated with gas 
exchange. This observation seems initially counter intuitive based on existing data 
suggesting increased miR-126 expression is beneficial in PAH muscle function 
through its angiogenesis promoting effects mediated by VEGF and SPRED[301]. 
Knock-out animal models of miR-126 have been studied in PAH[39], however no 
study to date has prospectively assessed serum and muscle expression of miR-126 
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following exercise therapy in PAH. There are several explanations for why this 
difference between this study and the existing literature exists: 
1. In addition to its proangiogenic effects, miR-126 also has a pro-proliferative 
role; increased levels directly correlate with survival and tumour progression in 
cancers such as oral cancer[302]. Given the parallels between cancer and PAH 
biology, the downregulation of miR-126 observed in this study, may be reflect anti-
apoptotic and anti-inflammatory effects of exercise[303].  
2. miR-126 may have different roles in different scenarios; it is recognised that 
expression of specific miRs varies between “high” and “low” responders to 
exercise therapy and based on the duration, modality and intensity of exercise.  
miR126 expression is also likely to have different roles in different body tissues 
(skeletal muscle versus ventricular muscle).  
3. The majority of the literature on miR126 in PAH pertains to animal models or 
invitro studies using miR126 mimic[304], it is possible that these changes do not 
translate over to in vivo human biology.  
The changes in miR-1 and miR-21 were mirrored in serum and muscle, with a trend 
to down regulation following exercise, without statistical significance. Based on 
the roles of miR-1 and miR-21, one would hope for a reduction in miR-1 and miR-21 
expression due to the association with myopathy, inflammation and vascular 
remodelling.  
 IL-6 and inflammation 
Serum IL-6 concentration was elevated in a significant proportion of subjects, with 
a wide range in individual values. Subjects with very high IL-6 values had poorer 
exercise capacity and evidence of insulin resistance. These subjects were more 
likely to have connective tissue disease. Those who were alive without transplant 
at censoring, had a significantly lower IL-6 value than those who had died or been 
transplanted. This prognostic role was corroborated by the negative correlation of 
IL-6 with several markers of exercise capacity and positive correlation with 
NTproBNP.  
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Initial analysis of IL-6 revealed a paradox; high baseline levels were associated 
with poorer prognosis, but increased IL-6 concentration was seen following 
exercise therapy and was associated with improved exercise capacity and 
prognostic markers. Il-6 is known as a myokine, a cytokine produced by skeletal 
muscle, and is involved in the physiology of adaptation to exercise[305]. Exercise 
has been shown to acutely increase the levels of IL-6 and has been associated with 
reduction in visceral adipose, improved post-prandial glucose handling and 
suppression of pro-inflammatory mediators[306]. The increase in Il-6 seen 
following exercise therapy may therefore be seen as a positive response. To 
provide greater understanding of the role of IL-6 in relation to PAH pathogenesis 
and exercise, basal and post exercise levels would need to be studied over a period 
of time. A methodological limitation to this study is that it is not possible to say 
whether proximity to exercise sessions resulted in falsely high IL-6 levels in some 
cases, as the timing of venepuncture was not strictly controlled in relation to 
exercise. 
NLR and PLR were raised in over half of the studied population, whilst CRP did not 
show any significant deviation from normal. The use of Epoprostenol in nearly half 
of this cohort and inclusion of subjects with liver disease may have reduced the 
efficacy of PLR due to the thrombocytopenic effect of both. 
 Future research 
Further research to identify appropriate biomarkers will aid understanding of the 
processes involved in the development of metabolic dysfunction and inflammation 
in PAH and may help to identify potential therapeutic targets and provide clarity in 
the role of exercise therapy. Following on from this pilot study, further research is 
planned to assess histological changes in skeletal muscle, muscle cytokine 
expression and mitochondrial function.  
 Conclusions  
Significant levels of metabolic dysfunction and inflammation were evident in this 
population in the face of clinical stability and optimal PAH therapy.  
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Metabolic dysfunction and inflammation were associated with markers of poorer 
prognosis and quality of life, particularly in relation to baseline serum IL-6. 
Composite measures of systemic inflammation, NLR and PLR, appeared to be more 
sensitive markers of systemic inflammation than CRP alone. Metabolic function was 
not strongly influenced by exercise therapy.  
Exercise therapy improved muscle strength and endurance. miR-126 may be 
directly related to PAH myopathy and influenced by exercise therapy, however 
further research is required to investigate this.  
It is clear that metabolic dysfunction and inflammation relate to prognosis in PAH, 
exercise therapy alone may not be sufficient in ameliorating these changes and 
further targets for intervention require investigation. 
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Chapter 10 Major findings and conclusions 
The work in this thesis was undertaken to establish 
• Whether PAH patients wished exercise therapy as part of their treatment 
and if so, what barriers may oppose their participation.  
• Whether exercise therapy is effective in an optimally treated UK PAH 
population 
• Explore potential mechanisms by which is exercise exerts its beneficial 
effects in PAH in order to 
o Further characterise persistent physiological and biological changes in 
those “optimally treated” prior to exercise therapy. 
o Understand factors that are modifiable with exercise therapy and 
therefore gain a better understanding of how exercise exerts its 
beneficial effects in PAH. 
o Identify key components of the programme to help develop and 
refine future exercise programmes and inform clinical service 
development. 
Efficacy  
• Overall, exercise therapy is a desired treatment option for patients with 
PAH in Scotland. It is highly effective in the majority, well tolerated and 
safe.  
• Improvement with exercise therapy as defined by an increase in 6MWD of 
greater than 30m appears to be a suitable means of defining improvement 
to the intervention. 6MWD correlated strongly with quality of life and lack 
of change in walk distance following exercise therapy discriminated well 
those with poorer quality of life and prognosis.  
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• A small subset of patients did not improve with exercise therapy in a post 
hoc analysis. It appeared that these patients were more likely to have 
severe PAH, high levels of inflammation and connective tissue disease. It is 
unclear whether this sub-group derives benefit from exercise, it is possible 
the 6MWT is the wrong end point in this sub-population due to 
musculoskeletal comorbidities. Exercise therapy may slow the disease 
trajectory and improve function, alternatively it may exert no beneficial 
effects. This specific population requires further research and an 
appropriately powered study to address these points.  
Disease insights  
This small but highly phenotyped population provided interesting and useful 
insights into the role of exercise therapy in PAH and the underlying systemic 
manifestations of the disease.  
Despite satisfactory improvements in haemodynamics with optimal drug therapy, 
and an acceptable mean baseline walk distance of 422m, the population studied 
displayed significant disease specific and systemic abnormalities. This highlights 
the ongoing need for new treatment strategies in this population.  
• At rest PA haemodynamics appeared to be satisfactory, with low PVR, 
preserved cardiac index and relatively low mPAP. This was in keeping with 
the majority of patients displaying normal RV function and volumes on CMR. 
On exercise, significant rises were seen in mPAP and TPR.  
• Gas exchange was significantly reduced and one third of the population had 
TLCO under 45%.  
• Quality of life was impaired and the majority of patients were in WHO FC III.  
• Excluding those with known diabetes, 43% of patients had insulin resistance, 
in the absence of other risk factors such as obesity.  
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• Over half of those included displayed elevated composite markers of 
inflammation (NLR and PLR), with a quarter having raised IL-6 values.  
 
Mechanisms of improvement in exercise capacity  
Key observations following treatment with exercise therapy  
• Significant improvements occurred in peak aerobic exercise capacity and 
endurance exercise capacity.  
• Cardiovascular efficiency improved, particularly on exercise, with increased 
pulmonary artery compliance, improved right ventricular oscillatory power 
fraction. Improvements in left ventricular function were seen in those who 
improved with exercise therapy.  
• Tidal volumes, gas exchange and ventilatory efficiency improved.  
• No clear change was seen in metabolic function. 
• Muscle strength and endurance improved.  
• Serum and muscle miR-126 appeared to be sensitive to change following 
exercise therapy, with down regulation in both. The clinical significance of 
this change is unclear due to miR-126s opposing roles of angiogenesis and 
abnormal proliferation.   
Bringing these findings together, improvements in cardiovascular and ventilatory 
efficiency are to be strongly linked. These changes appear to be associated with 
treatment response and prognosis. The underlying mechanisms for these 
improvements may include improved alveolar blood flow due to higher stroke 
volume, improved endothelial health and release vasoactive mediators such as 
nitric oxide, lung recruitment, reduced atrial stretch and reduced 
hyperventilation.  
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Based on these data, respiratory muscle training appears to be a key component of 
the exercise programme both in terms of controlling hyperventilation and 
improving tidal volumes. Aerobic exercise also appears to be essential due to the 
improvements seen in cardiovascular efficiency and LV stroke volume. 
Inflammation and metabolic dysfunction are highly prevalent, however the signal 
for improvement in these abnormalities was not strong. 
Future research and clinical implications  
From a clinical perspective, it is clear that dedicated PAH specific exercise therapy 
is of benefit for those with PAH. The initial time intensive approach provides 
accelerated acquisition of fitness, independent exercise ability and motivation. It 
would be desirable to develop a more accessible and less time consuming 
rehabilitation programme in order to make this treatment available to all those 
who may benefit. Key components of this programme should include respiratory 
muscle training and aerobic exercise with initial face to face sessions with a health 
care professional experienced in PH and rehabilitation.  
This research explored potential reasons for failure to improve with exercise 
therapy in a post-hoc analysis, therefore robust conclusions cannot be made from 
the data presented. Dedicated, controlled studies are required for “non-
responders” to exercise therapy, those who are in higher risk disease categories 
and those with CTD-PAH. It is vital to understand whether exercise therapy may 
have a role in slowing disease progression in these populations. Time to clinical 
worsening may therefore be a more appropriate end point in this group. 
Further research to characterise the improvements seen in vascular compliance, 
lung volumes and gas exchange would be of great interest. Exercise Cardiac MRI 
may provide useful insights into dynamic change in biventricular volume and 
function. Lung perfusion imaging and assessment of autonomic function pre and 
post exercise therapy could help to clarify whether the changes in improved 
compliance and reduced resistance on exercise are due to recruitment, improved 
autonomic function or other mechanisms. Measurement of vascular nitric oxide pre 
and post exercise therapy may help to understand the role of the endothelium in 
improved PA compliance. Finally, studies of respiratory muscle training in isolation 
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may allow assessment of the contribution this training modality provides to overall 
patient benefit and the degree to which it is responsible for the physiological 
changes observed.  
The pathways involved in metabolic dysfunction, myopathy and inflammation in 
PAH remain poorly understood. Further studies of the metabolome in PAH may 




Appendix 1: Patient survey letter 
25th September 2014 
Dear ___________ 
 
We are writing to you because you attend the Scottish Pulmonary Vascular Unit for 
treatment of Pulmonary Hypertension.  We would be grateful for your opinion on a new 
type of treatment.  Please find further details and a short survey below.  
Breathlessness is the most common symptom of Pulmonary Hypertension. People with 
Pulmonary Hypertension often feel their walking and activity is limited because of 
breathlessness. A programme of safe exercises specifically designed for patients with 
Pulmonary Hypertension is known to improve activity levels and quality of life. This 
programme is doing well in countries outside the UK. 
 
These training programmes would be planned in order to meet the needs of each person. 
The main part of the programme would involve: 
• A supervised training programme individually tailored to your abilities.  (This will 
involve stationary cycling and walking) 
• Gentle muscle strength training  
• Breathing exercises 
 
Exercises would be supervised by a physiotherapist and doctor. There would be 2 parts 
to the programme, which would last 14 weeks in total.  
• First phase: 2 weeks of supervised exercise 5 days per week at the Golden 
Jubilee Hospital 
• Second phase: 12 week training programme at home. You would be provided 
with equipment such as a stationary exercise bicycle. The physiotherapist or 
doctor would keep in regular contact by phone.  
 
The aim of this training programme is to improve your breathlessness, increase 
the amount of activity you can do and improve your quality of life. 





Dr Martin Johnson       Dr Alison MacKenzie 
Consultant Physician      SPVU Fellow 
On behalf of the Scottish Pulmonary Vascular Unit  
Prof A Peacock 
Director 
 
Dr M Johnson 
Consultant Physician 
 
Dr C Church 
Consultant Physician  
 
Dr M Sproule 
Consultant Radiologist 
 
Dr N McGlinchey 
Dr A Mackenzie 




Dr D Welsh 
Research Scientist 
 
Sr A Crozier 
Sr A Curran 




Sr V Pollock 
Clinical Trial Nurse 
 
Mr S Kerridge 
Data Manager 
 
Ms V Ferry 




Name (optional)  
Please tick the boxes that apply (YES or NO) 
2. The first phase of the programme would involve either 
a. Daily hospital visits for 2 weeks (excluding weekends) if you lived near 
the Golden Jubilee Hospital in Clydebank.  Transport expenses would 
be covered.   
b. A 2 week stay in the Beardmore Hotel, which adjoins the hospital to 
allow you to attend the daily sessions.  Accommodation and meals 
would be provided. 
Would you find this acceptable?  
 
Yes□    No □ 
3. The second phase would involve exercise at home with gentle cycling, 
muscle training and breathing exercises 5 days per week for a total of 12 
weeks.  
 
Would you find this acceptable? 
 
Yes□    No □ 
 
4. Is this programme something you would be interested in taking part 
in? 
Yes□    No □ 
5. If No what would put you off taking part? 
6. Are there any other questions or comments you have regarding this programme? 
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Appendix 2: Modified Borg dyspnoea scale  
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Appendix 5: Sample residential timetable 
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Appendix 10: EmPHasis-10 
 
 332 
Appendix 11: Camphor 
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Please read each statement carefully and decide whether it applies to you  at 
the moment  
   
1.   My stamina levels are low   
Yes r 
No r 
   
2.   I have to rest during the day   
Yes r 
No r 
   
3.   I feel worn out 
Yes r 
No r 
   
   
   
4.   I get tired very quickly 
Yes r 
No r 
   
5.   I’m tired all the time 
Yes r 
No r 
   
6.   I feel very weak 
Yes r 
No r 
   
   
   
7.   I feel completely exhausted    Yes r 
No r 
   
8.   I want to sit down all the time Yes r 
No r 
   
9.   I soon run out of energy Yes r 
No r 
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10.   Everything is an effort 
Yes r 
No r 
   
11.   I get out of breath when I stand up 
Yes r 
No r 
   
12.   When I talk I get out of breath 
Yes r 
No r 
   
   
 
 Please read each statement carefully and decide whether it applies to you  
at the moment 
 
   
   
13.   When I walk I get out of breath 
Yes r 
No r 
   
14.   I get breathless if I bend 
Yes r 
No r 
   
15.   I get breathless going up one step 
Yes r 
No r 
   
   
   
16.   I get breathless walking up a slight slope 
Yes r 
No r 
   
17.   I get breathless without doing anything 
Yes r 
No r 
   




   
19.   I have mood swings 
Yes r 
No r 
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20.   I get very down 
Yes r 
No r 
   
21.   I seldom feel happy 
Yes r 
No r 
   
   
 
 Please read each statement carefully and decide whether it applies to you  
at the moment  
 
   
   
22.   I’ve forgotten what it’s like to enjoy myself 
Yes r 
No r 
   
23.   I feel hopeless 
Yes r 
No r 
   
24.   It does get me down 
Yes r 
No r 
   
25.   I often feel anxious 
Yes r 
No r 
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Activities 
Please put a tick in the box R under the response which best describes 
your abilities at the moment.  Please respond to all 15 statements. 
Please describe your ability without the use of aids or assistance.  
However, do describe your ability taking into account oxygen if you use 
it. 
 










do on own 
 
1.   Cut your toenails ! ! ! 
2.   Have an all over wash ! ! ! 
3.   Get dressed ! ! ! 
Walk around inside the house (not including 
climbing stairs) 
! ! ! 
5.   Walk short distances on level ground ! ! ! 
    
6.   Walk longer distances on level ground ! ! ! 
7.   Walk up a slight incline ! ! ! 
8.   Climb a flight of stairs ! ! ! 
9.   Bend down to pick objects up from the 
floor 
! ! ! 
10.   Stand for a short time ! ! ! 
    
11.   Stand for a long time ! ! ! 
12.   Lift heavy items ! ! ! 
13.   Carry heavy items ! ! ! 
14.   Do light jobs around the house or garden ! ! ! 
15.   Do heavy jobs around the house or 
garden 
! ! ! 
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Quality of Life 
 
Please read each statement carefully and put a tick R next to the response that 
applies best to you  at the moment  
   
1.    I have to talk very quietly True Not True 
! 
! 
   
2.    I can't stay away from home True Not True 
! 
! 
   
3.  I've lost interest in food   True Not True 
! 
! 
   
   
   
4.  I can't put energy into my close relationships True Not True 
! 
! 
   
5.  Walking for pleasure is out of the question     True Not True 
! 
! 
   
6.  My condition puts a strain on my close relationships     True Not True 
! 
! 
   
   
   
7.  I feel very isolated     True Not True 
! 
! 
   
8.  I can’t do things on the spur of the moment      True Not True 
! 
! 
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10. It feels like my body has let me down     True Not True 
! 
! 
   
11.  I feel as if I’m not in control of my life     True Not True 
! 
! 
   
12. I feel dependent on other people     True Not True 
! 
! 
   
   
Please remember to put a tick in only one of the alternative responses for 
each of the statements 
   
   
13. .Sometimes it’s too much effort to speak      True Not True 
! 
! 
   
14. I feel as if I am a burden to people     True Not True 
! 
! 
   
15.  Travelling distances is a problem       True Not True 
! 
! 
   
   
   
16.    I don't like to be seen like this True Not True 
! 
! 
   
17.    I feel that I'm losing my role in life True Not True 
! 
! 
   
18.    I worry that I neglect people close to me True Not True 
! 
! 
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Please read each statement carefully and decide whether it applies to you  at the 
moment 
   
   
19.    I feel guilty asking for help True Not True 
! 
! 
   
20.  My condition limits the places I can go     True Not True 
! 
! 
   
21.    I dislike having to rely on other people    True Not True 
! 
! 
   
   
   
22.  I don’t want to talk to anybody    True Not True 
! 
! 
   
23. I feel as if I let people down     True Not True 
! 
! 
   
24.  I am reluctant to leave the house True Not True 
! 
! 
   







Thank you for taking the trouble to fill in this questionnaire. 
  
Please check all the pages to make sure that you have 
answered every statement. 
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Appendix 12: SF-36 
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